var title_f37_40_38528="Wall push-up exercise video";
var content_f37_40_38528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1070px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PC/72241/Wall_push_up.mp4?title=Wall+push-up+exercise+video\" style=\"width:480px;height:336px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strength exercise video: Wall push-up",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These push-ups will strengthen your arms, shoulders, and chest. Try this exercise during a TV commercial break.",
"    <br>",
"     <ol>",
"      <li>",
"       Face a wall, standing a little farther than arm's length away, feet shoulder-width apart.",
"      </li>",
"      <li>",
"       Lean your body forward and put your palms flat against the wall at shoulder height and shoulder-width apart.",
"      </li>",
"      <li>",
"       Slowly breathe in as you bend your elbows and lower your upper body toward the wall in a slow, controlled motion. Keep your feet flat on the floor.",
"      </li>",
"      <li>",
"       Hold the position for one second.",
"      </li>",
"      <li>",
"       Breathe out and slowly push yourself back until your arms are straight.",
"      </li>",
"      <li>",
"       Repeat 10 to 15 times.",
"      </li>",
"      <li>",
"       Rest; then repeat 10 to 15 more times.",
"      </li>",
"     </ol>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38528=[""].join("\n");
var outline_f37_40_38528=null;
var title_f37_40_38529="Patient information: Fetal alcohol syndrome (The Basics)";
var content_f37_40_38529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83399\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/61/27601\">",
"         Baby with fetal alcohol syndrome",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/28/39361\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/21/44371\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/23/4468\">",
"         Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Fetal alcohol syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/fetal-alcohol-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H26670680\">",
"      <span class=\"h1\">",
"       What is fetal alcohol syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Fetal alcohol syndrome (also called &ldquo;FAS&rdquo;) is a condition that causes brain damage and growth problems. It happens in babies whose mothers drank alcohol when they were pregnant. Compared with normal babies, babies with FAS tend to weigh less, have smaller heads, and be very fussy. When they grow up, they have life-long problems in how they think and behave.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26670695\">",
"      <span class=\"h1\">",
"       What are the symptoms of fetal alcohol syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A baby born with FAS has face that looks different than other babies (",
"      <a class=\"graphic graphic_figure graphicRef83246 \" href=\"mobipreview.htm?26/61/27601\">",
"       figure 1",
"      </a>",
"      ). He or she has: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A thin upper lip",
"       </li>",
"       <li>",
"        A smooth ridge between the upper lip and nose &ndash; This area is called the &ldquo;philtrum.&rdquo;",
"       </li>",
"       <li>",
"        A smaller-than-normal space between the upper and lower eyelids",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Babies with FAS also tend to be fussy and are very sensitive to noise.",
"     </p>",
"     <p>",
"      In children with FAS, symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        &ldquo;Developmental delays&rdquo; &ndash; This means they take longer to do things other children the same age can do, such as walking and talking.",
"       </li>",
"       <li>",
"        Being more active than normal",
"       </li>",
"       <li>",
"        Having weak, floppy muscles",
"       </li>",
"       <li>",
"        Having problems with learning, hearing, and seeing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In teenagers and adults with FAS, symptoms may include problems with:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Thinking and memory",
"       </li>",
"       <li>",
"        Paying attention and concentrating",
"       </li>",
"       <li>",
"        Getting along with other people",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with FAS are often not able to keep a job or to live on their own.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26670710\">",
"      <span class=\"h1\">",
"       Is there a test for fetal alcohol syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if your baby or child has it by learning about his or her symptoms and doing an exam. He or she will also ask questions about how much alcohol you drank during pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26670725\">",
"      <span class=\"h1\">",
"       How is fetal alcohol syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The problems caused by FAS cannot be undone. But a treatment known as &ldquo;early intervention&rdquo; can sometimes help. Early intervention programs have different types of experts. They will teach you how to help your child do everyday things he or she might have trouble doing, such as speaking and learning.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26670740\">",
"      <span class=\"h1\">",
"       Can fetal alcohol syndrome be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Women can prevent FAS by not drinking alcohol when they are pregnant or trying to get pregnant. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26670755\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/28/39361?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/23/4468?source=see_link\">",
"       Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/40/38529?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83399 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38529=[""].join("\n");
var outline_f37_40_38529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26670680\">",
"      What is fetal alcohol syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26670695\">",
"      What are the symptoms of fetal alcohol syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26670710\">",
"      Is there a test for fetal alcohol syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26670725\">",
"      How is fetal alcohol syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26670740\">",
"      Can fetal alcohol syndrome be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26670755\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83399\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/61/27601\">",
"      Baby with fetal alcohol syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/28/39361?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/23/4468?source=related_link\">",
"      Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_40_38530="Foot anatomy medial view";
var content_f37_40_38530=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Foot anatomy medial view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38530=[""].join("\n");
var outline_f37_40_38530=null;
var title_f37_40_38531="Mediastinal compartments";
var content_f37_40_38531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Alternative classification of mediastinal compartments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38531=[""].join("\n");
var outline_f37_40_38531=null;
var title_f37_40_38532="Radial head subluxation (nursemaid's elbow)";
var content_f37_40_38532=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radial head subluxation (nursemaid's elbow)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38532/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38532/contributors\">",
"     Brian R Moore, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38532/contributors\">",
"     Joan Bothner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38532/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38532/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38532/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38532/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/40/38532/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial head subluxation (RHS, also called \"nursemaid's elbow,\" \"pulled elbow,\" and \"annular ligament displacement\") is a common elbow injury that is unique to young children. The diagnosis is usually readily apparent, particularly when the child has a typical mechanism of injury along with no focal findings on physical examination. The displacement is generally easy to reduce.",
"   </p>",
"   <p>",
"    This topic will review radial head subluxation. Sports-related elbow injuries are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22937?source=see_link\">",
"     \"Elbow injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial head subluxation is the most common elbow injury in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. It typically occurs between the ages of one and four years, with a peak incidence between two and three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], although cases have been reported in children younger than six months of age and as old as eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/6\">",
"     6",
"    </a>",
"    ]. Girls are more often affected than boys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/4,5,7,8\">",
"     4,5,7,8",
"    </a>",
"    ], and the left arm is more commonly affected than the right [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual mechanism of injury is axial traction on a pronated forearm with the elbow in extension. With sudden traction on the distal radius, a portion of the annular ligament slips over the head of the radius and slides into the radiohumeral joint, where it becomes trapped (",
"    <a class=\"graphic graphic_figure graphicRef52710 \" href=\"mobipreview.htm?30/59/31664\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/9\">",
"     9",
"    </a>",
"    ]. The symptoms that develop are the result of displacement of the annular ligament. By the age of five years, the annular ligament has become thick and strong and is unlikely to tear or be displaced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual presenting complaint is that the child is not using the affected arm. The typical history is that the forearm was pulled while it was pronated and the elbow was extended. This often occurs as a parent or caregiver grabs the arm to prevent the child from falling or pulling away. Radial head subluxation (RHS) also can occur when a child is swung by the forearms or during play.",
"   </p>",
"   <p>",
"    The classic history of a \"pull injury\" is present in approximately 50 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/4,5,10\">",
"     4,5,10",
"    </a>",
"    ]. Other mechanisms include falling onto the elbow, minor direct trauma to the elbow, or a twisting motion of the arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/4\">",
"     4",
"    </a>",
"    ]. Among children younger than six months of age, the injury typically involves rolling over in bed, which somehow traps the involved forearm under the body and results in longitudinal traction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with RHS may hold the affected arm close to the body with the elbow either fully extended or slightly flexed and the forearm pronated (",
"    <a class=\"graphic graphic_figure graphicRef82235 \" href=\"mobipreview.htm?31/23/32127\">",
"     figure 2",
"    </a>",
"    ). The child is in little distress unless attempts are made to move the elbow. There may be mild tenderness over the anterolateral aspect of the radial head. However, the distal humerus and ulna are typically nontender and not swollen. Passive range of motion of the elbow, if the child allows it, is normal. Pain with even mild supination of the forearm is almost always present.",
"   </p>",
"   <p>",
"    Examination should include inspection and palpation of the entire extremity, as well as the clavicle, on the affected side.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RHS is made clinically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/1,2,11\">",
"     1,2,11",
"    </a>",
"    ]. Radiographs are usually unnecessary but should be considered to exclude fractures or dislocation of the radius or ulna when there is a mechanism of injury other than a pull, or minor direct or twisting trauma to the arm, or a physical examination that demonstrates focal tenderness or swelling. Although radiographs in patients with RHS may show displacement of the radiocapitellar line, this finding does not alter treatment or outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RHS can be made when the characteristic history and examination findings are present. Even in the absence of the classic history, the diagnosis should be considered when the examination is characteristic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduction of radial head subluxation (RHS) can usually be performed in the office or emergency department. Anesthesia and sedation are not required. Reduction may be attempted for the child with typical physical findings, even when the classic history is lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reduction procedure is brief, but painful. It is therefore important to explain the procedure to the caretakers before attempting reduction. The procedure is best performed with the child seated comfortably in the parent's arms and the examiner seated and facing the child.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Supination/flexion",
"    </span>",
"    and hyperpronation are two techniques for reduction of RHS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/1,4,14\">",
"     1,4,14",
"    </a>",
"    ]. Both techniques are effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/4,5,14,15\">",
"     4,5,14,15",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Supination/flexion",
"    </span>",
"    is the method that has been used most commonly. However, metaanalysis of four randomized trials found that successful reduction was more likely with hyperpronation (RR 0.45, 95% CI 0.28 to 0.73) although the quality of the evidence was felt to be low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/16\">",
"     16",
"    </a>",
"    ]. Based on this analysis, nine children would require treatment by the hyperpronation method rather than",
"    <span class=\"nowrap\">",
"     supination/flexion",
"    </span>",
"    to avoid one failed reduction on first attempt.",
"   </p>",
"   <p>",
"    In addition, hyperpronation may be less painful. One trial compared physician, nurse, and caretaker assessments of perceived pain (using a validated visual analog scale to assess pain) with each method of reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/15\">",
"     15",
"    </a>",
"    ]. Physicians did not note a significant difference in pain scores between the two methods. However, both nurses and caretakers perceived hyperpronation as less painful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hyperpronation method",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the hyperpronation method, the examiner supports the child's arm at the elbow and places moderate pressure with a finger on the radial head. The examiner grips the child's distal forearm with the other hand and hyperpronates the forearm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/4\">",
"     4",
"    </a>",
"    ]. A click may be felt by the finger over the radial head when the displacement is reduced (",
"    <a class=\"graphic graphic_figure graphicRef52541 \" href=\"mobipreview.htm?4/7/4208\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Supination/flexion method",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the",
"    <span class=\"nowrap\">",
"     supination/flexion",
"    </span>",
"    method, the examiner supports the child's arm at the elbow and exerts moderate pressure on the radial head with one finger. With the other hand, the examiner holds the child's distal forearm, and then pulls with gentle traction. While maintaining traction, the examiner fully supinates the child's forearm and then fully flexes the elbow in one smooth motion. A click may be felt by the finger over the radial head, or a pop may be heard by the examiner when the displacement is reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/8\">",
"     8",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef81909 \" href=\"mobipreview.htm?28/58/29602\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Postreduction evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following successful reduction, there is immediate pain relief. Reduction can be confirmed when the child moves the affected arm. This typically occurs within 5 to 10 minutes. Some children are initially reluctant to use the arm, but do so readily once they realize that it is no longer painful. After successful reduction, no additional treatment, immobilization, or activity restriction is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;RHS may recur when the child sustains another injury with the typical mechanism. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above.) Recurrence rates range from 27 to 39 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/4,5,7,8,17\">",
"     4,5,7,8,17",
"    </a>",
"    ]. There are no long-term sequelae associated with recurrent RHS. As the result of strengthening of the annular ligament, the injury rarely recurs after four to five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order to prevent RHS, parents and caregivers should be instructed to avoid placing excessive traction on the child's forearms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;After several failed attempts at reduction, radiographs of the arm should be obtained to evaluate for fractures of the radius or ulna [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. The child with normal radiographs who refuses to use the arm should be referred to an orthopedist. The affected arm should be placed in a sling. Spontaneous reduction of the radial head subluxation (RHS) may occur. No long-term sequelae have been reported from unrecognized or unreduced RHS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38532/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/4/34881?source=see_link\">",
"       \"Patient information: Nursemaid&rsquo;s elbow (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radial head subluxation (RHS) is the most common elbow injury in young children. It occurs when a portion of the annular ligament slips into the radiohumeral joint and becomes trapped. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A history of a \"pull\" injury is present in approximately one-half of cases. A typical history, though supportive, is not required to make the diagnosis. RHS should be suspected in young children who hold the arm pronated and either partially flexed or extended at the elbow and have no other physical findings (",
"      <a class=\"graphic graphic_figure graphicRef82235 \" href=\"mobipreview.htm?31/23/32127\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographs should be obtained when the history",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      examination are inconsistent with a diagnosis of RHS or when reduction attempts are unsuccessful. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because it is more effective and may be less painful, we suggest that the hyperpronation maneuver be used for the first attempt to reduce RHS (",
"      <a class=\"graphic graphic_figure graphicRef52541 \" href=\"mobipreview.htm?4/7/4208\">",
"       figure 3",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The",
"      <span class=\"nowrap\">",
"       supination/flexion",
"      </span>",
"      technique is a reasonable alternative, particularly if the clinician has more experience with it (",
"      <a class=\"graphic graphic_figure graphicRef81909 \" href=\"mobipreview.htm?28/58/29602\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be referred to an orthopedic surgeon when RHS cannot be reduced despite attempts using both pronation and",
"      <span class=\"nowrap\">",
"       supination/flexion",
"      </span>",
"      methods. The arm should be placed in a sling. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bachman D, Santora S. Orthopedic trauma. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1525.",
"    </li>",
"    <li>",
"     Young GM. Reduction of common joint dislocations and subluxations. In: Textbook of Pediatric Emergency Procedures, Henretig FM, King C.  (Eds), Williams &amp; Wilkins, Baltimore 1997.",
"    </li>",
"    <li>",
"     Ludwig S. Dislocations, subluxations, and diastasis. In: Illustrated Textbook of Pediatric Emergency and Critical Care Procedures, Dieckman RA, Fiser DH, Selbst SM.  (Eds), Mosby, St. Louis 1997. p.634.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/4\">",
"      Macias CG, Bothner J, Wiebe R. A comparison of supination/flexion to hyperpronation in the reduction of radial head subluxations. Pediatrics 1998; 102:e10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/5\">",
"      Schunk JE. Radial head subluxation: epidemiology and treatment of 87 episodes. Ann Emerg Med 1990; 19:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/6\">",
"      Newman J. \"Nursemaid's elbow\" in infants six months and under. J Emerg Med 1985; 2:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/7\">",
"      Illingworth CM. Pulled elbow: a study of 100 patients. Br Med J 1975; 2:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/8\">",
"      Quan L, Marcuse EK. The epidemiology and treatment of radial head subluxation. Am J Dis Child 1985; 139:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/9\">",
"      Kaplan RE, Lillis KA. Recurrent nursemaid's elbow (annular ligament displacement) treatment via telephone. Pediatrics 2002; 110:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/10\">",
"      Sacchetti A, Ramoska EE, Glascow C. Nonclassic history in children with radial head subluxations. J Emerg Med 1990; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/11\">",
"      Macias CG, Wiebe R, Bothner J. History and radiographic findings associated with clinically suspected radial head subluxations. Pediatr Emerg Care 2000; 16:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/12\">",
"      Snyder HS. Radiographic changes with radial head subluxation in children. J Emerg Med 1990; 8:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/13\">",
"      Frumkin K. Nursemaid's elbow: a radiographic demonstration. Ann Emerg Med 1985; 14:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/14\">",
"      McDonald J, Whitelaw C, Goldsmith LJ. Radial head subluxation: comparing two methods of reduction. Acad Emerg Med 1999; 6:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/15\">",
"      Green DA, Linares MY, Garcia Pe&ntilde;a BM, et al. Randomized comparison of pain perception during radial head subluxation reduction using supination-flexion or forced pronation. Pediatr Emerg Care 2006; 22:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/16\">",
"      Krul M, van der Wouden JC, van Suijlekom-Smit LW, Koes BW. Manipulative interventions for reducing pulled elbow in young children. Cochrane Database Syst Rev 2012; 1:CD007759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38532/abstract/17\">",
"      Teach SJ, Schutzman SA. Prospective study of recurrent radial head subluxation. Arch Pediatr Adolesc Med 1996; 150:164.",
"     </a>",
"    </li>",
"    <li>",
"     Thompson GA. Dislocations of the elbow. In: Fractures in Children, 5th, Beaty JH, Kasser JR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.732.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6331 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38532=[""].join("\n");
var outline_f37_40_38532=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hyperpronation method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Supination/flexion method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Postreduction evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6331\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6331|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/59/31664\" title=\"figure 1\">",
"      Annular ligament displacement in nursemaids elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/23/32127\" title=\"figure 2\">",
"      Radial head subluxation classic arm position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/7/4208\" title=\"figure 3\">",
"      Hyperpronation technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/58/29602\" title=\"figure 4\">",
"      Supination flexion technique",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22937?source=related_link\">",
"      Elbow injuries in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/4/34881?source=related_link\">",
"      Patient information: Nursemaid&rsquo;s elbow (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_40_38533="ECG digoxin toxicity in AF 1";
var content_f37_40_38533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1128px;\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Single-lead electrocardiogram (ECG) showing atrial fibrillation (AF) with junctional escape beats suggesting digoxin toxicity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 80px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 4 electrocardiograms in this sequence demonstrate increasing severity of digoxin toxicity in a patient with atrial fibrillation.",
"    <br>",
"     <br>",
"      This ECG shows atrial fibrillation with an irregularly irregular ventricular response. However, the longest recurring R-R intervals are constant, suggesting junctional escape beats due to AV nodal block. The escape interval of 680 msec indicates an accelerated automatic pacemaker with a rate of 88 beats/min.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       The four electrocardiograms are adapted from Childers, R, Med Clin North Am 1976; 60:3.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38533=[""].join("\n");
var outline_f37_40_38533=null;
var title_f37_40_38534="Abdominal hysterectomy PI";
var content_f37_40_38534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Types of abdominal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 762px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAL6AhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKTNAC0ZpuRTS4FK47EmaM1AZgO9MNwtTzofKy1mk3VVNwMU03A9aTqIagy3uo3VS+0Cj7SKXtUP2bLu6jdVH7SKQ3Qpe1QezZobhRuFZxuxTReCj20R+yZqZozWeLsU77UKftYi9my9mjNURdCl+0in7VC9my7mjNU/tIpRcCj2iDkZbzRmqvnj1oE4p86DkZazRVfzxThMDT5kLlZNRUYkFODCncVh1FANFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNLAdaivZ1t7dpGOAKwJ9XDHCmsqlaNPc1p0pT2N951HeoWulHesA3jP3pVlJ6muV4q+x0LDW3Nh7v0NV3uie9UwTSGs3WkylTSJ2nY96b5retQ0orPnZfKkTCQ+tG8+tRilouxWQ7eaN5ptFFx2HbjSFjSUUrhYazHFRFj61I1RGk2UiaNjUm41BHUwHNXHYmRICaNxoxQ1V0IDefWk8w+tIaaaltjsOMx9ab55Heo2qJjS5mVyosG5PrR9sI71TY8Gq0rYzR7VopU0zXTUOetWor4HvXLGUg9akjnIpxxLQ3h0zsYroHvVlJA3euPjuyo61ag1PawDGuqGJT3OaeGfQ6oHNFZtnfLKyqDyTitKuqMlJXRyyi4uzCiiiqJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAppNOPSmNQNGB4znMWlKAeXkC/oT/AErk7ZyxGa3vHbfJZR+rMx/DH+NYNmvIrxcXK9ZrsexhYpUUzWhq0gqvCOBVpBUxFMkFIaUU01ZmJmnCmU4UASClpBS0yQooooAKKKKAGNULVM1Qt1qWUiSKp161BHU6dauIpEtI3SlpprToZIaaaadTTWbLRG1RPUrVE/SpZaIm6VUlPJqy/AqpKeaiRrArv1oU0jHmhayNyTPFVpXKng1YPSqk/encEjT0C4ZtSt0zwXFd7Xm/h1saxa/79ekV6eBd4P1PMxytNBRRRXacQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABpppTTSaBo4bxpL5mrJGOkcYB+pOf8Ko2Y6UatL9p1S5l7FyB9BwP5U+0HAr5+pLnqyke7Tjy01E04egqytV4elWVrSJhIcOlNJpT0phNUQFOWminLTAkFLSCloJCiiimAUUUUANaoW61M1RMOaTKQ5KnWoUFTLVRJkSA8UhoHSkPQ1ZAlMNPpjVLKRG1RP0qR6ic1DLRDIeKpTGrUpqnMeDWcjaBATTlqMmnoayN+hL2qrcirQ6VDcDIqhIj0iTy9VtSeglX+den15Pkxyq46qQa9TgkEsMci9GUNXfgH8SODMI6xZLRRRXonnBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRQaAEqpqc/wBlsLibuiEj69v1q2awPGM4j01YR96Zxx7Dn+eKyrT5IORrRhzzUTjI+RzWhbDgVTjXgVo264ArwYI9ubLkVWVqCMVOK6EcshHqM05qaaYkKtSLUa1KtMTHiigUUyQooApwFOwXG0uKdilxTsK5Gw4pm3mp8UbaLBcYFpwFOA9qUCmkK4lBp1IRTFcZTHNSGo3qWUiFqgc8mp3qu/eoZpErSnmq0nQ1Ym9arPWTN4lc9acnWkbrQvWszZbFlOVpkg4NOjNOYcVRBnSr1Fd54Xn+0aNDzlo8ofw/+tiuHnXmtrwXeeTfS2rn5ZhuX/eH/wBaujCz5Kqv10McXDnpXXQ7YUUgpa9g8YKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAENcV4puPtGqeWD8kI2/j1P+fauvvJ1traSZ+iAn6154S0kjSOcsxJJ9TXn4+paKgup34GF259h8S5IrQhXAqrbrzV6McV58Eds2SoKl7U1ByKe3StjBkR60ynnrTD1pDQ9KlWoQakU0yWiUUoGaaKeKpEsUCnYoFLVpENhijFLiiqEGKXFJRQAtFNJozRcLC5oNNJozSuFg71G1SE1G1IpELjiq8lWnHFV5BUM0iU5RVdxVqWq0lYs3iVZKQUslNFZs3iTxmpuoqvGanU8U0SyGYVUWV7W5jnj+9GwYVdlGaqTrkGh+Q12Z6bazJcQRzRnKSKGFS1zHgm98y1e0c/NEcr/umunr3KNT2kFI8KtT9nNxCiiitTMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikoAWkJpainkWKJ5HOFUEk+1Juw1qc/4ou87LVT/ALT/ANBXPquamuJmurmSZ+rnOPSljTmvCqz9rNyPapQ9nBRJIExiraCoo1qwgqooibJFFI/SnimPVmZEetMY8041Gx5qSkPBqVagU1MvamgZKtSrUS1ItWjNj1p1NWnVaIF7U2lNIaYAKJJAiZNNzzUdyvmRED0qbglqVDqSliMHFWop1kAIPWsiCKSNmQpnJ4NaVvD5Y5rOMm9zacYrYtUCkFOXpWhkxCKaakNMamJMiNQyCrDVDJUs0TKUw61Slq9NVGXqawkdECu9RinvTO9Ys3RIh5qyvSqq9asp0poUhWqrKKstUUgpiQuh3X2HVYZScJna30NekA5GR0ryqZSORXf+Gb37bpMTMcyR/u2/DofyruwNSzdN+pw46ndKovQ16KBRXpnmhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAGkpTSUDCsPxTcGO1SBTzKefoP8it3pXFazcfadWkwcpH8g/Dr+ua5MZU5Kdu504SHNUv2KsSYAqygwKagHFS4rzIo9GT1HpxUyCol61OorRGMmOqJzUh6VC9NiRGTUbHmnPxUTdahmiJEPNToarp1qdKaFImWnio1NSCrRmyRTT657xxq8/h/wbrer2aRPc2NpLcRrKCULKpIBAIOOOxFcp4d8fXS+FBruvMk8TxwN5UWnNpYjMiknEt5Osco4xlD785Faxi2rmTaTsemE0014vrfxRm1ebwve+FLqa20++t9X+0RTQxsxkt7femT8w4bn5Tg98ir+h/Fq0tPCmmzaxDqOo30OlW1/qtzawxBLcSgAM4LLnJOcIpwO1U6crC50ermkrz64+K+iQahcwGz1N7W2u4LOa+RIzCjzKGjON+8qQeoU4/Kqh+KllpuiXuo6pHLcQwX91Zlohb2hBhIyAk1zmQnJxsyTj7q8Ax7ORXMj0vHOcUV5xefGDQreB54rDV7q3j06HVZJIYo8RwSMFBIaQHIJ5AB/Gr/xN8Z3nhnw9o2paJZLfC/vre3+cDHlyegLoQx7Z4B64o9m72DnR3QFPA4rz+9+Kej2LX6XdhqkU1jfW2nzx7IiVlnXcuCJCCB0Jz16Z61heEPidJb32r23is3ckD+JbvSrK9WKIQwqmCkTbSHzjPzFT15b0tU3YlzR66aYa8ttPjp4Su47uSMX4jgtXu1ISOQyojbThUcsh74kCcc9Oa7PwZ4otPFulNqFhC8cAfYN08EuTgHrDI4HXoSD7UnFrdDUk9jcaoX61MxqCTrWbNIlWeqMtXZjzVOWsZHRAquKiJ5qeTpVZutYs3RKp5qzEeKqJ1q1H0pIGSNUbCpT0qMiqJRVlXg1s+C7vyb6S3Y/LMOPqP8AJrLkXioIZGtrqOVOGRgRVQn7Oan2FUh7SDieoCnVFbyiaGOVOVdQwqUV7yd9TwmrBRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFJS0d6AIL6YW9nNMeiKWrgLclmLMcknJNdd4rl8vR5BnBkZVH55/pXI244FeVjpXqKPY9TBRtTcu5ei7VOBUEVWVrniayY5RzUwqNBUorRGTEPSoXqZqgehgiGQ1D3qWSoSahmqJVNTKarIamU0IJIsKayPFOuf2LYxi2h+16ndP5FlaA4M0pGeT2UDLM3ZQTVnV9TtNH0y41DUJhDawJvdiM+wAHUknAAHJJAFY/hXTbq4vpfEevRmPU7lPLt7UnIsbfORH/vtgM59cAcKK0j3ZjLsi1pvhmI+GLvStelfUn1IO2oyM7KJmcYYLg5RQAFABGAB35qfU/COiapo+m6Ze2bNaaa0b2YjnkjeBoxhGWRWDggd85rZBpQ1WpMjlRzFv8ADrwtbx2yRaYQLY3TRZuZmINyu2Y5L5O4cc5x2xUVz8NfCdxDbwyaURFBbR2gRLmZFkhQgokgDjzQCBjfurr91GarmfcXKuxwFj8LtIHijV9Y1RjfJd3cN5BaEvHDbvGm1coH2SH0LLx2rRm+GvhOaXzTpbpN5s8xkiu543LTf60FlcEq3dT8vXjk111LRzS7i5Ucmvw38KLaTWw0r9xNYppsi/aJebdW3Kmd2eD36+9a+teGdI1vRIdJ1K086xhMbRIJXRo2T7jK6kMCMdQc1qg07NHMx8qORvPht4VvL2S6utOmknleGWQm9nAleIYjdxvwzgfxEEnJyTk062+Hnhe11htTi01jdG6kvsSXU0kQnk+/KImcoGPqF9MdK6zNJmnzPuLlRytl4E0Owt2t9PGqWdsQQILbVruKOMFtx2IsoVOf7oHU+pqez8KWWj6PqNn4beXTLq8dp3vC7XEpmP8AG7Sli/ToT0z0610WaaxocmNJHO+F9el1E3Gn6rClrrtjhbqBTlXB6TRZ5Mbc4PYgqeQa2JD1rH8V6HJqYt73TZ1tNbsstaXJGVwcbo5B/FG2ACO2ARyBTPDmux61ayiSFrTUbVvKvLOQ5eCT+qkcqw4Yc+oES7ouPZmhKeaqS1ZkPWqsnWueTOqBE/Sq7jmpmNQnrWTNUKgqzFVdasRUkDJ+1NI5p46U3vVEDHXiqdwuBWgRmqV0ODQ1oOL1Oy8IXPn6QqE/NExX8OorcrifAtztvZoCeHXI+ortq9jCT56SPIxUOSq0FFFFdJzhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACGlpGpaAOX8bTcWkI7sXP4cf1rDtxV3xdJ5mtKg6Rxj8zmqkA4rxMRLmqyZ7NBctGKLcVWVqtFVlaURSJUp4pq04VoZMRqgap2qF6TGitJULdanfvULCoZqgWpQwVSzEADkk9qqLcwbtomi3em8ZrmNXlk8U6tNoNm7LpFsQNVnQkeYSMi2U+4ILkdFIHVuHFXCeiJtKH/CZavBrEwP8AYFjJu02M9LqUcfaSP7o5Ef4v/dx2wNV4FSKNI4kVI0AVVUYCgdAB2FTZqnK5naxJmlBpmaXIAyelNCK2r6paaPplxf6jMIbWFdztgk+gAA5JJwABySQBXH+L9c1NvHPhjw7YX0mk2mpQzzyXiRI0rlACIkEqsoPOTlScelT6YP8AhMdai1eUZ0DT5T/ZyHpdTLwbk+qryE9eX/umuo1bStN1m2FvrGn2d/bhtwiuoVlUH1wwIzWqajuZu72PJdI+Ll5o2jrceJrdL7TY9TvdNOtQsIxL5K7om8sLtPmYK8EDKnirviH4xy6HpVreXeh27yG0gu7yzivJXntElYAb8W5jHDKfndCScAdM+lTaFo9xpcWmT6VYS6bEQY7R7dGiTHTCEYGPpUeq+GdB1i5+0atoml31xs8vzbm0jlbbnO3LAnGe1XzQvqiOWXc888QfE7UwnjCOx0G4jsdB3pLqcN9EG3gKVCo8bcnJ6qwH8pdN+LNxe68mmWHhrUr+CGeC1u7mNZHeIyLkyEJD5ewcZJdSc5C4r0RtE0lor6JtLsTFfHddobdCLg9MyDHzfjmobjwv4fur6G9udC0qa8gCCKeS0jaSPb93axGRjtjpRzRtsHLLuc34Q8fz654on0XUdH/sa4RJJYre7klW5lRX2hwhhEZU88rI3+Hb211BdIzW00Uyo7RsY2DAOpKspx3BBBHYis7SPDmh6JNJNo2jaZp8si7Xe0tUiZhnOCVAyM1g67bzeGdUm8RaVFJLYTkHVrKJSxYAYFzGB/GoADAfeUf3lGZdm9CldLU7QtTCagtbqG8tYbm1lSa3mQSRyIcq6kZBB7ginlutZ3LsDGuU8U6RcvdR61oJRNatl27GO1LyLk+TIfqcq38J56FgemZqryNUuVi1G5kaJrNtrenLdWu9CGMc0Mg2yQSL96Nx2YH/ABHBBqeQ81zfiW1k0zU213Q9jXu0Le2IcKL2Mdxk4Eqj7pPUfKeCCNXS9TtdY06C/wBPlEttMu5GwQfcEHkEHIIPIIrKp3WxvC+zLJqPvTiaSsWbDlqxEKgWrMXamhS2JQOKQ06mmqM0A61Vu+lWu9Vrr7tDGtx3huTydYgbOAWx+fFekZryu0cx3UbjswNepA5wfUZr0MvfuyicOPj7yY6iiivQPPCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAENLQOtFAHnuuv5mv3R7AhR+AFLD0qtqDbtXu2/6asP1qxb9BXgN3m35nvJWgl5F2MVYTpUEfSp0rRGEiYUopBSirMwaoHqc9KhkpMaK71gzN/al5PE0pSxg+V9pwZG7j6VvtXCaPKzWjgHknJ9zV0YpyuzppRum0ReJo7drGe30wrbXLKVSXZ5mz/a255P9aq+GLHTNOtIrS2knhRM/MJDvZiclmPdickn1NdJ4ZjUC7kb/WmTafoBx/M1Z1XRrfURuP7q4HSVBz+PrVyrWlZo25oxfK7+pXg1C7spCWdry0HU4+dR/X8a6OzuYruBZbeQPGe4rh/I1XSs+dC0sI6yRfMMe460uk3MqXTTaa4y/wB+NujUpQjPWAp0VJXR39cd4hmk8S6rJ4asJGWxiAbV7lDjCEZFspH8bjlv7qe7Cn6z4mnEcOmaTEB4ivCY4oZBlYFH3p39UUEH3JVeprZ8O6Pb6FpUVlbF5CCXlmkOZJ5GOXkc92Y8n8hwAKzS5d9zhknflNKGOO3hjhgRY4o1CIijAUDgAD0qUGozQDSuOxLuxShqiJpM07isTbuaXdUBbFLuo5gsSbsmjNRZ5pSaLhY4pz/wg+pFlGPCt7KSwA402dj972hcnnsjezHb2Jao7uGK6t5YLmJJYJVKPG6hlZSMEEHqDXn9hqdz4ZvU0FpPN0yRtmmX87EhMD/j2cnqygfIc/MBjkrzSTntuOMdfI7jUL6Kyg8yYn0VR1Y+grmNRvbyYn7TJ9mhIyI0POPc1n3d2EvPOmnaeUfxN0H0HaprKwm1ecT3W9bQc8nBf6e1VyxgryPQhSUFdktnc6VH8ssKux65NY8NpHpfiG6v9IkeK1uhuntBzG8nH7wejY4OOvHpz1U2kWDR7Ps0Yx3HB/Osq3tFt76S2YlkGCpPXBpxqqr7thrkfvamxBMk8KyRnKtUlY2nZtNUltSf3cg3L9R/9atquKpDklYmStsOWrMfWoEHSrEY5pIzkS9qDS44oNUZjG61WuPu1O1QS8rUstFA8ODXp+mv52n2755KD+VeYyD5jXofheTzNGg9VyP1rswDtNo5cevcTNUUUd6K9U8oKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAB1o70DrTJnEcLueiqTQG55lI3mXcz/3pGP61et+grNg689a0oO1fPR1PoJKyL0fQVOvSoYugqZa2RzMlFOFNFOFWZgagkqZqiekCKzVxNrGNO1ue0l4TJaP3U9P8Pwrt3HNc54wtN9ml7GMTW5GSO6k4P+P506cuWR10HryvqM81dOvWlQboJQA4HUY6Gti2uYbhd0EiuPY8j6iuPW7MlryeR61GsjKCEn2yjna8AJx7MK3nSU3dGsqWl2d6DXJeM4rfRrSTWYTskUhTAgy1w7HCqg7uSQAO+a29Ft5lsTcm+V7YqXzNgBQOvPbFYOgq/ibV4vEF8hTTbfI0mBxgODwbog92GQg7Lz1fiPYzp+90OKOISlaD1MPw2t3HdzazqLAeIJyPOXqsMY+7AP8AZAJz6sSfTHoGm63b3ZEcn7i4P8Dng/Q96TUdHtdQy7Axz9pU4P4+tYs2kX9rw8MV/APThvy/wzQ5Rqb6M6kqco2Wh2Pas7UdXstOGLiUeZ2jXlj+Hb8a5G8uiieXE15bY+9E0rAD8KpW1uJpRtGc0Kl5jjhlvJm1P4qu52KWVqkY7NISx/LiqzalrL8m6K+yxqP6V0+m+HoYbZZZhzjOKWaCA5VYwK3VBIj29JO0InKjVtYiOTc7x6NGv+FWrbxbLG4W+tQV7tEcEfgf8a0p7KMDoKxb+wjGSBUypI1jKnPRo63T9Rtb+LfaTLIB1HQr9RVvNeWHdbT74XaNx0ZTgitm0129EX7+/CgdzGpasHSfQU8LbWLOm1+7+zWexGxLKdq+oHc/lXI6lYnxTaPo4QCzVRvfONh7MCOQwIyCOQRU00l1qcm2zgnlZvlM8owAPr0A+ldNpVjHpVgI85b70j4+81Vf2atHcTUaUNdzjvCtjFY6nLoviD9/qsQMltcSYCXsI/jVegdejrzg4I4YV2U8kcK5kdUXpljgVU8RaBL4gsY1j32l1A4mtLtQPMgkHRgO4PQqeGUkHrUmjWk+p6I8mtaa1rf20hhuI2BMbsAPnjY/eRgQQe3IPIIq/qsqmstDhljUnZ6jJLy3C7hKrDr8vJ/SsVJjPdy3ONq4CqD1wKZdWLF5pLe1uUgGQAXKKcd+aqxyPbQqrgCR8EJ/dFEKCpu56FNxkvd3LVuxm1uJv7oYn8jW8BWPoMJMs1w3X7g/r/SttBk1x13eZU97EkY5qxGOKjjWp1FQjCTFA6UN1NPxTXFUyEV5Khf7tTSDOajYcVBqtijIPmrt/Br7tNdP7r/zrjJB81dT4LfAuI89g1dGEdqqMMYr0mdSetFA5or2TxgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqlrcnlaTdt/0zIH48VdrG8XSbNElH99lX9c/0rOs+WnJ+RpSXNOK8zhIR0rTt+1Z8PUVo29eHA9yZdj7VYUcVBH2qwtbI5ZDxSigDilqjMaajantUbUhohcc1XuIlmhkikGUdSpHsatsM1E4/OpNIs89061mkufJiCuy5V1Y43Dnp78GrujrPHqEaRxblikwGJAKqeoNbtppCWslvIkhMkZYu2Pv5H/16uyW8TknaFYnO4cHNdMayT12OivVc4tRL87W9zYvYNZRvHMpSSN0BRweGBB4IPOc1PcGFhHbukaKnBPYCsZYZ1fctyemOVpTa+Znz5Xcn0O2up4mmlueP9XqPoNacwXE0duvnRpyAM8foarHV7k/d06bPur//ABFaNvDHAu2Jdo6/WpieK4ak4yldI76K5I2lqcR4lu7m5WNrmB4kQkLmIqMn3P0pugFRPGW6ZrrtUtRe2E9u2PnUgex7H864bRpCCobhgcVpSkmd8JKdNpdD1K9mQWyBT2rGkfk1HHOZIl3HpUU0mK627nnwp8ug2eTisW9lGDV2Z+tY16/BrOTOylDUybxxuNafhm7t7Qu8tukshPyueq/TisS7bLECvR9CsxYaZBDjD7dz+7Hk/wCFc1SSR1V5KELPqRf2zvwIrWVj/ut/RTUyzTMokuIxGgORx0q8TTWrOFRQldI82pFTi4rQsQ6qDCsZZFUd80S3O623NMBGecd6zHtbdiT5Sgn04qBrVc/fkI9C3FdqxkOqOF4OfRhq88VzaRRAuWzlVQ4zXOy6bJG00jDCIVbOc56Z/Ac10ccSR52KAT370pAIwRkd65auK5n7q0O/C03R3dyjo8ezT4R3IyfqTmtBBTIoljRUQYVRgCrMS1yPV3N5O7uSRrUyikQcVKBVJGLYmKY44qWmNzTJRVYVEw4qy681DKMCszZMoyda3fB0uNRK/wB5CKw3GTWj4ZfZrEHuSP0rSi7VIvzJrq9Nnf4ooNFe6eEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc145k22NvHn70mfyH/166WuQ8dNm4s489FZvzI/wrmxbtSZ04RXrI52HqK0bes+Ic1oW1eTE9aZfjqdKhj7VMvWtUc0iWg0UhqjMY1MbrTzTGpDQ01G1PpjdKRaIXpma8v8AHNtd2PxLl1htPv7jT7jw3NpySWlrJcET+aWClY1JXIPU8e9cl4d8OeIdB1vwZcSW+pxyQ6G9vtitxLGk+/csMrBG2K2RliRjnDDBq1Tur3J9pZ2se+bqXNeEWOv/ABJbR9WnuPtYvlsHZLU6ZIZI7kSDHln7MsbLtONu+QnGQTzjQ1XU/iBojbJbvUNTFxos80Ulto4IjvScojKisQQOPm4Ppmj2L2uh+1W9me0g5p2a8Zi13xsNZ8PrMNUnt57eyW6t7WwMDxysitM8skls0RXJIIWRCOnBFel6pc+II7orpemaVc22BiS51GSB89/lWBxj33VMoOI4yTNquA1BfsWv3MQ4UvvX6Nz/AFra+2eLv+gHoP8A4OZv/kWud8Wx+KZY0vn0bRUMI2uY9VlclSfe2HQ/zqqd0zpw9RKVn1Oos590Q55p00me9cNYan4l2DbpWjn66pKP/betK1v9ee5Rb3TdLhtyfneHUJJGH0UwKD+YrsvoNxXN/wAA2p5MA1j3snB5q1NLmsq9k61EmdNKGpJ4ftPt2tQqwzGh8x/oP/r4r0Ymuc8HWJtrFriQYe4II/3R0/P/AArfzXHUldmGJnzTsug/dTGagmmHpUGFhGNMPNDUKKksQCnBKeq1IFosJyI1TmrCJQi1Mq1SRDkIFwKeBRiiqIA9KjYVJ1pMUhohYVBP92rLiqs3SoZrEoseal0mTy9Tt29JB/Oo5B1qCNilwjehzUp2aZo1eLR6rRTUbcikdxmnV9CfPBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXB+L5fM1xl/wCeaKv9f613leda4/m63eN6Pt/Lj+lcOPdoJeZ24BfvG/Irx1dt+tVEHSrtuK89HpS2LsXSp1qCOpl7VojmZMKQ0ClqjMYaYRUhFNNIaIWFNPIqViKjPtUlETLTMVOcUxloKTIGFMNTlajZaRSYwU4UmMGikAoNNlRZYnjkXcjgqwPcGlpc0DR55FC1reTW7HJjcrn1x3q5k4qXVIx/wkE7DhXwf0wf1BqytuMZAruhqjulPZszJc7SaqWlv9t1KC3J+V25+g5P6CtW6i2g1F4cQf2yXPRFx+J4pT0RSnaLaOyVQqhVGFAwAOwp1IKXFcRwCU0j1p5FJtpDuRkZp6rTwtSBKdhOQ1FqULSqKkC07ENjVWngUoGKDTJuNNN5Jp2M04LigLjQKUjindqY3SgaIpDVSXpVl6ryVmzWBTlqsx5FWpR1qpIOKzkbo9O09/MsLZ/70an9Ksisnw1N52i25zyo2H8K1hX0FOXNBM+fqR5ZNBRRRVkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABOASa8vkk825lk/vuW/M16NqM3lWF046pGx/SvNIq83HvWKPSwEdJMuIauwdKox1fg6VxxOyZbToKlSok6CpkrRHOyQUtJS1RmFNIp1BpAV5VzVYsydelXHFQOmaRpFmfqms6dpNuLjVr+0sYC20SXMyxKT6ZYgZq1a3MF5bRXFrNHPbyqHjljYMrqeQQRwR71wfjXQ9TPjjw74isbBtVtdPjmhks0kjSRGcDEqeYyqSMYOSD6VyvjDRfG99qkEulLe6VpT2fyWumTJvtZzIWYsv2iFGYjqSXXJIwfvVagnbUltq9ke1EVTvr6zsTbi9uoLY3EqwQ+dIE82RuiLk8scHAHNeUP4Q8Wave+Kbi+8Qa/YOyL/ZSQagI4XfycFmRGJXDjoCByetLpuk+P7jT9K1DVZryLVZ9etZr20hvgI4LGJCrAAPtIY/MyrndkZBIo5I9w5pdj13bTSory7wVpPi+18dy3WsjVj4edrg2UE2prKbXLDHnDeTICM7Rl9n613mqW/iCW7LaVqelW1tgYjudOknfPc7lnQY9ttTKKTtcak2r2NQr6U0gisH7H4u/6Dmg/+Cab/wCSqins/FwhkJ1vQcBSf+QNN6f9fVLlXcd32Gakih7WeQqpdimCeWONxwPbn860IRE0Y+cCvPvHMPiiHTLCY6po8s0V0XiCabJGciMggsZ24IYcY/HisDT/ABTrkboNRvbGIAjfGdNl5HcK4lYfiR+Fdqajodsac6kE0vy/zPUdSEYB2sCaq+HWilj1BonDSxSKjjH3Tt3Dn3BNcVdeKnkUraRvcuem2MxqPqTz+Qrqvh3aNB4auHmYvdXF47zsRjLbEwB7YzSupM1qU3Tp6ncKOMjvTgKLdf3EZ/2R/Kn4rhscFxuKcFpQKeBQK4wCnqtISF61E046LQO1yyAB1pQw7VXj3N1qzGopolqw5QT1p22ngU4LVEXI8UhqUimEc0hojPFRualaoX60mUmQvUTipnFRMKhmkSq461TlHNaDiqdwO9QzZM6jwPKWtbmHsrBh+P8A+quoFcV4Ik238sZ6On8jXaLXr4OV6KPIxkbVWLRRRXUcoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGT4mk8nQrxu7AL+ZArgIegrtfHD7dE2/3pFH8z/SuJh6CvIxrvVS8j18Cv3TfmXY6vQVSiFXYBxWCN5lyPpUy9qhiqZe1aI5mPpaSlqiApKWkNACGonFS1G1JlIgaq8q1458XtY8Q+GfFlzbaVc3ssfiqzSysFErbbW7DqhZBn5Mo+crg7ue2aNc+Id94W8R2Xh20nj1KK0ns7G6N5AUnYOoBkEjT75CTzkRFfmALdM37FtJoFVSep6vMGHKmoVvNjbXO0+9eTWvxL1i+8QWdjMmlQpdahdWctiEcXVqkakqzsJOrY/ujoce2LaePtcbQLFbSLThjw/PrDm5E85LRyspTc0u7BA6kkg+3FQ6EjWNeD3Pfo51bvUwf3r57vvitqFhdacLVbWRZY7OW4tpYdjIJ0VjscygvjPURkDjJ9fV5vEd3DcvFb+H9UvY1xie3ktQj8A8B5lbjpyB09OahxlG3MVeMr8p126o7pv8ARZuf4D/KuaTxJqR6eENdP/bay/8AkikuPEOpNBIP+EQ10ZUjPnWXp/18VSi7k31K/jNGbTLLhWQXJ3K3c7OMf+PfpWVY6fbysu7TkbPrwP0qPxRrF9PpMHm+E9ZTbcjDPJZlTlWyOJzzwPyNR6BdTXM3lzaLd2SqMhrkxMrew8uVj+YxXVJanpYaa9lb16M3p9Ht7WLekNjAcdFLMRV7Qxt0dxtAUXDYbbt3ZC549sD86hlVUQMzWtvxxthw36mrGmrt0YEStJ5sjv8AN1HQY/TP5U1uTWd6evc6CA4gjB/uj+VKTTCwUe1QvN+FcLZwWLBcDvUUtyFHWs26vAp2qcsewotoJJm3S8D0qebojTktqy2JHlPHSrMMOME0+GIIOBVhFqkjOUuwiLiplFAWpFX1q0jJsctOpMUoqiWFMapDUbUmCImqNhUjdaa3SkUQsKiYVK3IqNulQzRFaTrVSccVdlqpP0qGbxLnhR9msxe+R+hr0Ada848Ptt1e3/3wK9HHWvSy9/u2vM83Hr94n5BRRRXccIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHOeOxnSI/wDrqP5GuNg7V23jYbtFJx92RT/OuJg7V4+MX775HsYL+D8y/CORV2EYqnB2q6lYo1luWIzU6mqyGp0NaIwaJaWm06qMwooooAaajNSNUZ60mNDTUbDNSGmEUmWjmv8AhE9JXXI9YeK5n1CJpGikubyaZYS/3vLR3KpkcfKBxx0rSkTNX3qB1qZNvc0hpsZc0OQeKyZIHtnMsAJH8Sf4V0Ui8VUkSs5RudEJ2KtleLIuVPTqK0UkEiEHoRg1i3VodxkgOyX9D9aksbwltknyyL1U1Kk1oypRTV0M8QL5mgTnzDHseKU8Z4yVwf8AvsflWZYMZFULJazj0IGf51s317Z2WmvPqSyvauywusabj82cdxgDA59cVzFnfXBuidM0tHtwfv3LbGb6AA4r0n0Zthm+Vq3U6OZJ7aAstnEpx97CoP0JNWrYMLCyR9u7YGbHTDMW/kayXuZzMjaho6fZurCK4LMfbDACtKC6lu7K0vLmFLeaUMzRxklVGWCkZ7Fdp/GiTtFszrXsky9LOB3rMmupJ5THbjJ7t2FMLNdy7IyRGOp9a1rS1SJAFUCvNbctiLKG5BaWSxcnLOerGtKFMUItToKuKsYzk2SIKmUUxBxUqjmtEYscop4pBTqozYUtFFMQhph61IaY3WgZG3Wo36GpG60xqkZA3Soz0qVhUTVDNUQS9Kqy9Kty96qyDioZtENHO3Vbb/rqv869JHWvNtNGNTtf+uq/zr0n+KvQy/4ZHn4/4kLRRRXoHAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBjeL13aFP7FT+tcHD0Feh+JE36HeD0TP5GvPIfuivKxy/eJ+R62Bf7trzL8HarqVRg6iry1zI3kTLU8dV1qeM9KtGMicUtIKWrMwooooEMamGpDTSKBojNNPFPNNapLRE9QtUr1E1SzREElVJatyCq0gqWaRKsnvWdeQ+YQVO2RfutWnIOKpTLzWclc3gyC2CalDPp1yArTrs57N/C34HB/4DUPh0XcNpG0kSKcDhzz+VPmhL4ePiVehqWCbcnPBHBHvVxryjFRL2vbqTapPNetb20kexJpVjZ4znCkgH6cZqO8le9vHSPhAcHHAHsKinldiI4/vt0PoPWrltEsKBU/E+tE67nHlZNrWZas4VjAAHFaSLxVW3FXYxUxMJscoqRBQFpwrRGTHrUgpi09etWjNj1qQUxadmqIYtFFFAgNManGmtQMjPWmv3p/emPUjIWFQNVhqgapZpEikqq/SrT9KrP0NZmyE07nVbT/rqv8AMV6QPvGvONJG7VrX2kX+dejj7xr0cB8LODH/ABIWiiiu84AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKesLv0q8U94m/lXmlueK9RvV32c6+qMP0ry2GvMx/xRZ6mXv3ZI0Lc8ir6dKzoDyK0I+lciOqZKtTx9KgWpkq0YyLA7U6mr0p1WZBRRRQIQ0w081GaBoaaaacaaaRSInFQsOaneoXFQzREDVXkqy1V5RUmqKziqswq29VJe9QzWJXXrXQeFNItdSa6NxuDKFxtOPWueB+aux8Af6y7+i/1q8NFSqpPYzxUnGk2jG13T4NP1J44NxwoyW61ThGTWl4tb/id3A/3f/QRWdDUVUlUaXcdJt0032L8A4q4nSqkHSridKaJkSZpwqPNPWtEZMlWnpUYqRKpEMeOtPpg60+qIYoopBS0CENManmmNSY0NPWmv0p3emv0pDIWqFu9TNUR6VLNIkEnSqspwDVqTpVOfoazZtEl0H5tZtv8AfFejAda878NLnXLf6k/oa9Er0sB8D9Tz8f8AGvQKKKK7jhCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAbKMxOPUGvKU4Yj3r1g8givKHG24lX0Yj9a83MPs/M9LL/tL0LkHUVfirPgNX4jXEjtmTr1qeOoFqaPrWiMJFhafUaVIOlWZMKKDSUCA1G1PNMakNDaYaeaYaChhqNqe1RvUstETdaryVO3WoXqDVFSTvVOXvVyWqkoqJG0Skxw1dn8Pj892f9lf5muLm4auz+HfIvT7IP51phP40TPG/wAFmd4t/wCQ5cf8B/8AQRWdCelaXi8Y1ub3Cn/x0VlwdRWVb+LL1Y6P8KPoacPSrSGqsPQVZSmiZEoqRajFSKa1Rkx4qRKjFSJVIhjx1p9MFPqiGFLSUtAhDTGp5qNqQ0NpH6UtNehjRE9RGpG71Ex4rORoiGXpVSYcVakNVZvu1DN4lvwoN2uxH0DH9DXf1w3g5c6wT6ITXc16eAX7v5nmY5/vPkFFFFdpxhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAHevLtQTy9Uul9JW/nXqNef8AiG2KazckDhm3fmBXDj43imd+AlaTRRi61fhNUEBBq5Aa85HoyLi1NH1qBanStEc8iwlPFRp0qQdKpGTA0006kNMQ00hpxphpDQ0000NSZpFjGFRtUjVG1JlIgfrUTVK9RNUmqK0wqlN0q/N0rPm6VnI2gUZTk12fw6GIr1vUqP51xcnWu4+Hq4sblvV8fpWmD/joyxv8Fmb41+XWc+samsiDqK3fHSf8TKFvWIfzNYkA6VniFatIeHd6UTRh6CrSVVh6CrKU0KRKKkWox1p6VojJkq1ItRr1qUdapEMd3pwpnenLTJY6lpKXtTJGmoz1p7VG1IpAaY3SnGmt0pMaIW6VC5qdxxUDKTUMuJA9Vp/u1fEDN2p/9nPJxikoSlsa88Y7knghSdRnY9o/6iu1rE8O6f8AZGlY9WAFbderhYOFNJnlYqanUbQUUUV0nOFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVi6vYCeZpAOSBW1SMoPWonBTVmXCbg7o4ifT2QnC1GkDp1Fdq1ujdRUL2KHtXJLCdjsji+jOWCkdqmStt9OHYVEdPI6CsXh5Iv28WUEp4q0bJh2pPszDtS9nJE86ZXoqwbdvSmmBvSlyMOZEBpjVYMLY6VG0TelJxZSaKrU2p2ib0qMxN6VNmWmiJqiY1O0belRMjelS0y00V3qImrDxt6VEYmPapszRNFWXpVGbvWo9u5H3TVSW0lP8JqHFmsZIx5OprvPAK/8SeY+sx/kK4+SwmOcIa7rwZbtBo21xglyf5VtgoP2132McdNOlZGV47XFxat6oR+v/wBeuKtGMkljI0khknYybQ5ACbSQMdOPlH416D41tmmS1ZRnG4H9K5W00iOKYSpCBJz8w9+30qcVB+2YsNNeyRRiuZkujI0kwga4KB2K+WqqMEYHPLA8/Tn1tzXFw08j2d0GhlaGNPkDYJ+9tP8AukN3q/BpESSiRYAGB3DrgE9SB0z71PZ6NBbOrQwlSuduWJC56kAnAJ7kdahQkVKSLI609KkFs/pT1tnz0rVQZk5IatSCnrbP6VILd/SqUGQ5oipy1MLZz2qaO0Y9RVKnJkuaRVxS4rRWzp4tBWioSMnVRkspNAiJ7VsC0HpT1tgO1UsOxOujHW3J7U/7IT2rZWADtTxEB2rRYZdSHXMQWBPapF04dxWyEFOCitFh4ol15GbFYKO1W47ZF7CrGKMVrGnFGcqjY1FC9KdRRVkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAGKTaKWigBNopuwelPopWHcjMY9KQxLUtFHKguyAwL6Uhtl9KsUUuRD5mVTar6U02aHtVyil7OI+dlE2KHtSf2enpV+il7KPYPaS7mf/Z0fpSjTYvSr9FHso9h+0l3KP9nxf3aUafD/AHRV2in7OPYXtJdyn/Z8P9wVYhiWKMIgwKkopqKWwnJvcgurdZ1AYZxVYadEP4RWhRScIt3Y1NpWRTWyjHYU77Ig7CrVFHJHsHPIrfZk9KUW6jtViinyIXMyAQL6Cl8lfSpqKOVBzMiEQ9KcEA7U+inZCuxNtGKWimIMUYoooAMUYoooAKKKKACjNFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVHcTJBC8shwiDJoAWWRIULyuqIOrMcCqL6vbj/VrPKPVIzj9a8y8d+NbgXzafpew3y/fkYBkteOgHRnxySeB+lcDcxNPiTUru9vZG53XF0yqf91Rzj8BXNPEKLsj2MNlM6seaTtc+i01e3J/eJPEPV4jj8xVyC5hnGYJY5P91ga+brWN7Vg9nJPZsOcx3Uy//W/Sti18Ta5bHdJIl5GP+fiIP/5EjwR+INJYldTSpks18Due/UV5JpXxGSMqL1Li0HdwftMI+uPnX8q9C0nxBZ6hBFKs0RSThJY3DxufZh39jg1tGpGWx5lbCVaPxI2aKKK0OYKKKw/FnirSfCVh9t12S6hswCWmhsp7hIwMZLmNGCDkctjPagDcorO0HWLTXdOS+08XX2Zz8pubSW2ZhgHIWRVYjng4wajt/EOl3HiS70CG63atawJczQeWw2xscK27G059Ac0AatFYXjbxRZeD9Ak1fU4rmW2SWKErbqrPmRwg4JAxlhnnpTPEniux8P6xoGm3kVy8+tXJtbdolUqjBd2XyQQMegNAHQUUUUAFFZXhfxDpfinQ7fWNBuvtWnTlhHL5bJuKsVb5WAIwVI5HatWgAoorK1zxDpehTaZFqt15EmpXS2VqPLZvMmbJVflBx0PJwPegDVooooAKKKKACiiigAoqOaVIImklcKi9Sa43xP41t9LPlbmE7jMdtEA07j1PZF9zUyko7mlKlOq7RR2ckscQzI6oPVjioBqNmW2i5hz/ALwrwzUfGGuXkha1e0sVY/f2+a34u/BP0WqUeteJQ+Y9faVv7jwxlT+BXNYPExPUjk1Vq7Z9EqwYAggg9xS14x4b8ez2lwsOtrHasTgXcIIhY+kiH7v1H6V65p16l7FuA2yLjcuc/Qg9wexrWFRT2ODEYSph3aaLdFFFaHMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXJ/ETWDpOiXM6YLwRGUKf4nJ2xj/vo5/CusrzT4zAnRLnrjfak/TzT/AFxUVHaLOnCQU60Yvuea6dZ+TYm5uMysVMsjN1kYngH6tya6LwzobaleO0zOyIypKyHDzSnkRqf4VA64rNvJQNMsolA58l29xk/1Fd38LmR4IQR8yXVwD/vYBH/jprgpRUpWZ9Pjq0qNFyibLeCbNrcKbTT9393y2/8AQ87vxrjvEHgZ4XZ7DzIZj92J3+9/uS/0b9K9ipk8Uc8TRTIrxsMMrDINdsqMZI+do5hWpSvc+cJEukma3vIDLNHwVI8qdfw7/hkU3Trm40m6e70iUKScTwyDEcw/uyp2Po4r3XUPDcFzHtHlyoPux3KeYB9G6j9a4TxL4MOfMsUe2vVzsQtuSUeisf8A0E/pXLKjKGqPapZnRxC5Kqtc6zwX4nt9VsI2VmVN3lskh+eB/wDnm/8AQ9xXXV84aRqFxpOpNcW6qkuPLnt3yElUHofTBzg9VPHSvW/CvjCzv4/Kjkd3QZeCT/XxD3H8S+4zW9KspKzPMx+Xyoy5oaxO0rlvih4eu/FfgDW9D06SCO7voPKjediqA5B+YgE447A10sMsc8SyQuHRhkEVJXQeUePePvhlq+vzaXJCdJ1CG30R9LNpqMjrFbTsBi7ixG2XGMchTgDBHajbfCTWNN1+fUrb/hHtVubjQU01rzVIS0kdysRjMuzYwkDjCNlgdpOd2MN7fRQB86WPwT8UxaR4htXu9Eh/tQ6fIIYH2QrLBIGkbZFbxouQOMJnnBJ+8fUPiR4Km8Xa54RuCthLp+l3rz3kF2CwmjZNu0LtIb6HAru6KAPmTxD8KfEmj+E/Bem6ZMz6+Li60i4ubJJJoY9PuS5Yu5UbVQHjOOWOM11998IbkeOrDUNJtNGTR7drWCRNRdL7dawoF2RwvbZhY/3kmA7kZPHd+Ifib4K8PTyQav4l02C4iJV4Vl8yRCOoKpkg/hWrb+KtJufB7eKLW5abRhbPeCZY2yY1BJIUgHoDxjNAHiFv8Dtet/Bui6NHJoatpt9NPOInATVEctsabzLd1Dxg7VDJKME8jArb0P4KN/wkHhq414pcaZo+ltapE2oyTTLOLppYm3rFEHRQRwygDAG04ydbTf2hPh3qF3Baw6rcrNO6xor2UvLE4A4U9zXpGu69pPh+2iuNc1K00+3lkESS3UojVnIJC5PGcA/lQB4doHwT8Rae9/5ut7b2e0u7X+1oLwLJN5u4q0sQtg7kEjlp2K4+U4wKu6l8ILu90Pw7CnhjwXa32j31vcTCORmTU40UiRZXNvuXcdpwRJnueOfbNO1Kx1OHztNvLa7i/vwSrIv5g1aoA8TtvhRrkfjO31T7TpkQj106sdTjkf7abbaB9g2+WF8odPv4x/AKxtD+BOoWcOhrejQpWt7XU7e/I3t9o88sYM5j+YISD833SMjJr6FooA+ab/4U62mv+CtFkkllgvtNSy8SzwJI9u8NtIskY80qPmYKIwDg4HTFfSqqFUKoAUDAA4AFLTZHSONnkYKijJJ6AUAOqvd3cVquZGyx6IvLH6CuJ8WeOYtNlFtCJJLlxlLeIgOQejOx+4D2715zq/iHVtTLwzTCBH+9BaZyR/tOfmP5gVhOvGOh6WGyyrX956I7Lxp4ybMlrpskb3oyN4+aK19WY9Gf27d/fzuGFPLlfzHcud0k8zEvO3dmPUj271Np2l3N+VisbdpdvGF5VPqeFX9a9G8I+EBCyzSkT3OcmcjMcXsmfvN79vbvze/WZ7N8Pl8LJ3f9fcc/ovhO5vEEh32+RnHlb5SPUjgIPQZ/CpNT8C3CIWhuDv7C4jaPcfQNkj869gtbeO2hEcK4Ucn1J9Se5qSRFkRkkUMjDBBGQRXQsPGx5Us3r8109D5zniZXa01CPypkPl72HKt/dceh7HkHtXSfDfXJ9NvxpE7MypuNqGOSAOXhz3GPmX6GtD4paRHbiOdR0ZYCe5jfO3PqVccH0NefpdTLJb3kJxcQskqH3HI/UEfRjXNrSmezHlx+HvbX9T6XikWWJJIzlXAYH1Bp9Y3hW8S80tZIjmJsSR+yOAw/mR+FbNegndXPkpx5ZNBRRRTJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuR+IelNqek3EMY+e4gaJfaQHfH+oxXXVBe24urWSFjjcOGHVT2P4GpkrqxpSn7Oakj5ugnN1YQgZVghjAPUMDuX9QRW34V18aNqubhxFY3hR/NPSCXorn/ZP3W+gqDxtpz6Vr8rKojhvSz8dI5gfnH/AH1hx7MaymT7TCYmVdkudgboH/ijPse1edd05H2fLDF0PJn0fYXaXkO4fLIp2yJ3U/571arwD4b+Mb2y1JtHvVmcWyHybhuTGg/5Zy+q9lbqK9V/4S9W5isJ3X13AV6FOfOrnyOKw7w8+RnVVFcwR3MLRTKGRu3p7/WqOka1aaplYS0cy8tFIMMPf3H0rTqzm2PKvG3hSSe4ee2XN6o3Y6C5X1H+32I7/lXnEsTF4mWR7e6ib91KCVZHHbPUH+fevpW7torqExzLkdQRwVPqDXCeLPBsd9vlcFZSMfao0zuHpInf/eH6dK5KtHXmie7gczUV7KtsVPh54ve8D29/hNRhH+kxAYEq/wDPZB6/3gP8K9LjdZI1eNgyMMgg5BFfO+p6JqekSxXEhdDCd0F9A24Kf9709mA/Gur8N/EFrVVTWALdj1njUtBJ7so5jPuMinTrW92ZOMy7n/e4fVeR6/TXdIwC7KoJABJxyTgCsmw8QWV5bieNw0RGRJEfMQ/iuf1r4w+KXirx/wDEP4iHRfs1zp/2GffbafE5VIdp+WZ343HoQ/T+7jPPTzI8d05J2sfQ/wC0b8SNf+HOh2FxoOmW8yXjtC17OSy274yo2DGSRuIJOPlPBrh/2cviB4rvNQ1y88ez38+n3cSS21xOmFEinBSNABgMGzwMfLXU6jquraxoFlY+JWtLqSJIzMI4PkklX+P5skHPPGKgCsFHyhR6Y61hKv8AynoUsvb1qM8w8e/CiHxT491rXLbUWtLC+n89YfIzICQN2fmwMtuP416Noy3Ol/DtfB0d8z6aLWW0aTyh5hSTdu55APzEDipmw3cAfU0qfd2pkj2NYurN9TtjhKMfsnmum/B3RNN1Oy1C01DUDNazpOqOUZSVYMAflHHFdh8Z7HVviToNhp0t1bWgtJzcBvJbEh2lQDzxjJ/OtsAgYIA9zQvGPm9uOaPay7g8LRatynG/s3eBJPA/je+1PxFeWiqbU29qyOdrMzDJOQMYC9/WtLxh+0pJ4b+KGpaUulxX/h21cW5dCUn3gfO6k/KwzkAEc4zkZrfZTk8A+4rA8U+D9H8TWhTVLRWkAwtwmFkT6H+hyK1jX/mOWrl0XrTZ734K8U6b4z8OWuuaI8zWNxnb5sZjYEHBBB9CCMjI9DW5Xz/8R/iRN4F+E8Fn4R0uW0u4lSzhlRA8NpGBjzCT1J6DI6nJz36f9n74sx/EnQ5YNQSODxBYqPtMacLKp4EqDsM8Edj7EV0KSkro8ydOVN8slqes1yfjvW49L06eRsMIFDbM/fkPCJ+fJ9q3NQ1SG0VgpEkoBO0Hhfdj0ArxLxZrg1zVE8h/OsreQspA4uJjxuA/ujoPbPqKyrVFFHbl+EdeorrRGdZW13dXexC82o3TF5pB94k9vbjqewrv/DvgeB1DTotwOp3ZEIP06yH3PFXfAfhs20B+1rm4k+e4PcA8iP8Aqf8A9VegqoVQFAAAwAO1Z0qP2pHZj8yd/ZUXZIzbTRbWCNFdfMCdEwFQfRRxWkAAAAMAdKrahfwWEQe4bk8KoGWY+wrGfXb1/mhsUSPsZJOT+AFdKSWx4spOW50dFc1F4leNv9NtQq/3o3z+hrJ8ReM/JsJ5LS1uZmUfLBEMSSfieAPpk+lDdghHndkYPxb1NHiitoyDJNOpQZ/gjzlvxdgK8/iUKojHJKgD8GP+FZlrql7r+rTXl9g3UrBEiAwIwOigdlX9TWtIFiWSVTlEJVT6hFOT+ZrzakuaVz7PBUfYUVE9e+E7lvDWn5PBtE/RnA/Su4rlvh5p7WGgWsTjDxwRRH/eC5b9WI/Cupr0Kfwo+RxLUqsmgoooqzAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOF+JehnU9PlWFAZnHmwn/psg4H/AlyteUaeEvFSPkLdplSR0kA/n/hX0LqtubmxkVP8AWr88Z/2hyP8ACvAtXUWWs6xbw/KIZhe249FcByP/AB4iuPEws+Y+iyau2nSKmk3Ai1PUFuE23O6IyHuVGR+Wf516tZXkX2OPyQpyOteXeI5I4L+w1mBQ0E67ZgOQVPDj6jg/hW/pMzRySQwtyh4BPWtcPK8bdjgzWk41vadJfpodsdOEo85gCeo9qjgE0UpeyuJopB2Dkg/UHg1nQeIJ0i8qS3bOMdKksNRkhnMkkTbG9ulbnmHa6Nqxu/3F2oiu1HQdHHqP8K1q4CeYalcr5UbYHOcYxViz1u60m7WC8Zp7ZuBuPzKfYn+tAHU3Ol207M4DRSHq0Zxn6jofyrmdS8B2F0zMIYNx/ijzC347eD+VbH/CT2AUGRbmMe8LN/6Dmo5vF+jxDmeY+wgf/Cs2oPc66bxFN3hc+fvjr9p+F+l6dqOgPc297dXXlks2UKBST8y45zjrWt8Otf8AFviTwfaeIJbHStT+0hkeIqBNtR2UAkYJ7kDnrW78aLTw/wDEbTNP027fVYfs1x5yNAiLuJUrglug5z07VieEdEj8MaNbabp1xcbLcvskkIDkFi3OAPX0rGfJFWid9L6xUlzVlp5/1c1I/EuhSSvDq2k3um3CnD+Xlwp9xww/75rSt08O3+BY67AGP8ErKrfk2DTJoLfxTb/Y9UCx36r/AKNeKPmU+h9R7f1rz24s2gvJ7LUIlW5gfZIvUZ9R6gjkfWsZStra56FGhGteMZOMl03XyueoDwvJJ81teQyD1C/4E01vC9+owrRY75Lf4V5rFokL8xqFPqvH8qux6JeoMw318g/2Llx/Wlzx7FvB1VtNfcd2fDV+RgtD/wB9H/CpU8MXp6tF+Bb/AArh1sNXHH9q6kB/19Sf40smjXEq/wClXl5KPR7h2/rT5o9ifqlX+dfcdpLoHkfNeahawqOu9to/Uis+eTw7Af8ASPEFqSP4YBvP/jua49NCiku4reCBXmkYKoxySa7aDS9J8OKIltY72/ABeSUZRD7D/J+lCafQirR9lZSm230SRnzXnh28tprWGw1fWYpVKPGsJCOp4IOcVy/gfSdF8IX7xeFdBhTV5MwNLf6jvuDk8psXGOg4HPFd4+v3z8RyiJeyxKFAr5w8AQyXv7TFpPfKwifV55mklUqpA3sCc/Stqa5rpOxwYiSp2lKF/Vt/lY9+1HS/Eusp5WptHDaZz9nV1hiP1AJLfjmuo8I+DPszx3D4kmX7kjIVjj90B5Y+5xXZnUNDtPm+16dER3EiA1SuPGOlodtq014/pDGcf99HA/WqVKKd5MzljK9SHJTjZeSNlFg02yYs2yKMFndu/qT71zN3rt9dsTaAWsHYkZdvc9hWVrniGbUohA0SQQqwYqGLMee56fhWvZiCS1B3qPlrdNNaHm1IShK0tyGztpbx/PuJ2kcDAZ+TipFQvcFC5wKz/NvICyW+11J45rPe6vrSYyOhfJ5xTIN68s4oz5o5x1B71k6ultLBnYAfaqtzrlxdLs8kr7kYrCuNTeSXyVyz9ABQBzOtW/2bW7W7tlzNdK8DYH3iMYP1wf0rU0GwGo+IbewRd9vbYMg/vbSDj8XKj6ZqLMl7r9nFaRmQQBo4Xx8ss7sFOD3C8DP1rrPgzYf6bqE8p3uhVN3qQCSfzeuJpTq6bH00KkqGBvLe35vT8D1W1hFvbpGDnaOT6nufzqWiiu0+ZbuFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAE4GT0rwHxAhfxfdzKreUII4pXx8se6P5dx7ckV766h0ZT0IwayNL8O6fp9teQrGZ/trl7lp8MZSeMHjGAOAOgrKrBz0O7BYqOGk5tXPO9a8Pw6mulXVjC/9n6nKi3CQjmCY8McYwAec9sj3pl94F1PQrMTQXKXqwHapRCr+X23Dnp0yO1emaHotrokU0ViZRDI+/y3csEOMfLnoOK06IU+V36ixWLdVKmtYra+/wDXQ8bsdaTKLcrsK8NkVvf2tZmDCMu71rrdS8NaVqBLT2iBz1ZPlNYg+HelByVmugp/h3D/AArU4jl5PEEts5MUe9R3QVHYHU/EN8ogtXKLyWcYUfU16VpHh7TtKQi2gBY9Wk+Y1qqoUYUAD0AoA89j8Fas4O++s7YNziOMsR+PFNPw5upf9frr/wDALf8AxavRaKz9nE6/rtZbP8EfPvxz8AyaL8LtY1XTtXvze2flygo3l/LvAbpz0Ynr2rzT9nrU5r7w9qsFzPJNLBdLJl2LHa6+p91NfYeq2dnqGm3NpqcEVxYzIVmilXcjr3BHcV4Td+J/AOo67baZ4Cn08SLA5lisbQwphSMHO0A9T61NSCUNDTDV51K6c2WlZ45A0Rw8ZDKffNVvidbiSPStft1wJh9muMdjyVJ/Jh+AqwOOD1281ozWx1nwZrOnKMyovnwj/aHzD9VI/GuVK6aPYU/Z1I1Oz/BnJaLN5m3NdXCQEFcB4duNyRt6129u+Y1NZI9WqtTSt4xIeRRqKRxWpIHNLYuOneqXiW5CQMM9qvociTc0iLwWFfU7/UpRmKyiIXP99s/0B/OmSySTSvJIcl23MfrVvTIfsfgaEH5Zb+Uysf8AZ7foo/OqIJz8xwMDiq2SRzTlz1ZS+X3f8EaX2BiRjufYVxXgfxjbfEPxWui6JDJDdeU7g3ajYVTknIJ9eOK7K6trm/tpbKxKC7ugYYmfIVXbgE45xk1l/s6/BnxF8P8Ax3qGp+IhZvB9haCCW2m3hmZ1J4IBHC9x3rWlBSvc4sXiZ0GuTqdtD8O9dyN1/p0I/wBhGJ/kK1Lb4cTZBu9dnJ7iGIL/ADJr0Sit1Sijhlj6z6/gjj7bwFYQNuN5fSNgj53XB/DbWJqOj6vpZZY0eeDs8Yzx7jtXpdFWklscs6kqjvJ3PHLfW3tJT9oRlYHnNXJfENtON2eT2Fel32mWN+MXlrDN7svP51Rj8K6JGfl0+Ifif8aZB5lJe3OpTCDTrd5HPHArtfCfgyHTwLvUwJ7xh9wjKp/ia6u0s7azTbawRxD/AGFAqegDHu/D9pcazpmogeW9gHVI0ACkEYHHtyRWV4O8P3GhatrAYKbKaXzbdwecEDKkeoxiutoqeRXubfWJ8jg3pt+NwoooqjEKKKKACiiigAooooAKKKq2uo2V3dXVra3ltPc2jKtxFHKrPCWGQHAOVJHIz2oAtUVU03UrHVLdp9Mvba8gV2jMlvKsihlOGXKkjIPUdqt0AFFFFABRRRQAUUUUAFFFFABRRRQAUVVi1Kxl1KbT4ry2e/hRZJbZZVMsanozLnIB7EirVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAB5618UeC/hn4v8ADvxL1DUjodzFoVlcXET3UmI1aLLKrqCQWH3TwDxX2vXiv7SXxP1j4e6fZW2l6Pb3MepxyR/bLhiyRsOCmwYycHIJPrwcUpK6sXTnyTUuxTHUh61vDFx5GsIvaUFMe/Ufyrj/AATr6eI/DFhqcQUvLGElUfwyDhh+f6EVupIYpUkTh1YN+Irg+Fn0LSqR06nJalZf2L4t1PTwNsSy+bD/ANc3+Zf54/Cul06XdEBR8VLVZDo+v24+Rx9lmPscsmfx3D8qoaXL8qkGomrSPSw9T2tGMnvszooX285rB8QSSXc8NrDkyzusaj3JwP51qGXbETUPg21OpeLhcMMw2KGUntvPyr/Mn8KSV2kNyVKMqj6I3fFAWF7SxhP7u2iCj9AP0FYjjJBH0q3qlx9qv55hypY7foOBVKV1hVpJWCxohYsxwFAGSTWkndnmU1yxSZwXxa8c3vg2x0+XRLhYNXluPMjYor7UXqdrAg5yB+de6fArxLr/AIv+HdnrfiiK2jurmR/K8iMoHiB2hiCTySG6YGMVwmjeBfAXxg8K/apL1LrUFJC3NpNtntV7KyH15OGXvxXuOk6fbaTpdpp1hEsNpaxLDFGvRUUYA/IV2Uo8sTxMXV9pVbWyLdFFFaHMFFFFABRRRQAUUUUAFZHiPxLovhmz+1eINUs9PgP3WuJQpb2UdSfYVz9/8UPC9j8Qrfwbc34TV5kznjy0c42xM2eHYHIH07kA+KfGz4Iaj4p+J02q2OrRQ6ZdQiW4e5kLtbOOCqjP3SMEcgDJ9qG7DScnZH0X4f8AEmleIfD8euaPdrc6XIrsk4VlyEJDcEA9VPauM0j45fDnVGCw+JraBz2uo3gx+LqB+tct4HuvD3gXwO/hOLxLBeQt5oM3LOnmD5guwEDBJIznrXlNv8EPCV1f2zaX4zSRFkVnguVUM6g8qCdvJHHSo9pHubvC1kr8p9jxusiK8bBkYBlYHIIPenV4p+0XqfiiXwNZxeArbU1uBcrLPLZErJHEgJAXackE46Z+7z1rm/2ZviZ438XeILzQ/EkcN1aWEBkmu5YvKnjbOFQ4wCTz1APB5qk7mDi1ufR9FY0fijQ5fEc+gJqlp/bUCq72ZkAkAYZBAPXjnjOMjNbNMR4rpXgm3074z+KtQ03wlYpDBpcEulyNYLHb/axuJ2PtADZxkqc1yGtzfEnxT4R1bSrmLXLoXOiSS38NzpaWwgvFkyILdvLXzVZRjgucchgTXv3ibxVo/hprJNXuZI5r2QxW0ENvJcSzMBkhI41ZjgdcDis/V/H/AIf0YWzatLqNlDceXsmuNLuo4gX+6rSGPajf7LEEdwKAPH/EviLx5pXhrSLXwfB4vluYNKjk8260tRHJIsmGiMQsy+4KCo3NECqqQWJy3f8Awus9Ri8d/EG+1GwubWO+uLKSJ5YWRJMWwDbCRyA3Bx0NN8OfFO0aTWo/E7rbyw+IrzRtPisrOeZ51hCsMqgcl8E5wAD2FaI+KXh2Se0mttRs5NJn0+41Brj9+JVjgP7z90IiOMHIZlb0U0AeZfDaz8b6HPoNjarq9lpup6nqyX0UunKUtRy0M+5o9y5Y8bmKtgcdcr4X8W/ErXdC8TPJqC2l5oUf9kGVNNN0tzfic75QkMTvhYtowqlQW3EEV6knxV8GNZ3t02sGGGzt4ruXz7WeJjDLjy3RWQFw2RjaD1HrUGl+PfAum2V0mmyCxSO+W2ltItKnhma6lG4KIPLDs7dThSfWgDyu+Txbrl94I1rWIfFtumnaxcxTT/Yo55Y4zEoSZI1tEcIxDD54sjnPbF+HxH8V21rVftaT2piF8qWI02aWNgImNu0EiWpTO4A/POwbONoOAfW7P4geEruztLlfEWmQx3btHCt1OtvI7q21l8uTawYHggjPI9agg+JHhOfVTp6awizb5Y1lkhkSB3iGZFSdlEbFRyQrHFAHl13qPxasPCvhm6mv7q7k1NTNfyR6UIp9OPkrsiaNIJmIL7izeUTnj5BzWrp2u+N5NT0iLxPeaxYaY2mK7Xmh6JJMbi680hhIktszxDaAcGNOpIPSu1g+Kfg6ayu7tdWdILW1+3O0tnPGWt923zUDIDIm443ICKwPG/xcsbLQzc+FpY7m+gv7S2ube9s54nSKc8OEYIxyvKsMg+9AHC+GYPGfhPw/4pt9MXxAL1/E7PcFtMWQrZPIN93b4h2zSEDlQWAHIQd9e01n4l3uo6RaebrMGlz6lqEP9oNpca3D2iRKbeSZGh2xMXyBlV3dCteir8TfCT2gnTUpXY3j6eLZbK4Nz9oQZePyAnm5A5Py8VDd/FnwRaR6U8+vRBNUTfZkQSt5o3+WRwvBDcEHBGDxwaAPOdA1X4ralY6VHPcala3uoaFcyyyXOlxxpaXschEQOYwFLqoyr5HzEgDjHXfAbxL4j8a6Hd+I9fcxWNwY4LK0EaAAxoFml3AZIeXfgE4G3Fbg+JXgu7nnspNXhKeXcFmmgkWCVIR++2SsvlyBRnIUmsHWPih4f8L6F4ePh7Rr2XS73ULfT4ki0u5tIo45dx8yIGHEnTIROWzxQBw+reK/i7pNxqscWn6jqMWjXNzF5i6WCdSSUMLZ02pyIyFLbPX5s1mfEPw/431bw94rsb2zur+/bQ9Nke4ttLiRr24EytLH5ixhnC9QgORtGByQfcR8RfC/9sppZ1J1u2uEtPmtZhGs7jcsLSlNiyEfwFg3bGaz7f4ueC7gRmDVLiQSxSzRbdOuj5qxEiQp+7+bbgkgZIAz05oA8p16HxjYeIfFniPwmfEkl4mj2H2WefSRvvmEoDxvG0I5CkkhFUjAPTr9H2zvJbxPKu2RkBZcYwcciuQm+KHg6GCSeXWkWKPT01QuYJcG2dgiuvy/NliF2jLA8EZrsYpBLEkihgrgMAylTz6g8g+xoAdRRUV1MLe1mnKSSCNC+yNdzNgZwoHU+goAlrJ8ReJdE8NQRTeINVstNilYrG11Mse8jqBnrXyV4r/aB8ZeKPGlnZ+CrK4s7OC6Ux2KR7p7ra3KynsDjlRwBnJPWvcPjT4Oh+KXhHTLP7U+l3ME63Rd4PN2ZQhoz8wGckcg4+Wk2kNRb2O90Dxl4a8QzeToevaXqE+C3lW90jvgdTtBzW9Xzv8AA34Sr8O/GN1rFxqcWqo1o1vF5MW1oyzKSSNx7Ljg965H43fEj4g+EvihdanozXtr4eRY4YEni32s4C5YkHgEsW6YbAFCaY3CS3R9bUVxnwi8XX3jjwNZa7qektpc05IEZbcsqj/lomeQpOcA+ncYJ7OmSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXH/FbwLZ/EPwfcaHey/Z3Z1lguQm8wyKfvAZGeCQRnoa7CigDwXUPBfhj4T6LplnZal5T3s4jb7ZODJcSnADKvQDscDAyM+tSDIZiw9iK4v8Aa6+G1/c6rZ+MNDiurtpylpdW8YZ2R+kbIBzg/dIHfHqa3vC0Gv2vhzT4vF9m9lrAiUusjAmRP4XOOjHHI6gg9K5a0Le8etgK/MvZPodZZWya3oGoaFcsA0qFoWP8LZyD+DAH6E157oVxIjNBcKUmiYxyIeqsDgj867G0mktbpJkPzxtwPX2/Gs/xtp8cWr2uuWY/0TUuJQP4ZgOv/AgPzU1hLWN+x62Fn7Oo4PaX5/8ABI7y4EdqSTjiuj0KE6J4SMkny3uonzD6qpHy/kvP1asHQdOGr6wkM3/Hnbr505PQqOi/if0zW1q999vvHm6RKCsa+ijv+NKCsuYrGT5mqS9X+i/UoHkHA+XOBXNfEjRfE+v+ENQs/CVi15OQBdBHCsIj1VQfvE4xgc4zXRBiCpZgqqCcn9a4z4JfGHXdU+JjeGrPTrS70i+upHSQ5SWCJRy5YcMMLnBHU4yK2ox5pXPOxtX2dO3VnV/sk/Dubw14du/EWs2slvq2pExRxTIVeGBW6EHkFmGcHsq19AUUV2HhBRRRQAUUUUAFFFFABUGoC5awuVsGiS8MTCFpQSgfB2lgOcZxmp68K/aj+I+ueAbXw2PDV2ltdXU0ry7olkDoiqNpDA8Ev2weKAPNfB3wQ1y1+It5q3xJ8ma0t2a8+0ecHjvZSSSxPBCrgswIHYdDXaeINbuPFV0U/erpIf8AdQdDOeu+T1J64PCj3q9qHirVfEXwm0XUNXECahq6pE4t1Kp5ZLOcAk9VVQee9VZLQW1rFH91piIQR1Axuc/jXFiJu/Kj6PKcNFR9rJa9CjGvlLttQkaKdu6JVC59AzZLH6Cp7q0nWLfeQ3QQj70kXy/+PKBXdeANFjuTDebQsswYwnAPkQKdvyj+8x7+lehPo9uUxHJcRv8A3xITn6g5B/KlCg5K5piM2jSqcijex8+WM89g4/s6+ktWbkCOQxA/8BOUNb1h4u1LTLzzr6ziuZHwGniUW9wwHTLD5H6ng4rrfFXgiCSKSQJHAScmaNP3bH/ponb/AHl/GuFn0HVLBGV4pPs/+0POhYezDkfiBUuM6bNoVMLjFdpJ/wBdTyn4ifDPVvEWtal4s8I6tJrN1LObi5tZR5F7bMTxhehA7EY4HGa+ntJ1JPhx8L9PufHuvPcy2sKLc3sx8xnkY8IuBl8ZwDySBk15JG0tvex3Vi7WuoQ8xsDuIHcf7aHuDWj498NwfF7wXHAl2+n6tprM8cJkJhjkYdGHeNsfK/Vee2RXRSrc2jPIx+Wuh78NUepeL/C2jfEzQbIyaiZNLkRpIpLaG1nWQOuNytNFIVIGcMhUjJ56Y5nWfgN4X1V4zPfayEjt7e2RTLFKUWHG0o0kbPGTtG7Yyg+lcx+yl4T8beGNP1RPErvZ6M0jJb6dONziUN80qnPyocHpkN19Cffba4huoRLbSxzRHIDxsGU4ODyPcEV0HknlGv8AwllfWtKuvDuqzWaDX7nXL2aV0MyPMgUiAGJk4IGA4Pfk1eg+C/hqCwgtIbnVFSPTrvTS3nIWkW5yZZGJT7+SSCMAelem0UAeUeI/g1o93pcotDeXN4ul2mlwLPeLAqrbspSTesLlX45O1gem0Zqr4Z+EVy7ajqPivVZV12fVk1S2utPkRpLZkTYuWaFUckZ3DygvtXsNFAGD4K8K6f4Q0dtP0wzyLLPJczzzsGkmlc5Z2wAMnjoAOOlconwb8NfaIxcS6jc6XDNczwaXLKn2aF51KyFcIJDkE4DOQM8V6TRQB5B4g+C1rJ4U1Kz0nUbu71VtJGj6fJqkqeXa24cMEHlxg44+8QzY4zV6D4N6TPZOdY1LVbvU7h7OWe68yIEG2A8uNAIwojHP8O49zXqNFAHnb/CXRRqs2q2moatZ6s2qT6tFeQyRF4JJkCSIgaMrsKgcMGPHWrPhj4XaB4a1TRr/AEt71ZdLtZrWJXkVlkEr73d/lyWyexA9q7uigDyyy+BnhGyku1hjk+xXImVrZre1JQSqysFn8nz1A3HH7zjp0yK1b74aW+oaDYaVf+IteuItNure8sJnNsJbSSEEJtIhAYYPPmBs4Fd9RQB563wn0R9Wa7lvdTktn1JNYlsGeL7PLeqMecwEe7J6lQwUn+HtUOl/B7QNNj0dILzVWGlxX0MO+WM7hd58zdhOSMnbjGO+a9IooA8f1j4MWlzq3w/itHRtF8Nq6XD3MhNxcoGV4oyFQKyh1yc46nAr2Dp1pokQyMgdS6gFlB5APTI/A/lXxf8AFO7+LnjLx5q3hV1ujBaybTb2GYLXyjyju5IyGGD87evHGKAPqb4m+OLD4feFZdc1O3urmJXESR265LO2doJPCjjqf16V4f8ABr46+JfFvjrVLfVNNR9HmjMqGEBY9NCg4Mjnqp7k856YHFejagsN18JLTw/8QngM8tmlvePHIW3suMNHxln+VTkDGfUVwBGmWulJoug6amn6GhDm1j5luWHRpm7/AEJP9BjUrKCO/CYCpiJbWRq3OqaVa6zqWp+E9NtYL7UXzc6qYeZm7+Uh7dyTwTyQetY11BLqjmXUri7vAOpklyPzPyj/AICK0dMsZtSfy7eISy8bsHEcaehPZf516LpHgeKS3SS6jE7kfemZlX/gKDoPqc1ypTqs92UsNgEk1r+J4+ml6eJP3SG3lHIaNiCP+BA5H5V0Nlr09pA+neJEOraPKm1zOgkkjQ+uciRPUHJ/lXc654Dtvs7OsZgI5EkTtIi+7K3OPcHivPbuGWyuXsdQBGxgobO4xk/dYH+JG7H8DScZ0mXCrh8dHlt/n8i98ffiBr/hf4eac/gyCCGznxDJqNuQRbJgeX5a9AGAI3dsY6kGu0+AvxFT4i+CY7u4KLrFmRBfRrx8+OJAPRhz9QR2riPDkNtqdjqXhLV4/M06+ify0BxtPV1Q9sj519GU12fhC2+G3wyntdD0a70+z1PUXjhCPN5l1cMfu7+pHJ46LzxXbSnzxufN4zDPD1HE9NooorQ5AooooAKKKKACiiigAooooAKKKKACiiigAooooAK+U9R+MmoeLfixD4bk0m0srG2uLm1LKxkldkDcluABlM4A/GvqyvmXWPg7ZeGPiTHr8Gs3FzcTyz3jwPCAFMhYY3A/7R7dqipbldzowqk6seU6UKcMSelXZIRceB9ZjmP7uD99GT/C64b+f86p5DcD0zU3inbB8Otpt2l+0TL8wx+7O7hj+C4/GuJdT3X8UV5of4UUSeFNWlhP74yqJPXaADj9WqoV+ZgGyMZqv8Lf3l/eRNCzie02tMW4UBsYx3zuH5VZZdhb+8MoR7ij7KNKmlaa9H+BPYWsWoajaWc+RBO4hcqecNxxW18MPgj4e+HXiCXWNIvNSubp7drfF28bKqkqSRtQHPyiuF8YX50vwprN6HMbxWzsjA4Ifb8uPfOK5r9i2TU9Q8R+Irq7vbue1trSOEJLKzKGd8ggE4ziM/nXRh9meRmPxRPrOiiiug80KKKKACiiigAooooAK4P4m/C7w98RZdOl8Rtej7AsgjFvMIxh9ud2Qf7o9K7yvL/2kvDtz4i+EmrpYvKLqyAvUWNiPMCZ3qcdfkLceoFAHN+OtN0/SvDGj2OiSrNpum3K2sTiQSYUQlQCw6kEYPvWfqk3mX1vz8iNgfRowR/I159+zkdQ1nwD4h0F7S4+zo63VjctGfKMwOfLDdMkr0/2jXWQzm4to2AO8qFAPUMvKj8sj8K4MQrSPq8pmp0eXset/C26R9KslLDcIWtj7PG5yPyINd9Xz34f14+HtR86V2/su6KvIw5MLdFmA9vusPQV7rpOpR38IwV80KGIU5BB6Mp7qexroozUo2PGzLDSpVXLoy/WfcaTayEtGpgkP8UR2/mOh/KtCitmrnnKTWx5z4w8IrdRFyES5zmK5QbQzdg47E/3v/1V5pbz3mlamZEZra/hJViV4PqrL3HqPxFfR8saSxtHIoZGGCD3FedeM/Cgu/mQql0OIZ2+7KOyOfUdj/8AXA5qtL7UT2sBmCt7KtrFnLa14i1DxP4Uv/Dukal/wj+u3cflwO5zFIe6RydULDI9RnjNeWfszap458MfESfwZJp082nBy1/bTnatl/02VugzxwOHyMetdVqdl5bPaX8TwunB3DDRntn29GFd58P/ABXILn7HfhG1gRhFlYgfbkXO35sffXJ+uSfWlSrfZkVj8tUV7Wjseu0V8T6l8VPiT4B+Kd/e+IEMwvJBv05yxtpYwcL5J/hwOARz/eBORX1prfjHTPDPhe01vxZJ/ZEMwjWRHDSmKR1z5Z2gkkcjOO1dZ4TVjpKK4HwT8W/CPjbxFNo3hy+lurqKA3BZoGjRlBAIG4Ak/MO1eDftI+MfiLH49ufCemTz2+mSxpLbJpsbLJPEwwS7j5uGDKcEDjpQNJvRH1B4t8QWfhbw3f65qSzvZ2UfmSiBN74yBwPxrwrRv2nLPXfGuj6Np3h+WGzvryO2a6urgBlDsFB2KCOpH8VXvhzrGr2nwkg8NeLNOSefyZLRvMmyDbsMBWxn5gCV+gHNYGieCfDehCJ9P0u1W4iYOk8i+ZKGB4YM2cH6YrKVaKOungas9Xodx+0l8Std+G+naHceH4bGQ3ssscpuo2fG0KVxhh6msb9nD4u+JPiPr+rWevQaalvaWqyo1rCyNuLgYOWPGM1PeE32Hvc3JzkGd/MIPtmmQRx2zb7RBbueC0Q2Ej6jFR9Y8jf+zX/N+H/BE+IH7RNr4K+Imo+HbvQpLy0s/LDXMFwFfcyKxGwjBxux1Fer/D7xlp3jvwzDrmjx3UdnI7IBcxhGypwehIIzxkHtXhPiPwVoXiKea41Wximu5TmS4BIlY46lup/Gulg1G50L4V3PhTwxbxQ3Edo9tZztIRtLZyzcfe+Zjkd8cVUa0XuZVMBVjrHU90UhlDKQQeQR3pa+JPg5efFDwx470jwxYy3MdlczbWgulM9qsQ5dlP8ADhQT8pHOBX1/r3i3QPD+o6fY63q1pY3V/uFsk77PM24zyeB1HXGe1bJ3OJpxdmblZPizWV8PeGtT1d7ea6FnA0wghUs8hA4UAep79utagdTHvDLsxndnjHrXiXiT9ozwxonj5dBSGbUNPUBJ9Qs2EgSYn7qqPvgdyD14ANAjxn4Fa14z8XfGO98TrqMkUZO/Ui3MTxfwQBTwBxx/dAJ+vtGv+M7vUriYaTMIrZDh79lBZ/8ArmDwq+h5Jq948urG2juLbRba3tLjWX3StDEI2eMDDyPgA5b7uTzjPpWJ4c0NtXlRkDJYQkKpAyWPoo7sf0Fclao2+WJ72AwtOFP29bYw1gmvLvcBPcXEnRpd0sr/AIdcfkK6bSvBl3dSIt4TAnXylAeU/wDAR8q/U5r03RPDUFlDgxrCrcmOM8t/vv1JrfhhjhTZDGqL6KMUQw/WQsRnD+GirIwdA8Ow6fBGhiSOFDlYQc5b+85/iNdFRRXUklojxZ1JVHzSDrXjfxZtYreeB4gAcywf8B2iRR+Bzj616/czpbwtJKcKPzPsPevCfiFrEep62lqkgdbQu07KcjzWwWUf7qgD6nFY4hrlPRymMniE1sYKXT2VxDqCZD20glH4fNj/ANCH41wXxx8Fa8fizb6v4P0i/vWuY4rxXtIGkCSocZJAwOFQ8+tdxeHFndIeMRkn6hOf512Xjb4sW3wt0fRjd6XNqL6ggAWOYR7CkUWc5BzncPyrLCvVo787irRkeyadNJc6fbTzwtBNLErvE3VGIBKn3HSrFYfgfxAvirwjpWupbNarfwLOIWbcUB7ZwM1uV2HzgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfDGqeJdd0f9oC6ste1jULm0g1SS2Ec1w7IInZhHwTjADqR6V9z18/6ha+G9O8aX/i7WLW2SVJ2kmu5ULlEUkAgc89BwMnis6kklZ9Tpw1OUm5Re2pdnt5oJAksckUpBwrqRkVL4qUXXw9DGZ4xbXCZUMAH+cDB9fvZGPSvN/hj8UrbXdR1HSdWnuJIppWlt3lbdIvP3kz+qenSvT9Qn08eGrvTbe5jv57psqEQ4TkcnPTGPrXLblume3FubjKOuq1W3n6fMz/AIXWwW/nnjugipCQ8BAJcFuvqAMA5HrUkhDzGQHhnJA+pq7on2Wx/tCK4ljtXuIUSKZl4HUEZ7dRWfqesaT4bgF3c3tve3WdttbRE4eTtknt7DmpXwpGlW7rSkl2sZnjfWtP8G2VtJ4kkEcd45jQIvmkEDJ3KORgEZ+or1D4Pf2Bd+DrbVvDVrZxx3oxNNbW4i85oyUywwMkYPJr5Q8X/D7xT4s1ay1mW6Sez1C4dXZjg22MF2K9wexHcAHHFfWnwgsYNL8DWem2albezd4UB64Bzk+5zk/WumkorY8nG+0aaktEztKKKK3PNCiiigAooooAKKKKACkdVdWV1DKwwQRkEUtFAHifxU+NPh/wJrUfhN9Hu2kXyhI6KsMMETYIdMZLFRzgADIxmsTxjp/2LWxcW5UWmo/vo3T7qy5BbHtkhx7Ma3f2hfg7P8SbjRb3R57a11G2Y29xLPnBtzk54BJKtnA/2jzWhqHgafRvh/Y6G19JqVzZW4MFzIgQtJGDhcDOAU+QcngVjXhzRPRy3E+wqq+zOCMPnQ7T8iTE7SekUv8AEp9jWh8MtU1bTTc20jbrK3lMdqrElo36sFP9zHUH14qLTVS9CRE4jvYt8bejj/IqHQLua1u7iGZPntpzIw9Vbv8AmP1rlw/x6nt5s37BtL+v60PXF1XXmTzQ8IXrtMfFaml+JopFMepL9mnXuoLI309Poa5y21RLuOMxvwRWq9qiwb14OK9A+TOks9Tsr1ylrcxSOP4Qefy61ZmjSaNo5UDowwVIyDXCw2ovOVG2RTkMDgg+xrd03WhB/o2qybZF4WYjhh7+hoAqeIPClvqEW14vPRR8nzbZY/8AdfuPY/rXmWseCbmDcloTdxqdwj/1cyH12nv7qfwr3aORJUDxsroejKcg0ye3huF2zxJIB03LnFYzoxkd+GzGrQ0WqPAn1d1NvbeKtLj1aO2kWWJrmMLcxOpyG+YYbGPY+5rV+IS6N8WPDNvot3q72RiuVuQmBDI7BWUKQ/B+8eVNesXWhWk6FSG2/wB1sOv5NmuO8SeErSCN3k0WK7tcZaS1/dyL9UHB+o/Kp5Zw6m7q4XEvWPK/L+l+Z5b4M+E8XgHXotY0mTU/tsasiTO6uu1gQflVfQ9810l7JLLcGWeR5J24aSRiWx6ZPb2qW10hI/8AkWPEV5YS9ra5bMZ9vT9DVa78Va9o10LPxFptpdMR8rMvlmQeqsMqfyrKUubVs66NHlfLSSb+5/j/AJjiAMEEk+uKZuB5bJI7ZqxH4u8OT4+3aRd2reqIHH5qQf0qZdY8Fy/8v8tuf9uOVcfmpFRZPZmrc4/FB/cU1G5c5XHpjJoIxwzE/RsVoLc+EZT8viG3HsZgv8wKmH/CL4B/t+1IH/TzHT5WR7Vdn9xlKBn7v5mkK54zkenWtOS98IwA79cRvaNy5/8AHVNVZNf8JQDMR1C5b/pnE4z+LbaOXzKjKUtov7iKKaS2lSa3lkimXoyEqR+Ned/GDwNf/EDVk1c6wBfpCsCRTLmLaPTaMqSSSeDkntXpNnr1rfOU0fwteXjjvK4AH1+9itJR4pdcwWOiaSnq58xv8P0qoNx2ZjXpqelSNvVpP/Mz/wBnPw5P4W+HWo6X4pkSWS5u5P3PmGVTCY1UADsD83GB1rgPDfwm8P8Aw98Qz63rt6L+SOd20uxVfnC5+RmB6sBjk4APPJxj0w6Xr+oSGKbxOpcjmKzG0/8AjgB/Wn2Xw6Pml5ZLuWRjlmEYQt9Wck1q6k5K0Uc0MLh6bvUn/X3I5a1hv/EutySOoWecfOeqW8I6L+X58+tezeFdJisbKLy0IjRdsQPXHdj7mm6H4attOtxGY0RM7jEhJ3H1Zjyxq/ruprpdoGVQ08h2RIehPqfYU6VLl1e5njsaq1qdNWijRdlRcuwUepOKxNT1vZL9n08JLL/FITlF/wATXOXEM9zma+led+vzHCj6DtWjYW9strvON2K3PNGy3F8cl9Sl3HsgCgfpUUOtajbsVWT7T7SL0/EYqSyaKSV+VODgCjUTHAQ6gK9AHKeNNV16502WOwlitrxgR5smeB6J2Q/7RB/rXlvhmExPNBdKyNbnNwG6jHO33yec969f1q7jliOQCcc157e2gfxHFjCRyWolnP8Asqx/oAK5cRBW5j28oxLVT2TW4iWb3slvaYxNdsFb28xufyUH8q2fjd8GtV+I1vpV3pOqWtpJZwyBLS5jYKxds53rnB2hRjaelZUWtRaBoOv+LrtVYWMRW3jbo0rgBR+qD6M1Yn7IWreMde1/Wri+1i5n8PwgyTRT/OHuJCSNhPK/xMccdOOaeGjZXJzmvzVFTXQ+kfBujjw94S0bRwQTY2cVuSvQlUAJ/Eg1sUUV0njBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAE4Ga8R02CK/1CCK6iSW3mfEkbjIdeTgjuDXtc5xBIfRSf0rxjw/uGo2jEZK4dVH8RCkgfj0rnrbo9LAfBN/11PmyLwGg8ULe2kqw2IkaVYNxV42zwgPp79eMe9afij4h614T1aGzhFvcfuhI3nAkjJOOQR2FdhZ3MchY3SDzHcswYY5Jya1EtdGuGBurCGb/fiDVzKreV56n0LwShTccP7rbv3Oe8E+Otb8X6dcu6WsBilEeY1ZsAjOcZPvXnM/g/xt4m16dr0XbLBKyC7uiY0AB6oP1+UV9A2Vrp0MbLpWiSJnkmJfLBPrxinXNxdRoVWxlQY6u2f601V5W3FGcsF7aEYVZPTfpcv+H4poPBWix3UxuLiDzbd5SMeZzndj8a9O+GYxoNwvpdP/AOgrXnOnTLc+GLRtu17Z5IJAORuJ3hvy4/CvR/hqMaDMT3uXP6LWtHWR5mYLlpyXn+p1lFFFdZ4YUUUUAFFFFABRRRQAUUUUAIwJUgEqSOo7V8V/DnxZ4lX9oOXTvEer3mpTCa509vOc7QU3EFUHyr80Y6AdTX2rXlYm+Fl54qnk0n/hHpPFwkmZTAFFwZwG3njkt97P40nsVH4kcMIJYdU1CxsUZ5LTUCbdV6kM+Ao/BhTNdlWDWrTVogVhkBWdCMEDo6keoODj2rZj06+kuNS8R2cJfTmupFWRRk/K4Ikx3TKgE/Wu3TQbPxLqtlrNvHbzaXdo322Bj92TaVyMd84yf9nPeuGMG3dH1NXEQjTSqaqzT9bbevY4zSZdzPDv2yKflI6H0P0rdjk1Qr5ZcMvrmtHWvh9FbWkbaA0oeHIEcj7jjsAT6ehrnUv77TZdt/bSKy8HKkV3o+Vdr6bG9Zrf2eXUBgeoq5bxSXkrvclVGOhrCk8TpPDtCt07DmsrUdRuLPTn1Ge7t7SwB2ma7lWJM+gJIyfbrQI6i31ObRr9o7WQNFJ/yzYblz64/wAK0z4xnRdzW1uy+8jRn8iteYfDbxNoPjXxdcaPbaw8t2lu0waKIhGAIBCs3U/NnpjFcB8f/EfiDwh45PhzQrZRBJBHPBOVaWaYMCDx90YYMOF7VEubodNB0Un7U+grr4gyRfdsrYe7XBP/ALLWJdfEHU7ucQW8lrbqQTmNCzdOmW4/SvDfgba+NfEHxJ0uHxTZar/YTLK8/wBosmjibEbbRu2j+Lb3r2Pxp8Qfh/4A8ead4c1HSLYGaMSXF2kSuLQsfk3ggk5GSccgYODmocaj6nSq+EjtB/182UQFMfPUDg+9atmsGt2L6NqpLxyDdBL/ABxOBwQfX/8AV3pviOC3g1u6FmYzauVliMZBUo6hsrjjHJxWchZJBJEdsiOCprm+F2PS/iRUl6o5KSCSx1C4sL5QLi3cxvjofRh7EYP41oW9hDNgY61o/FK2Uz6TrsAwl1H9nmx/eHK/puH/AAGqWhy7guaykuWVj1qNV1aKn16+pZ/4RyFhnA/KnL4bhB+6PyrcjfgVftFDDJGaErkSqyirnMto0UKZ2D8qTQdGTVdZFuQVgjHmTMOyjt9SeK3PEEqxW5A4OKg8NbrLwte37cS30vlRnvtXj+e78qpRXMZ1a0lSclu9EXb3VWSP7Ppm22soztjSIY3e+ayjI8h3Sbm553Nkn15poUrgg5PTFLBDLNLDBFgvLII1+pOP61TbZwqKijvNP8ZeHtPi+z2tnc2wXqiQdffIPP1qeXx/pwH7m1vZD2yqqP1avIPjne2HwzisZpLLVdTnv9wjlE6QwIVx8pwpOcEEDjjv1rD/AGddZh+JHiPWrPXbZYktrdJ7eOCRgcbtrbjnnqvpXUvaHmP6ne7bZ7RcePLiclYEtbNf7zsZX/LgfzrHfV3vblZZ7lrho2ySxHA9gBgD6V4V8W9Q8ZeG/iVrWneF9OnfSrd4/s+NNFwADGrH5mVs8k9690+E120vwZHiHxtZ28d2sVzNcP8AZEt3WJGbHCqMcLVRjK92zKrVoODjTizqk1C0ktCGxyKzEt/tBKwXDBfQV4T4a+NWh6vOltf213pVxIwVMZnjJJwBkAMPyr1LV7u+8LBG1cpaxu2xJJpFRXbrgEnBOO1aHEa89pd2jk20oz6Gql1LeFGN3KMAcAGqNn4lOqMY7AxXMoXcVhkEjAepAJ4rnfEPjDQdJ1GW18Va7Fp80JHm2qxvJMMgEDaoOOCDzjrQBtWKXmq3Dx28MsqoNzCMbiR7VXGhajPrWpW+ox+RcSWhnaJDkxQKhKpkcZJwDjuTXongjXtH1D4cvr3g62aa3MMzxpMNkkske4YfrjJX8jXzzaftRXk2sC4m8G2E00ii3BjuWWQoTnbkqQefas6lPnsjswmK+rNyS1aPVvDfiDwl4Y8HA+NLm0hs9RuJERLmAypIVPIICkdAvWvQvh7ZeF7fw+t14Ht7SHSL+RrlWtUKJI33SwB6fdxjjpXz3+038P8AX08O6KdDtGvdHguJHeGJS88EsxUKvH3kzwCB1PPavffhN4fufC3w48P6LfY+12tqomAOQrklmGe+CxH4U6ceWKTM8VUVWtKcdmzraKKKs5wooooAKKKKACiiigAooooAKKKKACiiigAooooAZcDMEg9VP8q8Z8PjOoaeM/ddTnPfsK9pIyMHvXimkLjVbZXO1ElUMenIbFc9fdHpYD4Zr+up5gkl011O0kSM7SuXXphixyMH3resgxKldOBP+8BWfcW97JrmoHYqSG5lLRuCNpLnitO2sJmI8yCHd7SFa4ran1imuVHRwy6uLYCKC0ijA6GTmsbUzkFr+62H/nmkuc/lV6HS4yv+kW6AepuTj8qhuoLWGF1trcM+OqJn9abTM4uKehoaQ0LeELQWylFM8okB6s/GD/3yRXqPw7Qr4aQt1eaRv/HiP6V50bdY9H0qO3DLEYBJtIwS5Y7yfxH5AV6f4IjMXhawDdWVnP8AwJif611UF73yPn8xknB26y/zNyiiiuo8UKKKKACiiigAooooAKKKKACvjf4gfC/xb4Z+OdrqvhaCRrPVdSEtteJEJI4Glb50lByABubrwV/HH2RRQB5B+0L4/wBW+GPhXR7nw5baexnuDbMLiIlVUISNqqy46Vx/7NfxS8TeNfF+oWGvRW0enizaeFbW0EUYkDqD83ckMep7V9E3Frb3IQXMEUwQ7l8xA20+ozUqqqKFRQqjoAMCgd2fLvx2uPi1H8Sb+LwX/wAJG2ieVC0X2KJjEDsG4BgOu4HPPevU/gVB4kuvhqU8ex3z6wbiYf8AExUmTZxt69uuK9QooEfB/wDwrv4z38pH2HXiN3/LW9CA8/7Tivqz4p+ApfiH8NYtDkeHT7/dBOruu5YZF++ML14Ljj1r0SigDxj4UfAHRfAOs22tHVL/AFDV4AwV+IoRuUqfkGSeCerGvYjbQG6Fz5EX2kJ5Yl2DftznbnrjPapaKACvEPj58EIfH81tqnh/7JY6/wCaqXM0uVSeLGMtgHLLgYOORwe2Pb6hvUmksp0tZfJuGjZY5MA7GI4ODwcGgDw228HXfgjR9I0bUNUbVGjtiiXBj2BQGOEAyeF3AD2pc4zx6YrxP4fePfFGtfElrDxhq91euUlgEUrAJHIpydqABQflI4Fe3qCCRjODXFVVpHvYOfNRXloWdVtDrHgDU7VRuntD9oiHfK/Nj8t4riPD1xuRGB4Ir0bwpceVqZifBSZSMHuRzj8s15xLZnRfEeo6Wc7YJj5RPeNvmQ/kRWU1dJno4KdpTpP1X6nZwtuQGtSylAGDWDYS7owCa0Vk2oTUpm8430MvxZdfKVTkngD1roNchWx03TNMU/8AHvCM/wC90z+e41zmnQ/2r4vsLcjdFG/nyf7qc/qcD8a2/EE32jV52PIRtg/Ac/rmrjs2cuJ0lCmuiv8Aov1M7hXI6k1g+NvFFx4N0B9cso4Zbq1kQwpMCUZywHIBBI5Pet5h82e+MmlufhtbfEnw5d2V9qFxYpFMjRtAFYlgD95T1HzDuOR1q6avJHJiZ8lKTNL4XeI7H46eDZp/F3hmz8iwvlVEaQyRySqgO4AgEYD4wSQc16vpmlafpUIh0uwtbOIDAS3hWNfyAFcr8HvAifDrwXHoS3YvJBPJPJcCPy95Y8fLk4woUde1dtXcfPBUF9aW1/ZzWl9BFcWsylJIZUDo6nqCDwRU9FAHktz8APAx8Tafren2c+nT2lzHc+Rby/uJCrBsFGzgZHRSKk/aC+Gmp/EzRdKsdK1C0s/sk7Tv9oDEOSuBjaD05/OvVqKAPBP2f/gvrnw18VX+p6rqWm3Vvc2ZtglsX3Bt6sCdygY+U/nV34j/ALP2neO/Hl14iv8AWrm0iuI40e2t4V3EooXO8k9QB/DXt1FAHL/DvwRpfgLw2NE0V7qSz81pSbmQOxZgAegAA46AUjfDvwa3k/8AFLaIpiYPGyWUasrA5BBAz1rqaKACiiigAooooAKKKKACiiigAooooAKKKjuJ47eIyTMFUd/WgCSiuR1rxvpulPsu7q0tHxkJPL85H+4uTWXD8TdIkYAalY/8DjlQfmVxUOpFdTojhasldRPQqKwtN8S2d/GHgZJl/v28iyr+hz+lacF/azsFjnTeein5T+RqlJMylTlHdFqiiimQFcFP4aeO/lkVcxmYvj23Z/rXe0hAPYVMoqW5rSrSpXt1PKb7w7cDXb6Z0VzLKz5IxkHkfpV2PTMLiS2U/WvSDGhOWRSfpSeVH/zzT8hWfskdax8rJM4CLSIjyLK3+pNF1pjSRlIoOf8AZXiu/wDKj/uJ+Qpdij+Ffyp+yQvr8tzi7rRJZFiCoFEcSoo9MAf1zXXafbi0sLe3HSKNU/IYqfav90flS1cYpHLUrSqKzCiiiqMgooooAKKKKACiiigAooooAKKKKACiiqtxf28DbGctJ/cQbj+nSi9hpN7FqiseXX7dH27CG9GkRT+WasQ6rbOVEhaEt08wYB/HpS5kU6cl0NCiiimQFFFFABRRRQB5V4j8P/CzwDd3/iLXbfTbHUL2SWczzsZJmd87jEhyQeT9wcZrmrSeO5giltrhZreVA8cq9JEIyrD6gg1t/tKfDY+PPBhutNi3a7pQaa2CjmZMfPF9TgEe4x3NeffCXwV4w8O+BPtHieBYLPeDbWzsTPAjZJLjoq5I46jJyBWNaF1fsd+Arck+R7P8zroZnhnjmjHzxsG/GqfxRtFF5pOv24/czp9mmI9fvIT+G4fhVgDAI3ck4JrVtraPXfD+oaDMwVpELQMf4HByD+DY/AmuVarlPW5vZTjV7b+hy+mzAopBrQup9kBOe1cvoU0qEwzqUmjYpIh6qwOCPzrWvDLctDa2w3zzMI0X1JrI9hpXv0Og+H8It7PVNbmH3v3MWe4XlvzbaPwqs5JYsxyzHn3JrZ1bytN0+00e1IZLdAZD/ePX9SS35VihegJGcZ+lavRKJ5HP7Scqvfb06CMj5dY45JpGBxHEpZ3OM4AHJNeG/Cr/AISXxr8eFmsLrUNK2TGW9MTNG0NtGceWw9+Fwe7dK9Fv/jBp3w/8d2tveaa9/CYf37xOBJb7jwVB4YkdiRwRzX0jpdnp0kx1m1sI7e8v4YzLM0ISZ1Ayqv3yNx4PSumjCyuzycfX55ezWy/M0qKKK3PPCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEYhQSSABySa8n+I3i+eG6Sw0tiL2VdwcDP2eM9CB/fbBIz0HNek65JssdnI85hGT6A9f0BrwHTA2t6hqWpS9bqdjn+7HnAA/4AAK58RNxVketlWGjVm5z2RStrSODEgTzLiYlvMYeZJIe7c9v9o1ft7e+uUYxrdTIOvlDcB7ZVcfrV7QrSLVdQ2y5W3dWnn28HyU4VB6AnH617JpuiwpZxrcKQdoxFGxRIh2UAY6Vz06TnqevjMwjhWopXZ4BLBGs+4lopk6lkKuv/Alww/EVrWWu63bRbobz7bbj+C4AuF/764cfrXrmt+F4b+LDqLlV+6spw6/7kg5H415jqng+6tbyR9O82XB+ZUwk6f7yHh/qOtOVKcNiKONw+KVqiSZ0Hhr4iw747e+U2TudqCaTfA59Fl6ofZhXpdjex3iEqCki8PG3Vf/AK3vXzvf20kW6PUIhlhh3MRUkf7aHt710XgfxLNpN3Bp97N/oxwtpcO27y89Inbuh/hPY8emLpV3e0jlxuWR5faUT3CorqYW9tLMUdxGhcqi7mbAzgDuajsbxLuMlcrIvDxnqp/z3qW5hFxbSwl5IxIhTfG21lyMZB7H3rs3PAaadmeU+DvjVpuu2dxf36abYWFvDLPOiaj513bInUy2/lqw7f6syY74qf4l/Fix0PwjrN34XuLa81qwgs7vyLmCXy/JuJI1Vj93OVfOA2Qeo7Vev/hJouq311d67f6rqlxNZS2KSXDwq0Mcg2kho41LtjADSFzxVC5+COg3en6paXmr67cf2jaWtlLK8kAdY7dlaPbtiAz8igkg5HvzQIn8VfGLRNHWxGnwXeozSaxDpN3B9mnhltDICdxQxFmOBlUwC/O0nBrfb4jeFl1caY2pSC7M62vNpMI1nZdywtJs2CQj+AkNnjGeKxrn4RaNdRXL3OqazLqs+pwau+pmSET/AGiEFYiFEfl7VBI27Mc/SpW+E+iPqzXct7qcls+pJrEtgzxfZ5b1RjzmAj3ZPUqGCk/w9qAGeB/ipY+JdAvNTn0rV7QW969mY4NOurotgttYbIc87TkYOw4DYJGUt/iPBq/jPwfZeHJrW90LW7e9le4MbrIrQbcAAkbeSQQy5+lQXXwb0S40ybTTqmsrpz6kdUS1LQSRRyksWGx4mEiEkfLJvxtGMc5u+E/hToXhi80O50651Fm0f7X9nWV49p+0EF9wVB0xxjGPegCjqnxRt/D/AMRde0nxG8VpoWn2dtMl3HazSMrytj94ybgq5wASAMnrXRD4i+FTdva/2souE1D+y2jMMgYXG0tjG37u0E+Z9zHO6s/xV8LtF8TXfiK4v7rUY31y0gs7kQyIAiROHUplDg5HOc/QVmWXwx8v4xX3i93gitfsCW9qkTFpfP2bGndSu0ME+Ufeznn0oAd4r+MOiaX4G1DxJoltfaxBa7Nh+x3NvbzZlEZ23DRFCASeRkEjHcVtX3xN8KafJHHqGozWspjjkkWWxuF+zrI21POzH+53Hp5m3Nc9/wAKO8Mvaa7BcXOoSf2zbpbXDRLb2wCrIJFZUhhRN25QdzKT26GrGr/BrQdW1k6vfXd3PqckKQ3FxPaWVwbjYMKzLLbsitgAZRVyAM0Aak3xY8EQarqmmz69FFeaZ5n2uN4ZV8ry2VW5K4PzMoGCck8Zqb/hZvhP7O0p1KUSLdLZG1aynF15xGQgtynmkkc8L0qvP8LvD9zofijSbs3c9n4hvm1C6DyKDHKSpHlkKMAFARnPvkcVnWvwc0K0jtmtLy8tb60uVurW9tLWytpYXAKkYit1RwQSCJFb2xzQBPD8VNNbx/P4dmsb62tYtMGpNf3FrcRBBnkSI8Q8tQoyZGIXPy9eKur8VPBx069vn1Z4rezt47uXzrOeNvIdgqSojIGdCSAGUEc9abf/AA107UtZbU9R1PVLm5n0xtIvd5hC3tuxJIkAiG05PWPYeB75yLj4K6Bd6bfWmoalrV29zp0OkpcSyxCS3tYpFdYo9sYX7yjJYMx9aANqP4peEHuWtzqc0cqXUdk4lsbiMRzSDMauWjAQN/CzYB5wTirek/ELwvq95Y2mnamZrq9nntoYvs8quZIADKGBUFNoI5bA5GM1j6j8JdCv7jVpprvU1bUryzvpgkkYCvbLtjC/JwCOucn0IqLwb8OF0T4o+LPF1wLYDUmAsoYXZvKDBTM7AqAHdlU8Z4zyc0AekUyaVIY2klYKi8kmql1qdtbq/wA4kZRkhTwPqeg/GvNPFPjxZC0WmSRTSg4E3WCI+o/56N+n8qidRRWp04fC1K8rRRr+LvG8VjKbSIPLdsNy2kTbWC/3pW/gX26/WvNdT1XU9XbbcXkixN0gtcxx49gOW+rHFVYArTOX3sZX3zPJzJcOe59vau38M+EZ7xib2N0U/MYQ2049ZG/h9lHP0ricp1XZH0UKGHwMOapv/Wx55JpGnx/661BbuzEE/p/jV7TJL3Rcz6JeSJEPvwOS8LD0ZD0+o/OvXpvAtmYtq2lv0/5ZyyI355rgfEfh6bQpjNaM4g3hGEnWNj0DgcFT0DDv1olSnDUqljsPiX7O33nbeBPGEOpRtDIDBJEB51uzZMOejKf4oz+ld9XzYly9jeW2qacmyaFjmI/k8Z/2W6exxXvXhbUY9Q02J4n3xlFkiY9TGwyufccj8K6KFTmVmePmeCVCXNHZmzRRRXQeUFFFFABXzZ+1d4+8Y+Er/TdP0eaC00W/hLeekeZZHVvnjYngDBXpgnJ5r6Trj/iT4H8N+N9OtIfFqE2tnN5yMJvKwSMYLeh9M9hQB5dpN7Hqei6XqUQP2e+tkuIyDnAIwyn3Vgyn6VftZntJVliP7yM5z6+341qatpvh/RNM0fSPCpg/s20SZVWKczBCzBiCxJOcknBPesjaojOev9K4Zrlk0j6GhN1KScupX8Z2MUerWmtWgxbaku2Uf3ZgOv4j9VNXvCMCW63et3IDeUfItlPdyPmP5ED8TR4jkitvAUKXBIkmulaDg9Q2Tz0HGevrUuizw33gvZCczWU5Mq4P8RJBz34P6VNveudHtJPDcvS/L8v60K00plLyM26RzuZvUmlsrSS6vobaLJkmZUHtk/0GTUeFy+BjB4rgPjjd3Fp4DmntpZIpTdRKHjYqy4JPBH0pxV2kZVJckHJdEdjN+zsrfFmz8SS6uL7RvtJu7i1uUxKGXlEBHysmQo5xwMc19CV4r+yXq+q638Mbi61vUrvUJl1CSGN7mUyMqKkeFyecZJr2qu8+bbuFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGX4gG62gHbzlB/EEf1rwLw27W+kTQH5XWYQuPTgr/MV9Ealbm6spYlwHIypPZhyP1ArwPxPaPp3iW9jVSkN+PtMWeMOT8w+ocH/voVyYldT3cmmrypvr+hc8CzCPU4oSebiyaNB6ujBtv5Bvyr3aGVJoUljO5HUMD6ivmwtJkTWkpgmicXMLjqhz1/Bsgj0Nes+APF0Gp2TLMFgkjbbcQ5/495D3/wCubdQe3Q0Yea+ErOMNJy9qtjvagurSC6UC4iR8dCRyPoeoqeius8FNrY53VvDyXEDIoFxD/wA8ZuSP91uoP+c1494n0JtGnIRWl0+UkKHXlG7oR6+3ccjmvoOsPxJo8eoQSEwiVXG2aLoXA6EHsw7H/wCtWFWkpLQ9HA4+VCVpapnlHh7xlcaSkaXomuLaMbUnjO6aIehB/wBYv6/WvWPD+v22rW8MkUsUiTDMU0ZyknqPUMO4NeNeINBm0h2lX99YucJKRgf7jj+E+/T+VUvDmrv4evpJoxLJpszA3VuPvxMOkij+8PXuPfBrCnVlB8sj1MVgKeJh7WgfRtFY+ha1BqNrCwmjkEigxSoflmHqPf1FbFdqdz5uUXF2YUUjuqIWdgqjkknAFeW/tFeMPEvgnwL/AGl4WtIpC0giuLtxuNop4VwnQ5PGTwCRwc8Mk9TrxT4g/tF+FvCeqXml29pqGp6nayNDLGieTGjqcEFm569wpFeafs6eJfGdt4j1TW/Eq6jqGm6lbgGS6m+YyKcoVDHhcFhwMc1r+LfA/h/xT41vvEmqWjCa62lrZZSI9yqF3HGCSQBntWcqsYnTTwlWpqlZeZ7JpvjqTWfg7L40020jjn/s2e8S2kcuqvGGypIwSMoR2r578PftO+LtT8Q6bYPpOhrHdXUUB2xy5AZgvB3+9egabbw2GlJpNivlabGGC2yuREAxJb5enJJz9ajj0vTUI2adZqynIKQoNp9uKz+sLsdSy19ZHe/G34lr8MdB0/Uf7OGotdXYt/J87yiF2MxYHB6YA6d6zPhN8cNE+I2rHSrPTdRstSWFp2WRVeMKMAneD6kDkDrXI65o9jr9rHbazBHeQxksiTsx2E8Ejng/Sj4baLpXw81m91DQ7Jd15GsUqSSMdqg5wh7ZOM5z0FNV4vcieXTXwu59DBgWKgjcOo9KWvh74r6j8QNN+I2peMtOmu7SGVgIZbKQuscKjCJIvTGOTkYyTX1d8Ptb1b/hWthrfj+Szsr02/2m5cDykjj6qXycBtuCegBOMVsmnqjinCUHaSsdnRUdvPFcwRz20qTQyKHSSNgysp6EEcEVJTIEYhQSSABySa898c+MRYiO3tYzPcTAmGDJAZenmSEc7fQdT/LqfFGoxWNg/nSBI9pklb+7GvLfnwPxrw4SXWs6pLchGN9qD/IinmOPoqj04GM+xNc9apy6I9XLcIq0nOfwoj1S8vdRcjUbt7gjkxKQkEfttHH55NXNL8PaheKHji8qE9Jpf3SY9ifmb8BXoHhTwfHDHHIyRu6/8tmXKqe4jU9f9413NrYW9uQypuk/56P8zfn2/Cs4UHLWR2181hR9ygjh/CngxbIrOBunP/LxIm3b/uJ1z/tH/wCtXeWtvHawiKFcKOSTySfU+9TUV0xgo7Hh18ROvLmmwrA8Y2UN5prJMoPmq0De6sp/kQD+Fb9cH8S/EMWnaa6pIpmcNDAoP3pWGM/RQSSfwom0o6jw8JTqJR3PHbd2nA3dZdpb6soB/XBr0z4Qahuga1Y/6iUxjP8AddfMA/76D/nXmloBFCmzJIZMZ9uf5AV3HwpB/tS/xyPNtcfXa5P6Vw0HaZ9TmkU8O79D2WiiivRPjwooooAK8n/aj06XUPgrrnkLua3aG4I/2VkXcfwBJ/CvWKZNFHPE0U0aSRuMMjjII9CKAPjX9nUzL4Y1KGaGZFW5EsbOhCsCoHyk9eR+or1gtkP7DIrhPF/xa02y+IEmkyW0yK14Y7i6m+RIUY8Mo5JAG05446Zrv5bbEMc8UsNxayZ8u4gcNG5B6ZriqJ35rHv4eUVFQTu0R/E9pIfDui26SxCBzloyPmZgnBHPTk9upFSfDdZJ9H1iMyqbcohEYXkOVPOfoo4pvjmMXXhXRroQF5o5vK8xUBKqQwwT2BIH41Y8ExQWWjardtbNFcqBCZD91hjhR2zk88dxU/bOj/mEa63/ABuVPvbccMwyayPEt9oGnWdrN4tS1k0trqPKXMfmIzZyAVwewat6ztmurqKCP7zcFuyj1NePftAaPq+tWmj3HhyCbUfD6hz5kS5czbthJQc7RgYPuadON2YYipyQdlc+r/An/CMNoCv4IXTBpDyMw/s5VWIvwG4XjdwM966GuL+DXh2Lwt8M9A0uLBdbZZZiO8r/ADv+pI+gFdpXcfPtW0YUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFec/FTQGvLF57aMmeMm4iA6lgP3if8CXke616NVPVrdrmydY/wDWoRJH/vDkfn0/GonHmVjbD1XRqKaPnCzLTBGiILnMkR7Mf4l+hHP41Uk/tCx17Tr3QJfKmmbywH5AX+JJB3UYNb+tWH9m63eQWoxEwF9aj/ZOcr+B3D6YqnrH+g3mn6jD/wAek7ZY9l3Da388158VaVmfYVantaDlFXuv6R6lpetapc26pYFI4V6ZXdj6Z7elaNt4g1CynC6nGk0JPLRrhl98dDXI+GNWEFu1rN8kycfWupsUS7Us5yR3r0z4pu7uzoV1/SyVBu0UnpvBX+YrTRldQyMGU8gg5BrhrhFWfySAQfWrVk8+isHTLWjH54vT3X0P86BG9qOlRXe9k2pI4w2V3LIPRl715v4i8CRxyGazP2KQdFJJhP8Aut1T6HI9q9PsdRtb0f6NMrt3Xow/CrZAIweQaznTjPc6sPi6tB3gz59hg1rwvLI8MTxQSNueKRfMtpD65X7p9xg11+hfEu3wsV+slow4Pm5mi/CReR/wIV6NLpdo5JEXlMe8RKfy61xPxM0220XwZrmtxW9nPNZWks6rcwqclVJHKgHrislSnD4Wds8bQxH8aGvdHzx+0h8Sdd8WeIo/B2hQXEWm71UJASx1CQkYII6oD0Hc8ntj0rR08Sf8Ijp+neNbpr26iiCSRup2EDoG4w7DjLHOT+dedfCPX7fx7qF4+tWkOl3GnqkkF7YBwyyMSOjEleAehFerXc3ivQ7Y3VrqMWt6aoyzPH5jKP8AaAw34gmipJtWY8NQpqXPTd77X0/HVfiVkG4Hc2fYc0MSOOQPyot/HdlOgOp6CjA/8tLV1YH8Gwf1q2niLwbMB5iXdsf9qCTj/vnNYWT2Z3yVWPxQfy1KakE7V4HvjFP24yQw98cVdXUvBkgwutrH7OWXH/fS1LHL4TblPEFt/wCBCj+Yp8pDq23i/uMwY5wCfqc0rDoQdp74Oa1GuPCcQy2uwHH92YN/IGq8ms+D0JxeXVwf+mcUh/8AZQKOXzBTb2i38mUggwc5IPX5c5rnviXp2s+KfBMug2Grvbw+YJfIkb5JtvIQnqozg46ZA4rpW8U6EZBHZ6LqN25OFD4XJ+hYn9K1IJtdnAaw8L2Fip6SXkuSPwABpx0d0xVoOUbVI2Xm0jzH9lDUvGWk6veaLqsUieGIi6sLwlfImHaI4OcnqOnfOev0tqGu21tbvKhUqgyZJD5ca+5Y/wBK+cPjZ488Z+BrXTfJvtNY33mLm3jH7ort45553evauo8DeH77xn4Q0XXNVv7u6lu7dZWzGzhWyQcZO0cjtXQ5ytdI8yGGoqfLOdrer/Qm8YeJ/wDhIJGt7VnksQwaabBXzyPuqo7IDz7nn69V4D8NyRP9ou12Xcyjco/5YR+nsx6e351p+H/BEVjMszRkOvKyzkMy/wC6o+UfXk12dtbw2cJVOFHzMzHk+5NRCk3LmmdGJxtOFL2GH279yZEWNFRFCqowAOwqnqGp21lCzvIruOBGhBZj6Yrmb7UbjWJXEEjxWQO1VU4Mnux/pUGn2kC3RSRQuK6Txy/Lf39187XItYz0SIAn8SaqSX17bMGW/mb2bDA/mKmvTAkyIpAB96tOkRt+VUr60AZd9rupvF88S+VjGEyu4+/t7DFeJeKv7WbxEl7rUqXMTHyoPJXaidxHt/h/XPqa9omvVWJ0JBUdK4HxgqTaZqDbR+7jEgPowYYrKrBSizuwGIlRqxSW+hl+UVBXO5okJduxkfgD8BXpPwl04rbS3hHyTTNKD/sqPLT+TmvNkgkll0/Tg+24uGV5G/uluB+Qyfwr6A8P2KWGlwQxp5ahRhf7oAwB+AA/WubDxvK57GcV+WmqfVmlRRRXcfMhRRRQAVBfSeTY3Ev9yNm/IVPWf4ibZoGpN6W0n/oJpPYqCvJI+VviF8MW8b6pps9hcQ2d4AYrmWUEq0YUsDgdWGMe4PXij4eeJYPDFvb6Ffzrc2c4/dxzyYLkDqp7Eev4GvSrVJPJv/KI8/7FcCP2byzzXzL4x8F6ndXQ1PSvNudwBMW75kx/d9vbqPeuJO9k3Y+i5ORTqQhzN2ufTV5qsOp2dvYWcH2ezjcSkySBmYjJA47ZOanhvbeys7izu4HmtpZPODRSBWU4HXP0rw3wpbavB4OElxeXsepCKRwjKSykZ2ggj2H51w1k3j/Xb62eRdUnjjkV9s2YYjg984GKIpyb12NKsoUoQjyN82tuvz63PWPi38UrfQ9Im0jwzBJHe3qFJLt23FU6EKRwD9Kt/BnWtc1bwXbx6vapFa2hItLnlXuFZskkdMA8bh1/DNLrHgmw1eyt11GKLyoH81EiznOOQW7j1+legGMQ6To0W0IUso0KqMALk7Bj/dxQppxtbUmrhp06vPze70Xy6nqfght/hTTSTnEe38iR/StysDwJ/wAipYfR/wD0Nq367IfCj56v/El6sKKKKoyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDx34rwrp+raZdIPuTyR/8AdQ+PzVvzrnJbV5NDutPuImC7pHtWYcSBSQyg+o9PpXZ/Euxm13X7DR7LabqV2cbukaLHgu3oMufypuh2/9oWl/4c1FPsmqo/2m2Eg5WQABsHupxnI6hj6VwzhebPpsLX9nho39X3tfc4bQr5jaW/nNukgPkynuR/C34j+RrsLZrxBvs5sxnnBNdLafD7TX0+3e7hEGp/ZxFM9u52O2OpXocHvgVyt7o+r6BKyNG8ttnAdASMV1wvyq54GJcHVk6exoxQahM4kZhvHNXzNezKIZQqjuc1h23ikQr5ckbK+MEEVGb+41O4EdgJDKegAqzA3tVgFpGk8M2ydOQynBFXLbxdd+Wu6OFyRn5kZc/iMj+VYEXhfxLfzKlyscEWeWZ+30611UXgXTyF+1z3UxAAwH2L+nP61Mr20NqLgpfvNilN46liU5s7YsP+ng/wDxNch488Uv4m8LalodwLe2gvojDI8RLuFPpnAzXoQ8CeHc5awLn/bmkP8A7NVPxH4E0e48M6tbabp0MN5NaSxwSrnekhQhWBzkEHBrPlqdzrVXCL7Df9ep4b8PfBNj4PhujY3VxcC9WMsZgoxtzwMf736V29heS2F2JrZyAPvJ2YelfPXwB1qZvFd9Y6jcTSy3EGU82QsQyNkjn2J/KvfMD5R15wawqJxlqzvw8oVKfuqy7FHxzpEFhLb6vpqBdOvjiSMDiKU88egbB47EH1rJtIopgOBmu4tbT+2fDmqaK5BZ4y8B9GByP/HgPzNeb6FcMdu7IYcEHsaxqLW/c9XBVHKDpyesfy6HRw6HDMucD8qk/wCEbh9B+Vadg48oVoQHe4pJGkqkkYMfh+JOQg/KqeoWsVuOFFdxJtjhYkdq5jTYP7T8W2duRmJH86T/AHV5/U4H403HWxEa7s5S2RvWltH4asIVijT+1Z13SSMMmMeg/l7nNZlxd3Fw/wC+lkkz0LNx+XSptXuDfalPKWO3cUH0FU8MWG3rjAq2+i2POinL357sw/Gfg3w94x061i1+bVLSW1ldo5rFUcEOFGGDehU9PWvRfA+u6J4S8I6ZoVp/aV1FYxeUsrwqrPyTk84718ofG3Wb+Tx/DY6bdTxPBBHCFhkK5diW7f7wr670/wCF2kw2VtHdXWozSpGquWmHzEAAnpXTBTUVY82q8O6kvaXuPuviCpBFpYhM9GuJQMfguf51j33im4vAFnv02N1jhGxPx6k/ia6q1+H/AIcgxmxMx9ZZWb9M4rWg8OaLAAItKsVx/wBMFP8AMVXLN7sh1sLH4Iv+vvOP8PahDFD5U2AymptQkt7i43QyGNunFbWueFLe+bzbJltZsYwB8h/AdK5DUPDmuWD+ZFF56DqYzu/TrWp55ZutMl2iTz2LHoTVJ31NE2+cuwcdappqupqfKls58j1Q8VNHaa5qjCO3s5UU9WZcAfiaAMrUrqSOYRoTI7fzqPxBouqx6T5txavDYI8clzLJwX+YbUUdcZ5JNel+FfB8GlsLm+23N71BPKp9Pf3rpry1gvbWS2u4kmgkG10cZDCpnHmi0b4aqqNVTavY8Z0XSDb+PNLS6yZZoVuXz2LKRtH0DY/A17ZWLqXh63vNb07VFdorizBTCjiRD/CfoeQa2qmnDkujXGYn6w4y62CiiitDjCiiigArK8WHHhnUz/07v/KtWsvxSu7w3qg/6dpP/QTSlsy6Xxr1PJI4pJLTU4bZgLmWynWJj67f8M15vps8yRx7YyRjgrzXplnG1wLqGIlJprWaKI9NrFDzXl2mRSFUaOZkwOhGcV5s9kfYYJ6y+X6nSWN/ch12wAt/tAj+ldEINXng3yTW0CHkfJmuatJ5FID6gI/+2RzWpJLZmPL6zdPJ6BMj8sVKOqa10/Ip6qZow6z6hCeOiDmukSZ7nQdJuJhiV4vKyRgsqNtVvy/lXMXciLEzW9tLK3/PWVAgrqHd5dI0czqElNqoZR2AY7T+I5qodTlxfwx9f0PUvBC7fCtgPVWP5sTW5WV4Uj8vw1pi/wDTuh/MZ/rWrXox2R8hVd6kn5sKKKKozCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCJbeFLh51ijEzgK0gUbmA6AmnNDG0qStGhlXIVyoyPXBp9FA7sKOo5oooEUp9J0+dt01lbO3qYxmpraztrUYtreKL/AHEAqeigAooooAKKKKAPFfH3iT4Z+B1vtDhj07T9dmZCYrSz/ebmIcF3C8A5B5PQ1SIwCV5zj9K5b9qH4VeIPFfjrR9T8KaXJevdWpguWVlVY2jb5WZmIAyGx/wGui06z1Cwsba11hFTU4EWK5VW3L5gUZIPcHr+Nc1dbM9XLp6Sh8zX0G5Nvq9u2cKzFD+P/wBfFcT4lsf7I8a6jbqNsUr/AGmIf7L8/ocj8K6liykFRhgcj2IqL4q2wnstF16EcKfs8xH91+V/Jgw/GsGrxPVoT9nXXaWn+RHpcu6IVr2z7XBrmNGm4WugiYZBrJHfURe1O4C2h57VS8DDy4Na1Vuqr5CH/wAeP67azvEF35dq3Patu1gOm+CNPt3GJbo+fID/ALXzfy2itI6u/Y5MQuSjyfzP/gsyioAznjNOyTjHBIpOiYxwKgvLTUL61ns9FjWXU5YXS3V22jftOMnsO9CVzBtJXZreA9f+GHjGTT9JZdKv/EUDEhLmyxN5iEsSjsvOME8HoK9nr5Y/Zf8AhZ4h8M/ELVNT8V6VNZNZWvlW7SYZZHkPLIwJDYVWBwf4hX1PXoJWVj5qcuaTk+oUUUUyQooooAKKKKACiiigAooooAKKKKACiiigAqnrEXnaRfRDkvA6/mpq5SMAQQeh4oGnZ3PGtBieS7Xb8skyNGh/usyEA/nXnuk6BMx2kyoyHadjcZHFfQNt4cjtriKSPoh6fpWJF4Ra1lcRlgoY4PqK43Rdj36GYRhJtdbfqee22jXMWN0lzgdwoatSC1mRcf6VKfQQBf1ruo9HuUGFz+Qq1HpdxjlpfpgCkqJrLMUzzDVLC+kgI8hUX/bOSa3PEFq5upW2BGEakqv8J2D5R9K7CTQppnTdtUAg881cm0KOe4LSHIZ8n35zVKiznrY+MmvK/wCht6dD9n061h/55xIn5ACrFFFdZ4bd3cKKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGJ431S90Pwjq2qaVZLfXtnbvPHbsxUSbRkjIBPQHjv0r5e+HnxU1Hx94m1NdeW0gunRZLdLZCq7V4I5JJIyOSa+uyAwIYAg8EHvXielfAzwX4Lu9Y8SXd7KhUyzQSzyeVDYI2cYAPzYBxlic+lROPNGxth6vsqil0K5J2jJyW5+hrXt7Ua94Y1LRJMCV4z5WezZyp/BwPzrldA1jT9fsEvdKukuLcsUJXI2keoPI/HtitvTbs2V7Fc5yAcMB3XuK41o9T3ZrnjePqjivD9wTGEkBSVTtZT1DDgj866uCX5OtZXjvT/wCyvFn2yAf6FqY89SOgk/jH48N/wKpIZ8Qbie1ZNcrsevCarQVRdQFsdZ16y08Z2SyAyH0Qct+gNdZ4puBPqPlJgJCNuOwJ5P8ASqPgqAWVje67cr80mYbcHuM8n8SAP+Amq0jtI7vIQTyzH1Jq0rR9Tz8RL2lay2jp8+v+QwjKZz34968x8c/F6+8EeMLSLw0tpcTwKftizpvVt2MJwQQcDOQe/wBRXb694l0Tw9d6ZD4gvvscN7MI/MCliifxMQOQB0z2yK7Sb4MeCNb8ZaT4y09E2IwuWht2D2122Mo5+hwTjhsc9870YXfMzzMdX5Y+zjuz0bwve3upeHdNvdVshYX1xAks1qH3+SxGducDkVp0UV1HkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAGKQqDS0UAN2Cl2ilooATaKNvNLRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXLfEnwTp3j/wrcaHqzzRRuRJHLE2GjkH3Wx0br0P88EdTRQB8eeEPgv4w8DeOJ7m7l3aFaxGR7q1lwl0pO1UKdQQTkgjgA4J61P4x+KNj4W8T/2VcWE10kcKtLJFIAyM2Tt2ng8YPUda+rPETomgai0mNot5M5/3TXzvr/gbw34gnM+qabE9w+N88bGOQnpyQefxrnq8qleR6eEdR0mqejua/hjWrD4l+CLuLThMslu5e1adArCRQDt6nj5tv/AvauMsPGPhq8+y28uvWVsJGCytIxXyx3JyPrXdfDjw3aaCi6ZpJlS2RZn3Od7AsMenPUflXhlh8G7DUNaFpH4kkjglmaKKV7IlmOTtyobIz+nesuWEviZ3QrYmlFxpRT0u/J+R7z418S6To1lHLdXC22kWoWKJgpYEkYHABJ4H+c1xeg/ETQPEevDS9LkuJJWRpFd49iNt/hGTnOMnp2ra8deFIdb0SXQLyd4lSRB5yKCfkxggH1H865zwv8LdB8O6nBe20l7PewsTHJLKAAcY+6oHY980e6077k/vVJKFuUxte+Dfi3xv8S7WWeR28P3g8wagQNttArYMYH9/OcDvnPrj668P6PY+H9EstJ0mBYLG0iEUUY7AevqT1J7kmovCrpJ4b01owAv2dBgeoGD+ua1a647I8Ss71JPzCiiiqMwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb+INz5HhmZB96d0iH55P6A15czbTj3BruPihc/Pp1qOnzysPwCj+bVyP2F2KxLPbvePF5y2m/Epj/vAd65KzvI9vBJQpJvqanhnMa6jLHJHFIkfyySDKqcE5PI4yB3rzDwvLO+t2kkU6pcvcRMJdm75iwBOO/U16V4V2Nez20qiSGaI7kYZDDPQg/jXC+GNPSTVba3vbGWWA3HlNGR8w2k5BGegxzz2NZPod+HaTq37L8mdv4pRY9XkOOGRX/Hp/SsgKcj16itXxLMs2qzYIKxqI+PUdf51XW2gUxQyTsuoywPdRQBcjy1IySe2c8fSm1ds56b5YK533w3uvP0FoCfmt5WXHoG+YfzP5V1deffDB9t5qMfaREkx9CwP869BrrpO8UeNi48taQUUUVocwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHmPxHkL+IUUchLdV/EljXmXxBuptP8VaRqlpKyzmyikG04K7Sy/rivRPHuX8UXQzgBEUf985/rXnHxEgaTxNEWQvF9hgMYU8hdp/rmuGq9WfTYCKfIvI6vRfGNlMn2yGwjbUGGGZZdqZPUleo98U7TybSWG93RyzxzNOwztDFs7vp1NeYR6cgYOsk8b+oUg/mK0I7S6YBRfXmz3yP1xWXOej9TjG/KtzuNZ8T6NYu9w1hM905LLC8wKs30HOKyvBs95qWtazr2pnM/2Uxqo4C7yFVQOwABrKstDUtvjaHzO7uxdq6XwratanWlZ2eI2y7if7+8bcfrTUm2Y1cPClTbjv/wAFHY/DZiniK4QnrbNx9HX/ABr0yvMPh4c+Js9SbeTP/fS16fXbR+E+bx/8X5BRRRWpxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeTeOBu8U35z02cf9s1rz7x4J4/FfmrteGa0geEZxhNu3H5hq9D8br/xVV8ORuEfP/ABXnnxBgY+IrWYSMsc9jCY8H7oGVI/ME/jXBV6n1GXvWHp/kVbS8uFUfuW/EGuk0x9Uu0AtlgjUdWYZrmbMzQqAbsqPUx5rbtJoDH/pOsTqP7saYrBHrVFdaIs6jBewKTNqNuPX5MUeDp3kvtStvN8+GW2aSR8cIU5U5+px+NVJXtWJ8uS7vR2BiH8zV3wnNMZdZR4FigNryR1Vgw2j8eaqPxGFf+DK52fw4G/xFK/pbuf/AB5a9Nrzn4Zx51i+kHaAD82P+FejV30fgPlMe/3zCiiitTjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8v8fW7HxQ2AQskUb5/76H9K4bx1pct5qOkzjPlPZiNApwVKMQfzzmvcNb0aPULiOZvvqm3P45/qaw9X8Ki4Fmy53QqY+PTOR/OuadJts9jC42NPkv0PJrHw/cIoKSXBHpkGte20+eLGZLv6eSDXfQ6BPCMKzH6gVai0m5B+ZpB/ugVmqJ2yzJPqcBLaXjL+5tpDx96XC/oKl0Wxnj0bUBPGmTcxsGXucHI/D+td8+kTuMDJ93NSW+glLTypGHLl+B6gD+lUqOpjVzBShymf8NbUwnUpGHJMaA/QE/1rt6oaNYpY2zqnV3Lk/gB/Sr9dMI8sbHjV6ntKjkFFFFUYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFGKKKAE2igKBS0UAJtFG0UtFAABgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In an abdominal hysterectomy, the doctor removes the uterus through an opening in the belly. If it is a \"total hysterectomy\" the doctor also removes the cervix. If it is a \"subtotal\" or \"supracervical\" hysterectomy, the doctor removes the uterus but leaves the cervix in place. To do this surgery, doctors sometimes make a horizontal cut (from left to right) at the bikini line. Sometimes they instead make a vertical cut from top to bottom. As part of a hysterectomy, doctors sometimes also remove the ovaries and the tubes that connect the ovaries to the uterus (fallopian tubes). This is called \"salpingo-oophorectomy\".",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38534=[""].join("\n");
var outline_f37_40_38534=null;
var title_f37_40_38535="Clinical manifestations and diagnosis of Shigella infection";
var content_f37_40_38535=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of Shigella infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38535/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38535/contributors\">",
"     Rabia Agha, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38535/contributors\">",
"     Marcia B Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38535/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38535/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38535/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38535/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38535/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38535/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/40/38535/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shigella species are a common cause of bacterial diarrhea worldwide, especially in developing countries. Shigella organisms can survive transit through the stomach since they are less susceptible to acid than other bacteria; for this reason as few as 10 to 100 organisms can cause disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/1\">",
"     1",
"    </a>",
"    ]. Ingested bacteria pass into the small intestine where they multiply; large numbers of bacteria then pass into the colon, where they enter the colonic cells. Given its relatively low infectious dose, Shigella transmission can occur via contaminated food and water and via direct person-to-person spread. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42008?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of Shigella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations, complications, and diagnosis of Shigella infection will be reviewed here. The treatment of this infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39334?source=see_link\">",
"     \"Treatment and prevention of Shigella infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/16/8457?source=see_link\">",
"     \"Treatment and prevention of Shigella infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H996709503\">",
"    <span class=\"h2\">",
"     General features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shigella is an infection of the lower gastrointestinal tract. Patients with Shigella gastroenteritis typically present with high fever, abdominal cramps, and bloody, mucoid diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever &ndash; 30 to 40 percent",
"     </li>",
"     <li>",
"      Abdominal pain &ndash; 70 to 93 percent",
"     </li>",
"     <li>",
"      Mucoid diarrhea &ndash; 70 to 85 percent",
"     </li>",
"     <li>",
"      Bloody diarrhea &ndash; 35 to 55 percent",
"     </li>",
"     <li>",
"      Watery diarrhea &ndash; 30 to 40 percent",
"     </li>",
"     <li>",
"      Vomiting &ndash; 35 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incubation period ranges from one to seven days, with an average of three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/6\">",
"     6",
"    </a>",
"    ]. The disease typically begins with constitutional symptoms such as fever, anorexia, and malaise. Initially diarrhea is watery, but subsequently may contain blood and mucus. Tenesmus is a common complaint.",
"   </p>",
"   <p>",
"    Stool frequency is typically 8 to 10 per day, but may increase to up to 100 per day. Significant fluid loss is uncommon (average approximately 30",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day); this is in contrast to small bowel infections, which are typified by large volumes of watery diarrhea associated with abdominal cramping, bloating, gas and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32025?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5625?source=see_link\">",
"     \"Approach to the child with acute diarrhea in developing countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spectrum of disease severity varies depending on the serogroup of the infecting organism. S. sonnei commonly causes mild disease, which may be limited to watery diarrhea, while S. dysenteriae 1 or S. flexneri commonly causes dysenteric symptoms (bloody diarrhea) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/8\">",
"     8",
"    </a>",
"    ]. In a normal host, the course of disease is generally self-limited, lasting no more than seven days when left untreated.",
"   </p>",
"   <p>",
"    The typical course of disease varies with age group. In a review of 318 infants and children hospitalized with shigellosis in Bangladesh, infants had fewer days with diarrhea (four versus six) and were more likely to have watery (as opposed to bloody) stools, hyponatremia, abdominal distension, and acidosis than older children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/9\">",
"     9",
"    </a>",
"    ]. Older children were more likely to have a leukemoid reaction than infants. The mortality rate for infants was twice that of older children. In another study conducted at the same institution, infants who were breast fed were less frequently infected and had a milder illness than infants who were not breast fed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Intestinal complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several intestinal complications can occur in the setting of Shigella infection; each is relatively rare (",
"    <a class=\"graphic graphic_table graphicRef69134 \" href=\"mobipreview.htm?11/47/12028\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Proctitis or rectal prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants and young children, the severe inflammation of the rectum and distal colon that is induced by invasion of the organism into the colonic mucosa may lead to proctitis or rectal prolapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Toxic megacolon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic megacolon occurs primarily in the setting of S. dysenteriae 1 infection. The pathogenesis of this complication is unclear; it occurs in the setting of pancolitis and seems to be related to the intensity of inflammation rather than being mediated by Shiga toxin. The incidence of toxic megacolon among patients admitted to the diarrhea treatment center in Bangladesh was 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Intestinal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe colonic disease may result in intestinal obstruction. The incidence in one series of 1211 patients with shigellosis was 2.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/11\">",
"     11",
"    </a>",
"    ]. The patients with obstruction were more likely to be infected with S. dysenteriae 1 and were more severely ill, as evidenced by a significantly higher white blood cell count and lower serum sodium concentration than patients without evidence of obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Colonic perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic perforation is an extremely rare complication of shigellosis. It occurs principally in infants or severely malnourished patients and is associated with infection due to S. dysenteriae 1 or S. flexneri. In one epidemic of S. dysenteriae 1 in Central America, colonic perforation was seen at autopsy in 1.7 percent of fatal cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Systemic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shigellosis may be associated with a number of systemic complications (",
"    <a class=\"graphic graphic_table graphicRef69134 \" href=\"mobipreview.htm?11/47/12028\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of bacteremia has been reported to be 0 to 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Signs that correlate with bacteremia are leukocytosis, hypothermia, temperature above 39.5&ordm;C, severe dehydration, and lethargy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacteremia is more common among children than adults, occurring primarily among children younger than five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/13,16,17\">",
"     13,16,17",
"    </a>",
"    ]. Among the 22 cases of bacteremia described among adults in the literature, one-third of patients were older than 65 years of age, and more than half had an underlying disease (most commonly diabetes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV infection does not appear to confer significant predisposition to Shigella bacteremia. Among adults in Soweto, South Africa, the rate of HIV infection nearly doubled between 1996 and 2006 although the rate of Shigella bacteremia remained stable (approximately 0.2 per 1000 adults; 0.8 per 100 children) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacteremia is associated with an increased risk of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/16\">",
"     16",
"    </a>",
"    ]. Young, malnourished children are at greatest risk. Additionally, the mortality rate associated with Shigella bacteremia may be higher in the setting of HIV infection. In a study of systemic Shigellosis in South Africa, HIV-infected patients were 4.1 times more likely to die than HIV-negative individuals (29 of 78 versus 5 of 40 fatal cases, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/19\">",
"     19",
"    </a>",
"    ]. We recommend antibiotic treatment for all patients who become bacteremic with Shigella. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39334?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prevention of Shigella infection in adults\", section on 'Clinical approach to therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/16/8457?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prevention of Shigella infections in children\", section on 'Antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Metabolic disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial volume depletion is uncommon in shigellosis because the stool volume is usually low. In a review of 412 patients with shigellosis, 36 percent had mild dehydration, 12 percent had moderate dehydration, and 2 percent had severe dehydration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/2\">",
"     2",
"    </a>",
"    ]. In another series, hyponatremia (defined as serum sodium below 120",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    was noted in 29 percent of patients hospitalized with diarrhea due to S. dysenteriae 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/20\">",
"     20",
"    </a>",
"    ]. Hyponatremia is generally due to the syndrome of inappropriate antidiuretic hormone secretion, not volume depletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/10,20\">",
"     10,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protein-losing enteropathy also may be observed. In one report that used the level of alpha-1 antitrypsin in stool as an indicator of protein excretion, protein loss was high during the acute phase in patients who had dysentery, remained high in patients who failed therapy, and fell to normal low values in those who were cured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased catabolism secondary to fever, stool protein loss, decreased intake due to anorexia and malabsorption can exacerbate pre-existing malnutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Leukemoid reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A leukemoid reaction (defined as a white blood count of",
"    <span class=\"nowrap\">",
"     50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or more) has been observed in Bangladesh among approximately 4 percent of patients, most commonly in children between 2 and 10 years of age (and not at all in children younger than one year of age) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/22\">",
"     22",
"    </a>",
"    ]. The white blood cell count in these patients ranged from 50,000 to",
"    <span class=\"nowrap\">",
"     195,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and was accompanied by an increased number of immature forms. In this study, the mortality rate also was increased among patients with a leukemoid reaction (21 versus 7 percent). In contrast, a study conducted in the United States found no association between disease severity and a high white blood cell count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Neurologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are the most common neurologic complication associated with Shigella infection. They tend to be generalized and are not associated with specific neurologic deficits but have been associated with a higher risk of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Seizures occur almost exclusively among children &lt;15 years. The occurrence of seizures is associated with fever (often greater than 39&ordm;C), increased proportion of immature leukocytes, low serum sodium, and high serum potassium. Seizures have been observed during infection with all serotypes of Shigella.",
"   </p>",
"   <p>",
"    The reported prevalence of seizures among children with shigellosis has ranged from 5 to 45 percent; among patients of all ages hospitalized with shigellosis the prevalence is about 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/10,23,24\">",
"     10,23,24",
"    </a>",
"    ]. Analysis of cerebrospinal fluid obtained by lumbar puncture is typically normal, although up to 15 percent may have mild lymphocytic pleocytosis with up to 12 cells.",
"   </p>",
"   <p>",
"    Neurologic complications of Shigella infection were previously thought to be induced by circulating Shiga toxin produced by S. dysenteriae 1, though this is not likely to be correct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/25\">",
"     25",
"    </a>",
"    ]. In a study of five children performed to determine whether seizures were associated with Shiga toxin, clinical specimens including stool, serum, and cell-free cerebrospinal fluid were examined in vitro for cytotoxic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/26\">",
"     26",
"    </a>",
"    ]. Cytotoxic activity was not detected in serum or spinal fluid, although it was present in stool, at levels 1000-fold below that of cultured S. dysenteriae 1. The stool cytotoxic activity was not neutralized by anti-Shiga toxin antibodies, no patient had neutralizing antibodies to Shiga toxin, and DNA hybridization studies of the Shigella isolates that probed for the gene encoding Shiga toxin were negative.",
"   </p>",
"   <p>",
"    Thus, although this study is too small to be conclusive, it did not demonstrate a relationship between Shiga toxin and seizures. Furthermore, the majority of patients who have seizures are infected with S. flexneri or S. sonnei, which do not express Shiga toxin. Taken together, these data suggest that other Shigella enterotoxins might contribute to the induction of seizures, although this possibility requires further study. The enterotoxin ShET1 has been identified in strains of S. flexneri 2a [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], and the enterotoxin ShET2 has been identified in members of all four serogroups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/29\">",
"     29",
"    </a>",
"    ], but the role of these or other as yet unidentified enterotoxins in Shigella-induced seizures is unknown.",
"   </p>",
"   <p>",
"    In addition to seizures, other neurologic findings have been described in up to 40 percent of children hospitalized with Shigella infection, including encephalopathy with lethargy, confusion, and headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/30\">",
"     30",
"    </a>",
"    ]. Obtundation, coma and posturing are rare. In cases of fatal encephalopathy, cerebral edema has been observed at autopsy.",
"   </p>",
"   <p>",
"    A particularly lethal form of shigellosis, known as the Ekiri syndrome, was responsible for 15,000 deaths per year in Japan during the pre-World War II era [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/10\">",
"     10",
"    </a>",
"    ]. The Ekiri syndrome was associated with S. sonnei infection and was characterized by the rapid development of seizures and coma in patients with high fever and few dysenteric symptoms. The mechanism of the fulminant course remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following S. flexneri infection, reactive arthritis may be observed alone or in association with conjunctivitis and urethritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The arthritis is a sterile inflammatory arthritis. Symptoms develop one to two weeks following symptoms of dysentery, regardless of whether or not the dysentery was treated with antibiotics. Approximately 70 percent of patients with arthritis are HLA-B27 positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/31\">",
"     31",
"    </a>",
"    ]. A 5 amino acid peptide encoded on a 2 Md Shigella plasmid has been associated with reactive arthritis in two separate studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. This peptide has sequence similarity to the HLA B27 alpha 1 domain, suggesting that molecular mimicry may play a pathogenetic role in arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is one case report in which bacterial lipopolysaccharide antigen was detected in the synovial fluid of a patient with post-Shigella reactive arthritis; the significance of this finding is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sterile reactive arthritis has also been described following infection with Campylobacter jejuni, Salmonella enteritidis, S. typhimurium, Yersinia enterocolitica, and Y. pseudotuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hemolytic-uremic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although relatively uncommon, the hemolytic-uremic syndrome (HUS) is the most frequent cause of acute renal failure among infants and young children worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/36\">",
"     36",
"    </a>",
"    ]. Ninety percent of cases of HUS in children follow a diarrheal prodrome; it is most often due to infection with enterohemorrhagic Escherichia coli (particularly type O157:H7), but may also be induced by infection with S. dysenteriae 1. The other 10 percent of cases have a variety of etiologies, including drugs, malignancy, pregnancy, and collagen vascular disease. Thrombotic thrombocytopenic purpura is a related disorder with overlapping clinical findings that occurs more commonly in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35704?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients present at the end of the first week and during the recovery phase of diarrheal or dysenteric symptoms with the combination of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure (initially oliguric and then anuric). The patient may be considered to have thrombotic thrombocytopenic purpura if fever and transient neurologic symptoms are also present. Seizures occur in approximately 10 percent and stroke or cerebral edema in 5 percent.",
"   </p>",
"   <p>",
"    The pathogenesis of HUS or TTP involves cytotoxic damage to the vascular endothelium. In most studies, Shiga-toxin production by S. dysenteriae 1 is thought to be directly involved. In the setting of infection due to enteropathogenic E. coli, antibiotic treatment may increase the risk of the development of HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some retrospective clinical data suggest that antibiotic use in the setting of S. dysenteriae 1 infection does not induce development of HUS, and that treatment with antibiotics may reduce its likelihood. In a retrospective review of several studies including 128 adults and 250 children with S. dysenteriae 1 infection treated with antibiotics, only one child developed HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/40\">",
"     40",
"    </a>",
"    ]. This may be due to a difference in the genomes between S. dysenteriae 1 and enteropathogenic E. coli. In S. dysenteriae 1, the phage that carries the Shiga toxin genes is unable to undergo lysogenic conversion, whereas the phage that carries these genes within pathogenic E. coli is not defective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H996709308\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In young girls, Shigella can cause vaginitis or vulvovaginitis with or without diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/43\">",
"     43",
"    </a>",
"    ]. The vaginal discharge usually is painless and may be bloody. Untreated Shigella vaginitis can persist for several months.",
"   </p>",
"   <p>",
"    Shigella is a rare cause of keratitis and should be considered as the cause of keratitis or conjunctivitis in young children who have had a recent diarrheal illness or who have a recent exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute myocarditis has been associated with acute S. sonnei gastroenteritis in two children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shigella should be suspected in the setting of frequent, small volume, bloody stools, abdominal cramps, and tenesmus, particularly if accompanied by fever. Nausea and vomiting are notably absent in most patients, and fecal leukocytes are generally present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis for this constellation of symptoms and signs includes infection with Salmonella, Campylobacter, Yersinia, enteroinvasive E. coli, or Clostridium difficile, or noninfectious inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32025?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13529?source=see_link\">",
"     \"Evaluation of diarrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Stool culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive determination of the infecting organism requires stool culture. Direct microscopic examination of stool specimen for the presence of white blood cells and red blood cells may facilitate early diagnosis of Shigella. Shigella is a fastidious organism; it requires prompt handling and optimally should be inoculated onto agar at the bedside. Culture from a stool sample may give a better yield than culture from a rectal swab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/46\">",
"     46",
"    </a>",
"    ]. If transport of the sample is required, the best medium is buffered glycerol saline (BGS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38535/abstract/47\">",
"     47",
"    </a>",
"    ]. The best yield is from a mucoid part of stool. The methods used to culture Shigella in the laboratory and newer, more sensitive techniques, such as polymerase chain reaction, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42008?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of Shigella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H996708448\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shigella is a common cause of bacterial diarrhea. It is transmitted by direct person-to-person spread and, less commonly, through contaminated food and water. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42008?source=see_link\">",
"       \"Epidemiology, microbiology, and pathogenesis of Shigella infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The incubation period ranges from one to seven days. Patients with Shigella gastroenteritis typically present with high fever, abdominal cramps, and bloody, mucoid diarrhea; tenesmus is common. Shigella gastroenteritis generally is self-limited, lasting no more than seven days in an untreated immunocompetent host. (See",
"      <a class=\"local\" href=\"#H996709503\">",
"       'General features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intestinal complications of Shigella infection include proctitis, rectal prolapse, toxic megacolon, intestinal obstruction, and colonic perforation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Intestinal complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic complications of Shigella infection include bacteremia, metabolic disturbances (hypovolemia, hyponatremia, protein-losing enteropathy), leukemoid reaction, neurologic disease (seizures, encephalopathy), reactive arthritis, and with S. dysenteriae 1 hemolytic uremic syndrome. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Systemic complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Shigella should be suspected in patients with frequent, small volume, bloody stools, abdominal cramps, tenesmus, and fever, particularly if accompanied by fecal leukocytes. Stool culture is required for definitive diagnosis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of Shigella is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39334?source=see_link\">",
"       \"Treatment and prevention of Shigella infection in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/16/8457?source=see_link\">",
"       \"Treatment and prevention of Shigella infections in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/1\">",
"      DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis 1989; 159:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/2\">",
"      Stoll BJ, Glass RI, Huq MI, et al. Epidemiologic and clinical features of patients infected with Shigella who attended a diarrheal disease hospital in Bangladesh. J Infect Dis 1982; 146:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/3\">",
"      Barrett-Connor E, Connor JD. Extraintestinal manifestations of shigellosis. Am J Gastroenterol 1970; 53:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/4\">",
"      Echeverria P, Sethabutr O, Pitarangsi C. Microbiology and diagnosis of infections with Shigella and enteroinvasive Escherichia coli. Rev Infect Dis 1991; 13 Suppl 4:S220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/5\">",
"      DuPont HL, Hornick RB, Dawkins AT, et al. The response of man to virulent Shigella flexneri 2a. J Infect Dis 1969; 119:296.",
"     </a>",
"    </li>",
"    <li>",
"     Maurelli AT, Lampel KA. Shigella. In: Foodborne Disease Handbook, Hui YH, Gorham JR, Murrell KD, Cliver DO (Eds), Marcel Dekker, New York 1994. p.321.",
"    </li>",
"    <li>",
"     Acheson DW, Keusch GT. Shigella and enteroinvasive Escherichia coli. In: Infections of the Gastrointestinal Tract, Blaser MJ, Smith PD, Ravdin JI, et al (Eds), Raven Press, New York 1995. p.765.",
"    </li>",
"    <li>",
"     Keusch GT, Formal SB, Bennish ML. Shigellosis. In: Tropical and Geographical Medicine, Warren KS, Mahmoud AAF (Eds), McGraw-Hill, New York 1990. p.763.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/9\">",
"      Huskins WC, Griffiths JK, Faruque AS, Bennish ML. Shigellosis in neonates and young infants. J Pediatr 1994; 125:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/10\">",
"      Bennish ML. Potentially lethal complications of shigellosis. Rev Infect Dis 1991; 13 Suppl 4:S319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/11\">",
"      Bennish ML, Azad AK, Yousefzadeh D. Intestinal obstruction during shigellosis: incidence, clinical features, risk factors, and outcome. Gastroenterology 1991; 101:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/12\">",
"      Azad MA, Islam M, Butler T. Colonic perforation in Shigella dysenteriae 1 infection. Pediatr Infect Dis 1986; 5:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/13\">",
"      Martin T, Habbick BF, Nyssen J. Shigellosis with bacteremia: a report of two cases and a review of the literature. Pediatr Infect Dis 1983; 2:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/14\">",
"      Koster F, Levin J, Walker L, et al. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Engl J Med 1978; 298:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/15\">",
"      Hawkins C, Taiwo B, Bolon M, et al. Shigella sonnei bacteremia: two adult cases and review of the literature. Scand J Infect Dis 2007; 39:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/16\">",
"      Struelens MJ, Patte D, Kabir I, et al. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J Infect Dis 1985; 152:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/17\">",
"      Davies NE, Karstaedt AS. Shigella bacteraemia over a decade in Soweto, South Africa. Trans R Soc Trop Med Hyg 2008; 102:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/18\">",
"      Morduchowicz G, Huminer D, Siegman-Igra Y, et al. Shigella bacteremia in adults. A report of five cases and review of the literature. Arch Intern Med 1987; 147:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/19\">",
"      Keddy KH, Sooka A, Crowther-Gibson P, et al. Systemic shigellosis in South Africa. Clin Infect Dis 2012; 54:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/20\">",
"      Keusch GT, Bennish ML. Shigellosis: recent progress, persisting problems and research issues. Pediatr Infect Dis J 1989; 8:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/21\">",
"      Bennish ML, Salam MA, Wahed MA. Enteric protein loss during shigellosis. Am J Gastroenterol 1993; 88:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/22\">",
"      Butler T, Islam MR, Bardhan PK. The leukemoid reaction in shigellosis. Am J Dis Child 1984; 138:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/23\">",
"      Ashkenazi S, Dinari G, Zevulunov A, Nitzan M. Convulsions in childhood shigellosis. Clinical and laboratory features in 153 children. Am J Dis Child 1987; 141:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/24\">",
"      Khan WA, Dhar U, Salam MA, et al. Central nervous system manifestations of childhood shigellosis: prevalence, risk factors, and outcome. Pediatrics 1999; 103:E18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/25\">",
"      Keusch GT, Donohue-Rolfe A, Jacewicz M. Shigella toxin(s): description and role in diarrhea and dysentery. Pharmacol Ther 1981; 15:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/26\">",
"      Ashkenazi S, Cleary KR, Pickering LK, et al. The association of Shiga toxin and other cytotoxins with the neurologic manifestations of shigellosis. J Infect Dis 1990; 161:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/27\">",
"      Noriega FR, Liao FM, Formal SB, et al. Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypes. J Infect Dis 1995; 172:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/28\">",
"      Fasano A, Noriega FR, Maneval DR Jr, et al. Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest 1995; 95:2853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/29\">",
"      Nataro JP, Seriwatana J, Fasano A, et al. Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun 1995; 63:4721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/30\">",
"      Avital A, Maayan C, Goitein KJ. Incidence of convulsions and encephalopathy in childhood Shigella infections. Survey of 117 hospitalized patients. Clin Pediatr (Phila) 1982; 21:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/31\">",
"      Simon DG, Kaslow RA, Rosenbaum J, et al. Reiter's syndrome following epidemic shigellosis. J Rheumatol 1981; 8:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/32\">",
"      Stieglitz H, Lipsky P. Association between reactive arthritis and antecedent infection with Shigella flexneri carrying a 2-Md plasmid and encoding an HLA-B27 mimetic epitope. Arthritis Rheum 1993; 36:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/33\">",
"      Adam T, Siewerdt R, Offermann I, et al. Prevalence and molecular diversity of pHS-2 plasmids, marker for arthritogenicity, among clinical Escherichia coli Shigella isolates. Microbes Infect 2003; 5:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/34\">",
"      Granfors K, Jalkanen S, Toivanen P, et al. Bacterial lipopolysaccharide in synovial fluid cells in Shigella triggered reactive arthritis. J Rheumatol 1992; 19:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/35\">",
"      Hughes RA, Keat AC. Reiter's syndrome and reactive arthritis: a current view. Semin Arthritis Rheum 1994; 24:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/36\">",
"      Siegler RL. The hemolytic uremic syndrome. Pediatr Clin North Am 1995; 42:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/37\">",
"      Ashkenazi S. Role of bacterial cytotoxins in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Annu Rev Med 1993; 44:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/38\">",
"      Proulx F, Turgeon JP, Delage G, et al. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr 1992; 121:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/39\">",
"      Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/40\">",
"      Bennish ML, Khan WA, Begum M, et al. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis 2006; 42:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/41\">",
"      McDonough MA, Butterton JR. Spontaneous tandem amplification and deletion of the shiga toxin operon in Shigella dysenteriae 1. Mol Microbiol 1999; 34:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/42\">",
"      Greco KM, McDonough MA, Butterton JR. Variation in the Shiga toxin region of 20th-century epidemic and endemic Shigella dysenteriae 1 strains. J Infect Dis 2004; 190:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/43\">",
"      Murphy TV, Nelson JD. Shigella vaginitis: report of 38 patients and review of the literature. Pediatrics 1979; 63:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/44\">",
"      Tobias JD, Starke JR, Tosi MF. Shigella keratitis: a report of two cases and a review of the literature. Pediatr Infect Dis J 1987; 6:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/45\">",
"      Rubenstein JS, Noah ZL, Zales VR, Shulman ST. Acute myocarditis associated with Shigella sonnei gastroenteritis. J Pediatr 1993; 122:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38535/abstract/46\">",
"      Rahaman MM, Huq I, Dey CR. Superiority of MacConkey's agar over salmonella-shigella agar for isolation of Shigella dysenteriae type 1. J Infect Dis 1975; 131:700.",
"     </a>",
"    </li>",
"    <li>",
"     Farmer JJ, Wells JG, Griffin PM. Enterobacteriaceae infections. In: Diagnostic Procedures for Bacterial Infections, Wentworth BB (Ed), American Public Health Association, Washington, DC 1987. p.274.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2718 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38535=[""].join("\n");
var outline_f37_40_38535=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H996708448\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H996709503\">",
"      General features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Intestinal complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Proctitis or rectal prolapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Toxic megacolon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Intestinal obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Colonic perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Systemic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Metabolic disturbances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Leukemoid reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hemolytic-uremic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H996709308\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Stool culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H996708448\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2718\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2718|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/47/12028\" title=\"table 1\">",
"      Major complications of Shigella",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5625?source=related_link\">",
"      Approach to the child with acute diarrhea in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42008?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13529?source=related_link\">",
"      Evaluation of diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12090?source=related_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39334?source=related_link\">",
"      Treatment and prevention of Shigella infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/16/8457?source=related_link\">",
"      Treatment and prevention of Shigella infections in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_40_38536="Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients";
var content_f37_40_38536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38536/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38536/contributors\">",
"     Barbara H McGovern, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38536/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38536/contributors\">",
"     David Thomas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38536/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38536/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/40/38536/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic liver disease has emerged as one of the most important comorbidities among HIV-infected patients who are living with hepatitis C virus (HCV) infection. Several clinical trials have been performed in this patient population to assess the efficacy and safety of antiviral therapy.",
"   </p>",
"   <p>",
"    Clinical trial data are discussed in detail below. The epidemiology, natural history, diagnosis and management of coinfected patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=see_link\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16229059\">",
"    <span class=\"h1\">",
"     ANTIVIRAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications with efficacy against HCV infection include drugs with general antiviral activity (eg, peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ) or agents that specifically target the hepatitis C virus (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16229648\">",
"    <span class=\"h2\">",
"     Peginterferon and ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon is an immunomodulatory agent that stimulates host antiviral genes;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is another nonspecific antiviral medication whose mechanism of action is poorly understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/1\">",
"     1",
"    </a>",
"    ]. In the past, standard interferon was given thrice weekly; subsequent development of the pegylated interferons enabled once weekly dosing with improved pharmacokinetic profiles. Starting in 2004, HCV treatment trials in HIV-infected patients compared one of two formulations of pegylated interferon in combination with ribavirin to standard interferon plus ribavirin in terms of efficacy and safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. These two pegylated interferons include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peginterferon alfa-2a (Pegasys, Roche Pharmaceuticals)",
"     </li>",
"     <li>",
"      Peginterferon alfa-2b (Peg-Intron, Schering-Plough Corporation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/36/24137?source=see_link\">",
"     pegylated interferon alfa-2b",
"    </a>",
"    , weight-based dosing (1.5",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    is employed. For",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/27/27064?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    , a standard dose of 180",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is used, regardless of weight. Both are administered once weekly via a subcutaneous route.",
"   </p>",
"   <p>",
"    In patients with HCV alone,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is administered at a fixed dosing of 400 mg twice daily for genotype 2 or 3 infection, whereas weight-based ribavirin (approximately 13",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in two divided doses) is preferred in patients with genotype 1 and 4 infection due to improved efficacy in patients with these more \"difficult-to-treat\" genotypes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the first large treatment trials in",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfected patients, fixed-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    was employed, regardless of genotype because of toxicity and drug interaction concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The optimal ribavirin dosing for HCV genotype 1 infection in HIV-infected persons is still uncertain. One randomized controlled trial did not detect a higher response with weight-based ribavirin, although the conclusions were limited by the high dropout rate (ie, greater than 50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/5\">",
"     5",
"    </a>",
"    ]. Most experts use weight-based ribavirin in",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfected patients because of the extensive data supporting the greater efficacy of weight-based ribavirin in patients with HCV infection alone and the absence of major drug interaction concerns with current day antiretroviral therapy (ART).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16229655\">",
"    <span class=\"h2\">",
"     HCV protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specifically-targeted antiviral agents effective against HCV include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    , which fall into the drug class of HCV protease inhibitors. In 2011, regulatory agencies in the United States and Europe approved the use of boceprevir or telaprevir, in combination with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , for the treatment of HCV genotype 1 infection in chronically infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The approval of triple therapy was based on phase 3 trials demonstrating significantly greater efficacy than dual therapy in achieving a sustained virologic response in HCV treatment-na&iuml;ve patients and in persons who had failed prior treatment. The treatment of the HIV-seronegative patient with HCV infection is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary data on the use of HCV specific protease inhibitors in coinfected patients are discussed below. The full safety and efficacy data on this combination will not be available until 2013. There are also significant drug-drug interactions with certain antiretroviral medications which can affect both HCV and HIV control. (See",
"    <a class=\"local\" href=\"#H16230082\">",
"     'Trials of triple therapy including HCV protease inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16229903\">",
"    <span class=\"h1\">",
"     TRIALS OF PEGINTERFERON WITH RIBAVIRIN FOR HCV TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are six different HCV genotypes that are found worldwide; most of the clinical trials of HCV therapy in the HIV-infected host have enrolled patients with HCV genotype 1, 2, 3 or 4 infections. Generally speaking, HCV genotype 1 and 4 are less interferon-responsive than HCV genotypes 2 or 3.",
"   </p>",
"   <p>",
"    Preliminary data on the use of pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    plus an HCV specific protease inhibitor in",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfected patients with genotype 1 infection demonstrate that earlier viral suppression may be achieved with the use of triple therapy compared to dual therapy. Rapid viral suppression has been identified as one of the most important predictors of viral eradication in HCV-infected patients, with or without HIV coinfection. (See",
"    <a class=\"local\" href=\"#H16230082\">",
"     'Trials of triple therapy including HCV protease inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     APRICOT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest international treatment trial to-date included 868 coinfected subjects who were randomly assigned to 48 weeks of treatment with either standard interferon (3 MIU three times weekly) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (800 mg daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/27/27064?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    (180 mcg weekly) plus placebo, or pegylated interferon alfa-2a (180 mcg weekly) plus ribavirin (800 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/2\">",
"     2",
"    </a>",
"    ]. Eligible subjects had compensated liver disease, a CD4 count of &ge;100",
"    <span class=\"nowrap\">",
"     cells/mL,",
"    </span>",
"    and stable HIV disease with or without antiretroviral therapy. Approximately 85 percent of the patients were taking ART; about 16 percent had either bridging fibrosis or cirrhosis. This is the only major trial which included a monotherapy arm.",
"   </p>",
"   <p>",
"    The overall rates of sustained virologic response were 12, 20, and 40 percent in the three groups, respectively. In those with genotype 1 infection, the sustained virologic response rates were 7, 14, and 29 percent, respectively, while in those with genotype 2 or 3 infection, response rates were 20, 36, and 62 percent, respectively. Achievement of an SVR was associated with lower level viremia (&lt;800,000 int.",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    and non-1 genotype. Baseline CD4 counts or HIV RNA levels were not associated with outcome.",
"   </p>",
"   <p>",
"    Of those who did not achieve at least a 2-log drop of HCV RNA by week 12, the SVR was 2 percent. Of those who did achieve this benchmark, 56 percent achieved an SVR.",
"   </p>",
"   <p>",
"    Neutropenia and thrombocytopenia were more common among patients treated with regimens that contained peginterferon alfa-2a, and anemia was more common among patients treated with regimens containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Ten patients developed opportunistic infections, including six cases of esophageal candidiasis; these events were similar among the three arms of the study.",
"   </p>",
"   <p>",
"    Fourteen patients with cirrhosis and Childs-Pugh scores of 5 or higher developed hepatic decompensation. A subsequent multivariate analysis identified",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    use as a significant risk factor for decompensated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This pivotal trial supported the use of pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    for the treatment of HCV in the HIV-infected patient. However, the use of fixed-dose ribavirin, regardless of genotype, left unanswered questions about the possibility of improving treatment responses in patients with genotype 1 and 4 infections. Furthermore, all patients were treated with 48 weeks of therapy, regardless of genotype; whether 24 weeks of combination therapy was adequate for genotype 2 or 3-infected patients was not addressed within this trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     RIBAVIC trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective multicenter randomized controlled trial called RIBAVIC included 412 patients who were randomly assigned to pegylated interferon (1.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per week) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (800 mg daily) or standard interferon (3 MU three times weekly) plus ribavirin (800 mg daily) for 48 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients had a mean absolute CD4 cell count of 480; 83 percent were taking antiretroviral therapy. Bridging fibrosis or cirrhosis was present in 39 percent of the patients.",
"   </p>",
"   <p>",
"    Of the 315 patients who have reached the 48-week point in the protocol, an end-of-treatment response was observed more often in patients receiving the pegylated interferon combination therapy (44 versus 27 percent). The overall proportion achieving a sustained virologic response was 20 percent in the standard interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    group versus 27 percent in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/36/24137?source=see_link\">",
"     pegylated interferon alfa-2b",
"    </a>",
"    plus ribavirin group.",
"   </p>",
"   <p>",
"    For those infected with genotype 1, response rates were 6 percent in the standard",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    group compared to 17 percent in the pegylated",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    treatment arms. For patients infected with genotypes 2, 3, or 5, SVR rates were not significantly different between the pegylated versus standard interferon arms (44 versus 43 percent).",
"   </p>",
"   <p>",
"    Treatment was discontinued in 149 patients (37 percent) including 17 percent who developed adverse events or significant laboratory abnormalities. Histologic benefit was reported only in those who had a sustained virologic response.",
"   </p>",
"   <p>",
"    The RIBAVIC trial had a similar study design as the APRICOT trial. The clinical outcomes also supported the superiority of pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    versus standard",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    combination therapy for the treatment of",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfected patients with genotype 1 infection. As in the APRICOT trial, the use of fixed dose ribavirin for genotype 1 infected patients may have had a negative impact on overall outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     AIDS Clinical Trial Group (ACTG) 5071",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another prospective, randomized trial compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/27/27064?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    (180 mcg weekly) with standard interferon alfa 2a (6 million int. units TIW for 12 weeks followed by 3 million int. units TIW for 48 weeks) in 133 coinfected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/4\">",
"     4",
"    </a>",
"    ]. Both arms used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    starting at 600 mg daily, but increased in a stepped fashion 200 mg each month until a dose of 1000 mg daily was attained, if tolerated. Eighty-six percent of the patients were taking antiretroviral medications; 10 percent of the subjects had evidence of cirrhosis.",
"   </p>",
"   <p>",
"    The sustained virologic response rate was significantly higher in the pegylated interferon group (27 versus 12 percent). The response rates were much higher in those with genotypes 2 and 3 compared with genotype 1 (73 versus 14 percent). Fifty-one percent of those who achieved an early virologic response at week 12 (eg, 2-log drop) achieved an SVR. In contrast, none of the patients who achieved a 2-log drop in viremia at 12 weeks achieved an SVR. A histologic response was noted in 36 percent of the virologic non-responders and 52 percent of the virologic responders.",
"   </p>",
"   <p>",
"    This trial also supported the superiority of pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    versus standard",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    for the treatment of",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfected patients. Although ribavirin dosing was slowly increased as tolerated, a targeted dose of weight-based ribavirin for genotype 1 infection was not achieved until the third month of treatment, which may have affected clinical outcome for those with genotype 1 infection.",
"   </p>",
"   <p>",
"    Side effects were similar to the other trials described above and included flu-like symptoms, fatigue and weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     PRESCO trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trials listed above utilized a 48-week treatment course regardless of genotype. However, in patients with HCV alone, treatment duration of 24 weeks is as efficacious as treatment for 48 weeks with lower rates of toxicity and treatment discontinuation. In contrast, treatment response rates are generally lower in genotype 1-infected patients, particularly if they have not achieved complete viral suppression by 12 weeks of treatment.",
"   </p>",
"   <p>",
"    Subsequent trials were designed to address whether: 1) a 24-week treatment duration may be adequate in HIV-infected patients with genotype 2 or 3 infection and whether 2) an extended treatment duration may be of additional benefit in HIV-infected patients with genotype 1 infection.",
"   </p>",
"   <p>",
"    The Pegasys Ribavirina Espana Coinfeccion (PRESCO) study evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/27/27064?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    plus weight-based",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in 389",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients in Spain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/9\">",
"     9",
"    </a>",
"    ]. The study was originally designed to study 24 weeks of treatment for genotype 2 or 3 infection and 48 weeks in those with genotype 1 and 4 infection. However, a protocol amendment was introduced after the initiation of the trial that added two additional arms: 48 weeks of treatment for patients with genotype 2 or 3 infection and 72 weeks of treatment for patients with genotype 1 infection. Patients enrolled after the protocol amendment were assigned to these longer duration treatment arms. One third of the patients had cirrhosis at entrance to the study; 84 percent were taking ART.",
"   </p>",
"   <p>",
"    An SVR was achieved in 194 (50 percent) patients including 35 percent of those with genotype 1 infection and 72 percent of those with genotype 2 or 3 infection.",
"   </p>",
"   <p>",
"    Lack of a comparator arm of fixed-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    makes it difficult to assess whether weight-based ribavirin had any significant impact on virologic outcome. Also, the high drop-out rate of patients assigned to the extended treatment arm prevents any assessment of the potential benefit of longer duration of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     LAGUNO trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laguno and colleagues conducted a randomized, single-centre, open-label clinical trial that assigned 95 patients (47 with genotype 1 infection) to standard interferon or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/36/24137?source=see_link\">",
"     pegylated interferon alfa-2b",
"    </a>",
"    (100 to 150",
"    <span class=\"nowrap\">",
"     mcg/week)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (dosed 800 to 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    based on weight) for 48 weeks in Spain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/10\">",
"     10",
"    </a>",
"    ]. Eligibility criteria included patients with an alanine aminotransferase level &gt;1.5-fold upper limit of normal, a CD4 cell count &gt;250",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    and HIV RNA &lt;10,000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    Thirty percent had either bridging fibrosis or cirrhosis upon entry.",
"   </p>",
"   <p>",
"    The SVR rates were significantly higher in the pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    arm compared with standard",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    (44 versus 21 percent). Among patients with genotypes 1 or 4, SVR were 38 versus 7 percent while the response rates for both arms were similar in patients infected with genotype 2 or 3 (53 versus 47 percent). Patients with lower HCV RNA levels (&lt;800,000 int.",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    had higher rates of SVR (49 versus 22 percent).",
"   </p>",
"   <p>",
"    Side effects were frequent in both arms leading to treatment discontinuation in 14 patients overall without statistical differences between arms. No cases of decompensated cirrhosis were noted.",
"   </p>",
"   <p>",
"    This trial also supported the superiority of pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    combination therapy. Although weight-based ribavirin was used, the small study sample of genotype 1-infected patients does not allow any conclusions regarding efficacy of this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     CRESPO trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who attain viral suppression on treatment after four weeks of therapy have high rates of SVR, while those who do not achieve this benchmark by 12 weeks have overall low rates of SVR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/11\">",
"     11",
"    </a>",
"    ]. A 2-log drop in viremia by week 12 is considered significant; yet patients with detectable viremia at this time point have high rates of virologic relapse after treatment discontinuation. Some have advocated varying treatment durations based on virologic response.",
"   </p>",
"   <p>",
"    A small trial of response-guided therapy was conducted by Crespo and colleagues in 60",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/36/24137?source=see_link\">",
"     pegylated interferon alfa-2b",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/12\">",
"     12",
"    </a>",
"    ]. Treatment duration was individualized on the basis of week 4 and week 12 virologic responses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who achieved a rapid virologic response (eg, viral load &lt;50 int.",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      at week 4), completed 24 weeks of therapy, regardless of genotype.",
"     </li>",
"     <li>",
"      Patients who did not achieve a rapid virologic response were reassessed at treatment week 12. Patients with a complete early virologic response (eg, HCV RNA level &lt;600 int.",
"      <span class=\"nowrap\">",
"       units/mL)",
"      </span>",
"      were treated for 48 weeks. Patients with a partial response (eg, decline in the viral load &ge;2 log10) who attained an undetectable viral load at week 24 were treated for 60 weeks. The primary efficacy end point was an SVR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, 33 (55 percent) of 60 patients achieved a sustained virologic response. A rapid virologic response was significantly more common in genotype 3-infected patients and in genotype 1-infected patients (58 percent versus 16 percent). Of the 19 patients with a rapid virologic response, 17 (90 percent) achieved an SVR after 24 weeks of therapy. The rate of sustained virologic response was significantly higher among patients with genotype 3 and low pretreatment HCV RNA levels. A high relapse rate (46 percent) after 48 weeks of therapy occurred among patients infected with genotypes 1 or 4 who first achieved undetectable viral load at treatment week 12.",
"   </p>",
"   <p>",
"    Another small trial in 121 coinfected Spanish patients evaluated the utility of monitoring HCV RNA at earlier time points to predict response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/11\">",
"     11",
"    </a>",
"    ]. One hundred twenty-one coinfected patients were randomly assigned to receive standard interferon alpha-2b (3 MU thrice weekly; n = 61) or peginterferon alpha-2b (1.5",
"    <span class=\"nowrap\">",
"     mcg/kg/week;",
"    </span>",
"    n = 60), plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (800 mg daily), for 24 weeks (for genotype 2 or 3 infection) or 48 weeks (for genotype 1 or 4 infection). As noted in earlier trials, the overall SVR rate was higher in the peginterferon group (55 versus 26 percent). Among the patients in the pegylated interferon arm, the SVR rates were 45 percent among those infected with genotypes 1 or 4 and 50 percent in those with genotypes 2 or 3.",
"   </p>",
"   <p>",
"    Among genotype 3 patients, 17 of 20 (85 percent) whose HCV RNA was already undetectable at four weeks achieved an SVR after 24 weeks of treatment.",
"   </p>",
"   <p>",
"    These preliminary data suggest that a response-guided approach may be feasible in",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfected patients, although larger studies are needed. The high rates of relapse among \"difficult-to-treat\" genotypes 1 and 4, despite achievement of viral suppression at week 12, are consistent with findings from larger trials, such as APRICOT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     TURAL study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tural and colleagues compared a cohort of 104 coinfected patients with an age-, sex- and genotype-matched cohort of HCV-monoinfected patients (n = 104) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/13\">",
"     13",
"    </a>",
"    ]. All patients received pegylated interferon alpha 2a (180",
"    <span class=\"nowrap\">",
"     mcg/week)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ; genotype 2- or 3-infected patients received 400 mg of ribavirin twice daily while patients with genotype 1 or 4 received 1000 to 1200 mg daily. At baseline,",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients had significantly higher HCV RNA levels than the matched cohort of HCV monoinfected patients.",
"   </p>",
"   <p>",
"    Among patients with HCV genotype 1, coinfected patients achieved significantly lower rates of early virological response (64 versus 87 percent), end-of-treatment response (47 versus 80 percent) and SVR (27 versus 56 percent) despite the use of weight-based",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    This study suggests that despite use of weight-based",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , there may be qualitative differences in treatment efficacy between",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients compared to those with HCV infection alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Perez-Olmeda trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perez-Olmeda and colleagues conducted a controlled trial in 106",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients who were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (400 mg bid) plus interferon alpha-2b at two different doses (3 mU three times weekly or 5 mU daily for the first six weeks, followed by 3 mU three times weekly until completing six months of therapy (induction arm)) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/14\">",
"     14",
"    </a>",
"    ]. All patients had CD4 counts above 350",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and 89 percent were taking ART.",
"   </p>",
"   <p>",
"    Adverse effects leading to treatment discontinuation occurred in 12 percent of patients. An SVR was reached by only 16 percent of patients, with similar efficacy rates in both arms. Patients with HCV genotypes 2 or 3 had a sevenfold higher response rate than those with HCV genotypes 1 or 4.",
"   </p>",
"   <p>",
"    This study demonstrated that induction strategies with interferon do not have any appreciable effect on outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16230082\">",
"    <span class=\"h1\">",
"     TRIALS OF TRIPLE THERAPY INCLUDING HCV PROTEASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two HCV-specific protease inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    , were approved in 2011 for use in combination with pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    among HIV-seronegative patients with HCV genotype 1 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Promising data from two phase 2 trials in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients have demonstrated that the addition of an HCV protease inhibitor to pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy increases the proportion of patients who achieve viral suppression on treatment. Furthermore, the proportion of patients who have maintained viral suppression 12 weeks after discontinuation of treatment (ie, SVR-12) was significantly higher among patients who were assigned to triple therapy compared with dual therapy. The adverse events associated with the use of HCV protease inhibitors was also similar to those seen among patients with HCV alone.",
"   </p>",
"   <p>",
"    However, clinicians need to be aware that there are multiple drug-drug interactions between these HCV protease inhibitors and certain antiretroviral medications, which can negatively impact management of both HIV and HCV. Complete safety and efficacy data will not be available until 2013. Preliminary results from these small phase 2 clinical trials are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16230299\">",
"    <span class=\"h2\">",
"     Telaprevir-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized controlled trial, 60",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfected patients were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/27/27064?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (400 mg twice daily) plus either placebo or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    for the initial 12 weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients in both arms subsequently received an additional 36 weeks of peginterferon with ribavirin. Patients in part A of the trial were not on ART; patients in part B were on predetermined ART regimens that included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    . Telaprevir was dosed as 750 mg every eight hours, except when administered with efavirenz; in these patients, telaprevir was dosed as 1125 mg every eight hours due to a drug-drug interaction. All telaprevir doses were administered with food with 20 grams of fat or greater for better absorption.",
"   </p>",
"   <p>",
"    Sixty-eight percent had genotype 1a; 32 percent genotype 1b; 83 percent had a high viral load (ie, &gt;800,000",
"    <span class=\"nowrap\">",
"     IU/mL);",
"    </span>",
"    10 percent had advanced liver fibrosis (ie, bridging fibrosis or cirrhosis) on biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/15\">",
"     15",
"    </a>",
"    ]. The preliminary findings are highlighted below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, significantly greater proportions of patients assigned to the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      -containing arm had achieved viral suppression at 4 and 12 weeks of treatment compared with the placebo arm (63 percent versus 5 percent, respectively). &nbsp;",
"     </li>",
"     <li>",
"      At 12 weeks after the discontinuation of therapy, viral suppression was maintained in 74 percent of patients assigned to the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      arm compared with 45 percent of those assigned to the placebo arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were no unexpected adverse events. The following side effects were significantly more common in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    -containing arm: pruritis, rash, nausea, vomiting, anorexia, and dizziness. No patient developed a severe rash on the telaprevir arm. No HIV RNA breakthroughs were seen among those patients who were taking ART during the trial in either arm.",
"   </p>",
"   <p>",
"    These data are encouraging in the differential response in SVR-12 rates that was observed between the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and placebo arms. However, the trial included a small number of patients and few had underlying cirrhosis; thus, the overall efficacy of triple therapy in hard-to-treat patients is still unknown. Larger phase 3 trials will compare 24 and 48 weeks of triple therapy in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3374124\">",
"    <span class=\"h2\">",
"     Boceprevir-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase 2 clinical trial, 99",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients with genotype 1 infection received four weeks of pegylated interferon alfa 2b plus weight-based",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    and then were randomly assigned (2:1) to either pegylated",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    (800 mg every 7 to 9 hours) or pegylated",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    plus placebo for an additional 44 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/16\">",
"     16",
"    </a>",
"    ]. Enrolled subjects were allowed to take the following antiretroviral medications:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    or a ritonavir-boosted protease inhibitor. The use of nonnucleoside reverse transcriptase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ) was not allowed due to concerns regarding drug-drug interactions. Baseline HCV RNA levels were greater than 800,000",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    in 88 percent of patients; 65 percent were infected with HCV genotype 1a; 82 percent were white; and 5 percent had cirrhosis. Almost all patients had a baseline HIV RNA of &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and the median CD4 count was 577",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    in the boceprevir arm and 586",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    in the placebo arm. The preliminary findings are highlighted below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proportions of patients who achieved viral suppression at weeks 8 and 24 were higher in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      -containing arm (38 and 71 percent, respectively) compared with the placebo arm (15 percent and 34 percent, respectively).",
"     </li>",
"     <li>",
"      At 12 weeks after the discontinuation of therapy, viral suppression was maintained in 61 percent of patients assigned to the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      arm compared with 27 percent of those assigned to the placebo arm.",
"     </li>",
"     <li>",
"      Treatment discontinuation due to an adverse event occurred in 20 percent of patients assigned to the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      arm compared with 9 percent of those assigned to the placebo arm. There were no unexpected adverse events; side effects that were more commonly reported in the boceprevir arm included decreased appetite, pyrexia, dysgeusia, vomiting, asthenia, and neutropenia. Anemia was observed in 41 percent of patients assigned to boceprevir compared with 26 percent of the patients on the placebo arm. Use of erythropoietin occurred in more patients on the boceprevir arm (38 percent versus 21 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, subsequent pharmacokinetic data from healthy volunteers has suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    has significant drug-drug interactions with ritonavir-boosted protease inhibitors (ie, lopinavir,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    ) which lead to lower serum drug concentrations of both HIV protease inhibitors and boceprevir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/17\">",
"     17",
"    </a>",
"    ]. Interestingly, the numbers of patients who developed virologic breakthrough were equivalent in both arms of this trial; it is possible that the anti-HIV activity of pegylated interferon may have been protective.",
"   </p>",
"   <p>",
"    Among healthy volunteers, there are no clinically meaningful drug-drug interactions between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , an HIV integrase inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/18\">",
"     18",
"    </a>",
"    ]. In light of these additional pharmacokinetic data, we prefer to use pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    plus boceprevir in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    plus raltegravir. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/56/11144?source=see_link\">",
"     \"Pharmacology of integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3374278\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials of maintenance therapy were designed to determine if long-term administration of HCV treatment could lead to lower rates of hepatic decompensation and hepatocellular carcinoma in prior interferon-nonresponders, with disappointing results. Maintenance therapy has no role in the treatment of HCV-infected patients, with or without HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35768?source=see_link\">",
"     \"Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link&amp;anchor=H6411393#H6411393\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\", section on 'Maintenance therapy in nonresponders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3374285\">",
"    <span class=\"h2\">",
"     ACTG 5178 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACTG 5178, also known as \"SLAM-C\" (Suppressive Long-term Antiviral Management of hepatitis C virus and HIV coinfected patients), enrolled 330 US patients who did not achieve a virologic response on prior treatment for HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/19\">",
"     19",
"    </a>",
"    ]. During the first 12 to 18 weeks, patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/27/27064?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    and weight-based",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . The vast majority had HIV viral suppression on ART (74 percent).",
"   </p>",
"   <p>",
"    Nonresponders (n = 86) were randomly assigned to continue on pegylated interferon therapy alone for 72 weeks versus no study drugs to determine if maintenance therapy may slow fibrosis progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/19\">",
"     19",
"    </a>",
"    ]. However, the safety monitoring board determined that the hypothesis could not be tested since there was little disease progression in the patients assigned to the observation arm. Whether effective HIV suppression on ART contributed to the slow progression of liver disease is unknown.",
"   </p>",
"   <p>",
"    Early virologic response was seen in 183 (55 percent) of the patients, which is higher than historic controls on fixed-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Of these, 169 enrolled into a 72 week treatment arm. SVR rates among the 94 patients who have attained 96 weeks of follow-up to date are 51 percent (40 percent in patients with genotype 1 and 4 infection; 83 percent in genotype 2 and 3 infection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38536/abstract/20\">",
"     20",
"    </a>",
"    ]. Furthermore, those who achieved a complete EVR had higher SVR rates than those who only achieved a partial EVR (64 versus 13 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3374292\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SLAM-C study does not support the use of maintenance therapy in patients who have not responded to treatment for HCV. However, the study results suggest that ART may have some benefit in slowing down fibrosis progression.",
"   </p>",
"   <p>",
"    The overall response rates with weight-based",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    are higher than in historical controls; however, these patients were not treatment-naive so extrapolation to this group should be guarded.",
"   </p>",
"   <p>",
"    The study also gives some insight into the importance of achieving a complete early virologic response (eg, non-detectable viremia) at 12 weeks as a predictor of SVR. Those patients who achieve only an incomplete early virologic response (defined as a two-log drop in viremia at week 12) have a high chance of relapse (eg, 1 out of 3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are six different HCV genotypes that are found worldwide. Generally speaking, HCV genotype 1 and 4 are less interferon-responsive than HCV genotypes 2 or 3. (See",
"      <a class=\"local\" href=\"#H16229903\">",
"       'Trials of peginterferon with ribavirin for HCV treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized clinical trials have demonstrated that pegylated interferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      combination therapy is associated with higher sustained virologic response rates compared with standard interferon and ribavirin therapy for HCV genotypes 1 through 4. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=see_link\">",
"       \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Side effect profiles in",
"      <span class=\"nowrap\">",
"       HIV/HCV-coinfected",
"      </span>",
"      patients related to peginterferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      are similar to those seen in patients with HCV infection alone and include flu-like symptoms, malaise, and weight loss. Laboratory abnormalities include anemia, neutropenia, and thrombocytopenia. (See",
"      <a class=\"local\" href=\"#H16229903\">",
"       'Trials of peginterferon with ribavirin for HCV treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Large registration trials among HCV genotype 1-infected patients who are HIV-uninfected have demonstrated that the addition of an HCV protease inhibitor (either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      ) is associated with significantly greater sustained virologic response rates compared with dual therapy. Similar preliminary data have been reported for HIV-infected patients; two small randomized clinical trials have demonstrated that the proportion of HCV genotype 1-infected patients who maintain HCV viral suppression 12 weeks after stopping HCV treatment with pegylated",
"      <span class=\"nowrap\">",
"       interferon/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      plus an HCV protease inhibitor (ie, boceprevir or telaprevir) is significantly higher compared with patients taking pegylated",
"      <span class=\"nowrap\">",
"       interferon/ribavirin",
"      </span>",
"      dual therapy. (See",
"      <a class=\"local\" href=\"#H16230082\">",
"       'Trials of triple therapy including HCV protease inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The side effect profile of the HCV protease inhibitors in HIV-infected patients is similar to that already shown in large registration trials among patients with HCV alone. The most common adverse events associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      include headache and dysgeusia, while",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      is associated with rash and pruritis. Both agents are also associated with symptoms of gastrointestinal disturbance and high rates of anemia. (See",
"      <a class=\"local\" href=\"#H16230082\">",
"       'Trials of triple therapy including HCV protease inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to using HCV protease inhibitors, clinicians should carefully check for information on drug-drug interactions, which can lead to a negative impact on HIV or HCV suppression. (See",
"      <a class=\"local\" href=\"#H16230082\">",
"       'Trials of triple therapy including HCV protease inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Trials of maintenance therapy were designed to determine if long-term administration of HCV treatment could lead to lower rates of hepatic decompensation and hepatocellular carcinoma in prior interferon-nonresponders, with disappointing results. Maintenance therapy has no role in the treatment of HCV-infected patients, with or without HIV infection. (See",
"      <a class=\"local\" href=\"#H3374278\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38536/abstract/1\">",
"      Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38536/abstract/2\">",
"      Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38536/abstract/3\">",
"      Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38536/abstract/4\">",
"      Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451.",
"     </a>",
"    </li>",
"    <li>",
"     Rodriguez-Torres M, Slim J, Bhatti L, et al. Standard versus high dose ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1) HCV patients coinfected with HIV: final results of the PARADIGM study. Program and abstracts of the 60th Annual Meeting of the American Association for (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm255390.htm (Accessed on June 09, 2011).",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm (Accessed on June 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38536/abstract/8\">",
"      Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18:F21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38536/abstract/9\">",
"      N&uacute;&ntilde;ez M, Mari&ntilde;o A, Mari&ntilde;o A, et al. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007; 45:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38536/abstract/10\">",
"      Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38536/abstract/11\">",
"      Crespo M, Sauleda S, Esteban JI, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007; 14:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38536/abstract/12\">",
"      Van den Eynde E, Crespo M, Esteban JI, et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis 2009; 48:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38536/abstract/13\">",
"      Tural C, Galeras JA, Planas R, et al. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients. Antivir Ther 2008; 13:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38536/abstract/14\">",
"      P&eacute;rez-Olmeda M, N&uacute;&ntilde;ez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2012b/Abstracts/42969.htm (Accessed on July 03, 2012).",
"    </li>",
"    <li>",
"     Sulkowski M, Pol S, Cooper C, et al. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV coinfected pateints: interim on-treatment results [Abstract LB-37]. In: Programs and abstracts of the 49th Annual Meeting of the Infectious Diseases Society of America. Boston, MA. (Accessed on February 10, 2012).",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm291144.htm (Accessed on February 10, 2012).",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2012b/Abstracts/45378.htm (Accessed on April 30, 2012).",
"    </li>",
"    <li>",
"     Sherman K, Andersen J, Butt A, et al. Sustained long-term antiviral maintenance with pegylated interferon in HCV/HIV-co-infected patients: early viral response and effect on fibrosis in treated and control subjects. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 3-6, 2008; abstract # 58.",
"    </li>",
"    <li>",
"     Chung RT, Umbleja T, Butt A, et al. SLAM-C (ACTG A5178): Role of early virologic response in extended therapy with PEG-interferon and weight-based ribavirin in HIV/HCV coinfection. Presented at the 16th Annual Conference on Retroviruses and Opportunistic Infections, Montreal, Canada February 8-11th, 2009; abstract # 103LB.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3749 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38536=[""].join("\n");
var outline_f37_40_38536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16229059\">",
"      ANTIVIRAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16229648\">",
"      Peginterferon and ribavirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16229655\">",
"      HCV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16229903\">",
"      TRIALS OF PEGINTERFERON WITH RIBAVIRIN FOR HCV TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      APRICOT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RIBAVIC trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AIDS Clinical Trial Group (ACTG) 5071",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PRESCO trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LAGUNO trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CRESPO trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TURAL study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Perez-Olmeda trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16230082\">",
"      TRIALS OF TRIPLE THERAPY INCLUDING HCV PROTEASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16230299\">",
"      Telaprevir-based therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3374124\">",
"      Boceprevir-based therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3374278\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3374285\">",
"      ACTG 5178 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3374292\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35768?source=related_link\">",
"      Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/56/11144?source=related_link\">",
"      Pharmacology of integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15785?source=related_link\">",
"      Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_40_38537="Postoperative complications among patients undergoing cardiac surgery";
var content_f37_40_38537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postoperative complications among patients undergoing cardiac surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38537/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38537/contributors\">",
"     Frank E Silvestry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38537/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38537/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38537/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38537/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38537/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/40/38537/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of cardiopulmonary bypass distinguishes cardiac surgery from other types of surgery. It also introduces a unique set of potential postoperative complications. These include vasospasm, altered platelet-endothelial cell interactions, and a generalized inflammatory response due to blood contacting the synthetic surfaces of the bypass equipment. The result is low flow in the microcirculation of the heart, brain, and other organs, which may lead to organ dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The postoperative management of patients following cardiac surgery is reviewed here. Preoperative pulmonary assessment and potential complications of coronary artery bypass grafting are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=see_link\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine monitoring following cardiac surgery typically includes continuous telemetry, measurement of the arterial blood pressure via an arterial catheter, measurement of the cardiac filling pressures via a pulmonary artery catheter (ie, right heart catheter, Swan Ganz catheter), continuous assessment of the arterial oxygen saturation via pulse oximetry, and continuous measurement of the mixed venous oxygen saturation via an oximetric pulmonary artery catheter. Such monitoring allows instantaneous assessment of cardiopulmonary physiology. The expected postoperative values are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef75511 \" href=\"mobipreview.htm?9/13/9435\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although pulmonary artery catheters are used routinely in most centers, there is a paucity of empirical evidence to support this practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In a trial that randomly assigned 1094 patients undergoing coronary artery bypass grafting (CABG) to receive either a central venous catheter or a pulmonary artery catheter to assist in perioperative management, there were no significant differences in the length of intensive care unit stay, occurrence of postoperative myocardial infarction, in-hospital death, major hemodynamic aberrations, or major noncardiac complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/5\">",
"     5",
"    </a>",
"    ]. Most pulmonary artery catheters are removed within 12 to 24 hours of surgery if significant vasopressor, vasodilator, or inotropic therapy is no longer required.",
"   </p>",
"   <p>",
"    Fluid shifts should be closely monitored by frequent assessment of the central venous pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary artery occlusion pressure (ie, pulmonary capillary wedge pressure), chest and mediastinal tube drainage, urine output, and patient weight. Measurement of arterial blood gases, hemoglobin concentration, platelet count, coagulation parameters, serum electrolytes, and serum creatinine is routinely performed on a daily basis.",
"   </p>",
"   <p>",
"    Monitoring following cardiac surgery initially occurs in the intensive care unit (ICU). However, the use of clinical practice guidelines and clinical pathways, combined with improvements in cardiac surgical care, has decreased the length of stay in the intensive care unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/6\">",
"     6",
"    </a>",
"    ]. Many patients are now ready to be transferred to \"step-down\" units within 24 hours of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CARDIAC DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor cardiac function during the early postoperative period is associated with an increased risk of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/7\">",
"     7",
"    </a>",
"    ]. It is usually suspected when there is unexplained postoperative hypotension, tachycardia, or pulmonary edema. Evaluation of suspected cardiac dysfunction consists of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Telemetry &ndash; Assess the patient&rsquo;s continuous telemetry to identify or exclude cardiac dysrhythmias.",
"     </li>",
"     <li>",
"      Echocardiography &ndash; Perform transthoracic or transesophageal echocardiography to assess biventricular function, to look for residual or unexpected valvular disease, and to exclude pericardial tamponade.",
"     </li>",
"     <li>",
"      Invasive hemodynamic assessment via a pulmonary artery catheter &ndash; Use a pulmonary artery catheter to measure cardiopulmonary pressures, evaluate pressure tracings, determine cardiac output via thermodilution or the Fick equation, and calculate the systemic and pulmonary vascular resistances. This information can be used to identify valve dysfunction, detect pericardial tamponade, determine whether pulmonary edema is likely cardiogenic or noncardiogenic, and distinguish whether hypotension is most likely due to cardiac dysfunction, hypovolemia, or vasodilation.",
"     </li>",
"     <li>",
"      Electrocardiography &ndash; Obtain a 12-lead electrocardiogram to look for myocardial ischemia and to assess in detail any dysrhythmias noted on telemetry.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These four tests are likely to identify the cause of cardiac dysfunction. A chest x-ray may be helpful in the rare instances when these tests do not find the cause of cardiac dysfunction, since it can identify non-cardiac causes of cardiac dysfunction.",
"   </p>",
"   <p>",
"    The most common causes of cardiac dysfunction following cardiac surgery are mechanical complications, physiologic complications (inadequate preload, excessive afterload, and poor ventricular inotropy), dysrhythmias, and myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanical complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical complications of cardiac surgery are usually detected by echocardiography or invasive hemodynamic assessment. Examples include spasm or occlusion of a coronary artery graft, prosthetic valve paravalvular regurgitation, cardiac tamponade, hematoma, and systolic anterior motion of the mitral valve with left ventricular outflow tract obstruction. Treatment of the mechanical complications of cardiac surgery is usually surgical.",
"   </p>",
"   <p>",
"    Not all mechanical complications of cardiac surgery involve the heart. Non-cardiac mechanical complications include pneumothorax, hemothorax, and endotracheal tube malposition. These complications can be readily identified on a chest x-ray. Pneumothorax and hemothorax often require tube thoracostomy, while endotracheal tube malposition requires repositioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21471856\">",
"    <span class=\"h2\">",
"     Physiologic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once mechanical complications have been excluded, an initial decision should be made about whether the patient&rsquo;s cardiac dysfunction (ie, low cardiac output) is most likely due to an insufficient stroke volume or heart rate. If it is likely due to diminished stroke volume, then it should be determined whether this is likely due to inadequate left ventricular preload (ie, intravascular hypovolemia), excessive left ventricular afterload (ie, hypertension),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poor inotropy (ie, cardiomyopathy). Data from the echocardiogram",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    invasive hemodynamic assessment can be used to inform these judgments. Treatment should be directed at the presumed abnormality, while the underlying cause is sought.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Inadequate preload",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best measure of left ventricular preload is the left ventricular end diastolic volume (LVEDV). It can be estimated by echocardiography or certain invasive hemodynamic measures: the pulmonary artery occlusion pressure (if a pulmonary artery catheter is in place) or the left atrial pressure (if a left atrial catheter has been placed). These hemodynamic measurements approximate the left ventricular end diastolic pressure (LVEDP), from which assumptions about the LVEDV can be made.",
"   </p>",
"   <p>",
"    Left ventricular preload may be inadequate during the immediate postoperative period because of loss of vasomotor tone, increased capillary permeability, intraoperative and postoperative blood loss, or high urine output due to hypothermia. In addition, left ventricular compliance is frequently reduced following cardiac surgery, producing diastolic dysfunction; a higher LVEDP is required to maintain a given preload in affected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/11\">",
"     11",
"    </a>",
"    ]. The reduced compliance is the result of postischemic injury and \"myocardial stunning,\" which results in inadequate myocardial diastolic relaxation. As an example, patients with significant left ventricular hypertrophy due to aortic stenosis or hypertrophic cardiomyopathy often require pulmonary artery occlusion pressures of 18 to 22 mmHg to maintain an adequate preload to support the cardiac output.",
"   </p>",
"   <p>",
"    Inadequate preload should be corrected by administering intravascular volume. Such patients should be monitored closely because many will continue to exhibit signs of cardiac dysfunction even after their preload has been corrected. This suggests that there is coexisting poor inotropy and therapy should be redirected toward the poor inotropy as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Excessive afterload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative hypertension is common; it can cause decreased stroke volume and increased myocardial oxygen demand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The presumed etiology is systemic vasoconstriction, likely related to hypothermia induced during bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/14\">",
"     14",
"    </a>",
"    ]. The observation that rewarming does not closely correlate with resolution of the hypertension suggests that other factors may also be involved, such as humoral factors provoked by cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Consequences of systemic vasoconstriction include tissue hypoxia in the skeletal muscles and secondary metabolic acidosis.",
"   </p>",
"   <p>",
"    Patients judged to have excessive afterload should be treated with a vasodilator. Sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    is the vasodilator of choice to reduce excessive vasoconstriction in the immediate postoperative period. The blood pressure must be continuously monitored during therapy because vasoconstriction may improve quickly during rewarming from the hypothermia, leading to hypotension that requires immediate discontinuation of the sodium nitroprusside. Hypotension that persists despite the discontinuation of sodium nitroprusside should be initially treated with intravenous fluids, but may require vasopressors. Such hypotension is more common with normothermic bypass and longer cardiopulmonary bypass times, and less common in patients with diabetes, peripheral vascular disease, or a left ventricular ejection fraction of less than 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients will continue to exhibit signs of cardiac dysfunction even after their afterload has been reduced. This suggests there is coexisting poor inotropy and therapy should be redirected toward the poor inotropy as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21471923\">",
"    <span class=\"h3\">",
"     Poor inotropy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired ventricular function is suggested if the echocardiogram shows poor ventricular contraction and a low ejection fraction, or if the invasive hemodynamic measurements include a low cardiac output accompanied by a normal or high pulmonary artery occlusion pressure and normal or high systemic vascular resistance. Postoperative ventricular function may be decreased due to intraoperative events, postoperative events,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hibernating myocardium. Examples include inadequate myocardial protection during cross-clamping of the aorta, ischemic myocardial injury during off-pump operations, uncorrected valvular lesions, reduced or inadequate intraoperative coronary blood flow, cardiac tamponade, or ischemia or infarction due to coronary artery air embolus, coronary graft vasospasm, or coronary graft thrombosis.",
"   </p>",
"   <p>",
"    Patients with poor inotropy due to ischemia, poor inotropy plus inadequate preload, or poor inotropy plus excessive afterload, should initially have their ischemia, inadequate preload, or excessive afterload corrected, respectively. Correction of the ischemia or excessive afterload may improve inotropy, rendering an inotropic agent unnecessary. Correction of the inadequate preload makes it less likely that hypotension will occur if an inotropic agent is started (most inotropic agents cause vasodilation at low doses and, thus, hypotension is common immediately following initiation of the inotropic agent).",
"   </p>",
"   <p>",
"    Patients with persistent poor inotropy despite correction of potential underlying causes require pharmacologic inotropic support to augment contractility (",
"    <a class=\"graphic graphic_table graphicRef65593 \" href=\"mobipreview.htm?8/40/8844\">",
"     table 2",
"    </a>",
"    ). The patients who are most likely to benefit from inotropic support are those with a cardiac index less than 2.0",
"    <span class=\"nowrap\">",
"     liters/minute/m2",
"    </span>",
"    despite an optimized heart rate, rhythm, preload, afterload, and without evidence of tamponade. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    is an effective inotrope following cardiac surgery, even though is rarely used as an inotrope in other settings. Epinephrine produces consistent increases in the cardiac output with variable effects on arterial blood pressure following cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     Dopamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    also increase cardiac output and heart rate, and appear to have efficacies similar to epinephrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/19\">",
"     19",
"    </a>",
"    ]. Dobutamine produces greater reduction in left ventricular preload than dopamine and it augments coronary blood flow. However, the importance of the latter phenomenon is unclear, because surgically revascularized patients rarely exhibit ischemia in the absence of mechanical compromise of the coronary circulation.",
"   </p>",
"   <p>",
"    Phosphodiesterase inhibitors such as inamrinone (formerly known as amrinone),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , enoximone, and vesnarinone increase myocardial contractility, enhance myocardial relaxation, improve coronary blood flow, and reduce the systemic vascular resistance. The effect is to increase the cardiac index and decrease left ventricular preload and afterload, with minimal change in myocardial oxygen demand. Such agents are probably beneficial when used briefly following cardiac surgery, despite concerns that they may increase mortality when used in chronic heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with profound ventricular dysfunction who are unable to wean from cardiopulmonary bypass despite the use of inotropic drugs often require the addition of mechanical assist devices, such as an intraaortic balloon pump or ventricular assist device, until native ventricular function recovers from the stresses of surgery and cardiopulmonary bypass. These devices reduce ventricular wall stress and augment coronary and systemic perfusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dysrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trauma of cardiac surgery predisposes patients to atrial and ventricular arrhythmias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial fibrillation &ndash; Atrial fibrillation can disturb normal atrioventricular synchrony and result in a 15 to 25 percent reduction in cardiac output [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/23\">",
"       23",
"      </a>",
"      ]. Initial management involves slowing the ventricular heart rate using negative chronotropic agents. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12074?source=see_link\">",
"       \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"      </a>",
"      .) The optimal heart rate usually occurs at rates between 80 and 100 beats per minute [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/24\">",
"       24",
"      </a>",
"      ]. Once the ventricular heart rate is controlled, restoration of sinus rhythm with electrical or pharmacologic cardioversion may be considered. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link\">",
"       \"Restoration of sinus rhythm in atrial fibrillation\"",
"      </a>",
"      .) Postoperative prophylactic therapy with beta blockers or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      can help prevent postoperative atrial fibrillation and may have a role in the management of some patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link&amp;anchor=H13#H13\">",
"       \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Prevention of AF and complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ventricular arrhythmias &ndash; The hemodynamic instability of patients with ventricular arrhythmias is variable and depends upon the rate of the tachyarrhythmia and left ventricular systolic and diastolic function. Sustained ventricular tachyarrhythmias should be promptly converted chemically or electrically. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11050?source=see_link\">",
"       \"Cardioversion for specific arrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bradyarrhythmias &ndash; Bradyarrhythmias are particularly common after valve surgery and are probably a consequence of direct surgical injury and local edema. If the bradycardia is symptomatic, temporary electrical pacing may be required. In some cases, permanent pacing may be necessary. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=see_link\">",
"       \"Indications for permanent cardiac pacing\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative myocardial infarction (MI), defined as new Q waves on the postoperative electrocardiogram, occurs in 4 to 5 percent of patients undergoing coronary artery bypass grafting (CABG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. It is usually due to poor distal perfusion after grafting of the more proximal coronary arteries. The incidence of perioperative MI after other types of cardiac surgery is uncertain. It is important for clinicians to realize that the diagnostic accuracy of elevations in the serum creatine kinase (CK), CK-MB, and troponin is reduced after cardiac surgery because the enzymes are released as a routine sequela of the procedure. The diagnosis and management of perioperative MI are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=see_link&amp;anchor=H3#H3\">",
"     \"Early cardiac complications of coronary artery bypass graft surgery\", section on 'Perioperative MI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     VASODILATORY SHOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiopulmonary bypass can be complicated by vasodilatory (distributive) shock, which is a consequence of severely decreased systemic vascular resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/27\">",
"     27",
"    </a>",
"    ]. The cardiac output is typically increased in an effort to compensate for the diminished systemic vascular resistance, but may be normal or low if there is coexisting left ventricular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link&amp;anchor=H6#H6\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Distributive'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of vasodilatory shock has been estimated to be 5 to 8 percent following cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], and even higher among patients who are undergoing insertion of a ventricular assist device for end-stage heart failure (42 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/29\">",
"     29",
"    </a>",
"    ] or who have a left ventricular ejection fraction &lt;35 percent (27 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/27\">",
"     27",
"    </a>",
"    ]. Risk factors include a reduced ejection fraction, prolonged aortic cross-clamp times, male gender, and preoperative therapy with angiotensin converting enzyme inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/27,30\">",
"     27,30",
"    </a>",
"    ]. Patients who develop vasodilatory shock following cardiac surgery have an increased likelihood postoperative bleeding, renal and liver injury, neurologic dysfunction, and respiratory failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with vasodilatory shock respond to intravenous norepinephrine, often at low doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/28\">",
"     28",
"    </a>",
"    ]. There are limited data about the outcome of patients who develop vasodilatory shock after cardiopulmonary bypass. Small studies have reported mortality rates between 5 and 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of vasodilatory shock following cardiac surgery is uncertain. One hypothesis is that vasodilation is a consequence of a systemic inflammatory response to ischemia, reperfusion, surgical trauma, endotoxin release, or blood contact with the bypass circuit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Alternative proposals include a relative deficiency of arginine vasopressin (AVP) or increased production of nitric oxide (NO):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with post-bypass vasodilatory shock have inappropriately low serum AVP concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/27,33\">",
"       27,33",
"      </a>",
"      ]. Moreover, in a retrospective cohort study of 40 patients with norepinephrine-resistant hypotension following cardiac surgery, treatment with AVP at doses ranging from 0.01 to 0.10",
"      <span class=\"nowrap\">",
"       U/min",
"      </span>",
"      was associated with an increase in the mean arterial pressure from 58 to 82 mmHg, as well as an increase in the systemic vascular resistance from 771 to 1192",
"      <span class=\"nowrap\">",
"       dyne-sec/cm5",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Production of NO is increased in many types of vasodilatory shock, including post-bypass vasodilatory shock [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. Because NO causes vasodilation via activation of soluble guanylate cyclase,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      was studied as a potential therapeutic agent (methylene blue is an inhibitor of guanylate cyclase) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/28,35\">",
"       28,35",
"      </a>",
"      ]. A trial randomly assigned 56 patients with vasodilatory shock despite norepinephrine therapy following cardiopulmonary bypass to receive methylene blue (a single dose of 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      infused over one hour) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/35\">",
"       35",
"      </a>",
"      ]. In the methylene blue group, the mean duration of vasodilatory shock was significantly shorter (less than two hours versus greater than 24 hours) and mortality was significantly lower (0 versus 21 percent). The patients who died during the trial all had positive blood cultures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HEMATOLOGIC DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo cardiac surgery are at increased risk for both bleeding and thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative bleeding is common, with severe bleeding (requiring transfusion of &gt;10 units of packed red blood cells) occurring in 3 to 5 percent of patients who have undergone cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/36\">",
"     36",
"    </a>",
"    ]. Such extensive bleeding is usually due to one or more of the following factors: incomplete surgical hemostasis, residual",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    effect after cardiopulmonary bypass, clotting factor depletion, hypothermia, postoperative hypotension, hemodilution (dilutional thrombocytopenia and coagulopathy), or platelet abnormalities (platelet dysfunction and thrombocytopenia).",
"   </p>",
"   <p>",
"    The association of cardiopulmonary bypass with both thrombocytopenia and platelet dysfunction was illustrated by an observational study of 60 patients undergoing coronary artery bypass graft surgery (CABG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/37\">",
"     37",
"    </a>",
"    ]. The study compared patients who underwent CABG using cardiopulmonary bypass to those who underwent off-pump surgery. It found that those who underwent cardiopulmonary bypass had more severe thrombocytopenia and abnormal platelet activation postoperatively. This may explain why surgery using cardiopulmonary bypass is associated with a greater risk of bleeding than off-pump surgery.",
"   </p>",
"   <p>",
"    Postoperative bleeding frequently requires fresh frozen plasma and platelets to correct the coagulation abnormalities. Transfusion of packed red blood cells may also be necessary to replace blood loss. Extensive bleeding can be mitigated in some cases by the administration of the antifibrinolytic agent, epsilon-aminocaproic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=see_link\">",
"     \"Use of blood products in the critically ill\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo cardiopulmonary bypass appear to be at increased risk of developing thrombosis, probably due to increased platelet activity. This was demonstrated by a trial that randomly assigned 80 patients to undergo CABG with or without cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/40\">",
"     40",
"    </a>",
"    ]. Platelet activity during the early postoperative period was higher among patients who underwent cardiopulmonary bypass than among those who did not. This platelet activity may be resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , as suggested by another study that reported that the antiplatelet effect of aspirin was impaired after CABG with cardiopulmonary bypass, but not after CABG without cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been hypothesized that the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    resistance noted in these studies may be due to the increased platelet turnover that follows cardiopulmonary bypass. Data looking at the long-term outcome of patients who develop aspirin resistance after cardiopulmonary bypass are lacking. However, there is evidence that the platelets of patients who develop graft thrombosis are more likely to be resistant to aspirin than patients without thrombotic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/42\">",
"     42",
"    </a>",
"    ]. Pharmacological approaches to improve antithrombotic therapy in patients to develop aspirin resistance after CABG are being explored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PULMONARY DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary dysfunction is a significant cause of morbidity following cardiac surgery. Common types of pulmonary dysfunction include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pleural effusion &ndash; Pleural effusions are common postoperative findings in patients who undergo various cardiac surgical procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/43\">",
"       43",
"      </a>",
"      ]. Most are a consequence of the surgery itself (nonspecific pleural effusions) and follow a benign course. However, pleural effusions may also occur with post-cardiac injury syndrome (PCIS) or may be the initial manifestation of a potentially serious complicating event. Causes of pleural effusion after cardiac surgery are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef55729 \" href=\"mobipreview.htm?2/1/2075\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16728?source=see_link\">",
"       \"Pleural effusions following cardiac surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumonia &ndash; Sternotomy and thoracotomy incisions produce pain, which impairs the ability to cough and breathe deeply. This increases the risk for pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=see_link\">",
"       \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=see_link\">",
"       \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atelectasis &ndash; Atelectasis occurs in up to 70 percent of patients following cardiac surgery, usually as a result of single lung ventilation and intentional lung collapse during the surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. Management consists of incentive spirometry and early physical mobilization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35795?source=see_link\">",
"       \"Atelectasis: Types and pathogenesis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decreased thoracic compliance &ndash; Chest wall and lung compliance decrease postoperatively. This effect peaks approximately three days after surgery and may complicate the extubation of patients, especially those with underlying lung disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21112?source=see_link\">",
"       \"Weaning from mechanical ventilation: Readiness testing\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14423?source=see_link\">",
"       \"Methods of weaning from mechanical ventilation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Difficulty weaning &ndash; Some patients prove difficult to wean from mechanical ventilation following cardiac surgery. The prognosis of such patients varies widely across series, but is not uniformly poor. As an example, a series of 124 patients who received greater than seven days of mechanical ventilation following cardiac surgery found that 85 percent of the patients survived until discharge and 99 percent of the survivors were successfully weaned from mechanical ventilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diaphragmatic dysfunction &ndash; Phrenic nerve injury during surgery is rare, but may cause diaphragmatic dysfunction or paralysis if it occurs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12247?source=see_link\">",
"       \"Causes and diagnosis of unilateral diaphragmatic paralysis and eventration\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44469?source=see_link\">",
"       \"Treatment of diaphragmatic paralysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) &ndash; ALI and ARDS are types of hypoxemic respiratory failure characterized by acute onset, bilateral infiltrates, a decreased ratio of arterial oxygen tension to fraction of inspired oxygen, and lack of evidence of elevated left atrial pressure. They differ only in the severity of hypoxemia, with ARDS being more severe than ALI. ALI and ARDS complicate less than two percent of cardiac surgeries that used cardiopulmonary bypass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10505?source=see_link\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients undergoing cardiac surgery for structural or congenital heart disease frequently have pulmonary hypertension, which can complicate postoperative management. As an example, pulmonary complications (eg, pneumonia, atelectasis) may cause hypoxic vasoconstriction, worsened pulmonary hypertension, and hypoxemia. The result may be hypoxemia that seems out of proportion to the severity of the pulmonary complication. Inhaled nitric oxide (NO) causes selective pulmonary vasodilation and, therefore, can mitigate the exacerbation of pulmonary hypertension and stabilize hemodynamically compromised patients with severe pulmonary hypertension. It cannot be used long-term, but may be useful while the acute process that led to the deterioration is reversed. Inhaled NO requires a special device to administer and weaning it can cause rebound pulmonary hypertension. Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    may facilitate inhaled NO withdrawal by preventing rebound pulmonary hypertension in patients who have failed previous attempts to wean the inhaled NO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/4/38982?source=see_link\">",
"     \"Inhaled nitric oxide in adults with pulmonary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=see_link&amp;anchor=H29#H29\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'PDE5 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NEUROLOGIC DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of postoperative neurologic sequelae after coronary artery bypass graft surgery (CABG) is approximately 2 to 6 percent, with the frequency increasing among older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/50\">",
"     50",
"    </a>",
"    ]. A prospective cohort study followed 2108 patients undergoing CABG for postoperative neurologic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/51\">",
"     51",
"    </a>",
"    ]. The complications were placed into two categories: type I neurological complications were defined as focal injury (eg, stroke), stupor, or coma at discharge, while type II neurological complications were defined as deterioration in intellectual function, memory deficits, or seizures. The incidence of all adverse cerebral events was six percent. Patients with cerebral complications had higher in-hospital mortality, longer hospitalizations, and a higher rate of requiring discharge to a chronic care facility than did those without neurologic sequelae. Type I complications occurred in three percent, primarily consisting of nonfatal strokes. Type II complications also occurred in three percent and consisted primarily of deterioration in intellectual function (",
"    <a class=\"graphic graphic_figure graphicRef68686 \" href=\"mobipreview.htm?14/21/14685\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Early recognition of neurological complications is important. Although treatment is largely supportive, prompt initiation of therapy may prevent worsening of the complication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurological complications following cardiac surgery may be a result of a variety of processes. These include atheroembolism of aortic debris, embolism of left atrial or left ventricular thrombus, cerebral hypoperfusion, air embolism, and microembolism of granulocyte aggregates, fibrin, and platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RENAL DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute renal failure occurs in up to 30 percent of patients who have undergone cardiac surgery, when defined as a 50 percent increase in the serum creatinine concentration above baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/53\">",
"     53",
"    </a>",
"    ]. It is severe enough to require dialysis in 1 to 5 percent of patients and it appears to be associated with increased mortality. In a prospective cohort study of 43,642 patients who had undergone CABG or valve surgery, acute renal failure was associated with a 30-day mortality of 64 percent, compared to four percent without renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/54\">",
"     54",
"    </a>",
"    ]. More recent data suggest the incidence of renal failure following cardiac surgery has increased, while the associated mortality has decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/55\">",
"     55",
"    </a>",
"    ]. This probably reflects an increase in comorbid disease and improvements in postoperative care.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk factors &mdash; Postoperative risk factors for acute renal failure include poor cardiac performance and perioperative hemodynamic instability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/45,54\">",
"       45,54",
"      </a>",
"      ]. Risk factors that cannot be controlled postoperatively include advanced atherosclerotic vascular disease, reduced creatinine clearance, a long duration of cardiopulmonary bypass, and the use of radiocontrast agents immediately before surgery.",
"     </li>",
"     <li>",
"      Mechanism &mdash; Mechanisms of perioperative renal failure include renal artery vasoconstriction, hypothermia, loss of pulsatile flow during cardiopulmonary bypass, and atheroembolic disease.",
"     </li>",
"     <li>",
"      Prevention &mdash; The best preventive strategy is to optimize renal perfusion (ie, avoid hypotension and hypovolemia) and to avoid potentially nephrotoxic agents (eg, aminoglycoside antibiotics, angiotensin converting enzyme inhibitors, and radiologic contrast agents) in the immediate postoperative period. There is no clear evidence supporting the efficacy of pharmacologic therapy (eg, low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      , loop diuretics) to prevent acute renal failure after major surgery. In addition to lack of proven efficacy, there is some concern about toxicity (eg, arrhythmias, myocardial ischemia, and intestinal ischemia with dopamine). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link\">",
"       \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment &mdash; There is no convincing evidence of benefit from early",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aggressive dialysis, and there is some concern that renal function might be impaired by this approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38537/abstract/56\">",
"       56",
"      </a>",
"      ]. Thus, the decision to perform dialysis generally should be based upon the presence of uremic symptoms, fluid overload, or electrolyte abnormalities, rather than a specific blood urea nitrogen or serum creatinine concentration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21471558\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine monitoring following cardiac surgery typically includes continuous telemetry, measurement of the arterial blood pressure via an arterial catheter, measurement of the cardiac filling pressures via a pulmonary artery catheter (ie, right heart catheter, Swan Ganz catheter), continuous assessment of the arterial oxygen saturation via pulse oximetry, and continuous measurement of the mixed venous oxygen saturation via an oximetric pulmonary artery catheter. Such monitoring allows instantaneous assessment of cardiopulmonary physiology. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postoperative cardiac dysfunction is usually suspected when there is unexplained postoperative hypotension, tachycardia, or pulmonary edema. Evaluation consists of reviewing the patient&rsquo;s telemetry, echocardiography, invasive hemodynamic assessment via a pulmonary artery catheter, and a 12-lead electrocardiogram. These four tests are likely to identify the cause of cardiac dysfunction. A chest x-ray may be helpful if these tests do not find the cause of cardiac dysfunction. The most common causes of cardiac dysfunction following cardiac surgery are mechanical complications, physiologic complications (inadequate preload, excessive afterload, and poor ventricular inotropy), dysrhythmias, and myocardial infarction.(See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cardiac dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac surgery using cardiopulmonary bypass can be complicated by vasodilatory (distributive) shock. Most patients with vasodilatory shock respond to intravenous norepinephrine, often at low doses. The pathogenesis of vasodilatory shock following cardiac surgery is uncertain. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Vasodilatory shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who undergo cardiac surgery are at increased risk for both bleeding and thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bleeding is usually due to incomplete surgical hemostasis, residual",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      effect after cardiopulmonary bypass, clotting factor depletion, hypothermia, postoperative hypotension, hemodilution (dilutional thrombocytopenia and coagulopathy),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      platelet abnormalities (platelet dysfunction and thrombocytopenia). Postoperative bleeding frequently requires fresh frozen plasma and platelets to correct the coagulation abnormalities. Transfusion of packed red blood cells may also be necessary to replace blood loss. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increased risk of developing thrombosis is probably due to increased platelet activity caused by cardiopulmonary bypass. This platelet activity may be resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . Pharmacological approaches to improve antithrombotic therapy in patients to develop aspirin resistance after cardiopulmonary bypass are being explored. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary dysfunction is a significant cause of morbidity following cardiac surgery. Common types of pulmonary dysfunction include pleural effusion, pneumonia, atelectasis, decreased thoracic compliance, difficulty weaning from mechanical ventilation, diaphragmatic dysfunction, acute lung injury, and acute respiratory distress syndrome. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pulmonary dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurological complications may follow cardiac surgery. Patients with cerebral complications have higher in-hospital mortality, longer hospitalizations, and a higher rate of requiring discharge to a chronic care facility than those without neurologic sequelae. Early recognition of neurological complications is important. Although treatment is largely supportive, prompt initiation of therapy may prevent worsening of the complication. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Neurologic dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute renal failure occurs in up to 30 percent of patients who have undergone cardiac surgery and it appears to be associated with increased mortality. The best preventive strategy is to optimize renal perfusion (ie, avoid hypotension and hypovolemia) and to avoid potentially nephrotoxic agents (eg, aminoglycoside antibiotics, angiotensin converting enzyme inhibitors, and radiologic contrast agents) in the immediate postoperative period. There is no convincing evidence of benefit from early",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aggressive dialysis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Renal dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/1\">",
"      Cameron D. Initiation of white cell activation during cardiopulmonary bypass: cytokines and receptors. J Cardiovasc Pharmacol 1996; 27 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/2\">",
"      Gold JP, Roberts AJ, Hoover EL, et al. Effects of prolonged aortic cross-clamping with potassium cardioplegia on myocardial contractility in man. Surg Forum 1979; 30:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/3\">",
"      Leibowitz AB, Beilin Y. Pulmonary artery catheters and outcome in the perioperative period. New Horiz 1997; 5:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/4\">",
"      Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/5\">",
"      Tuman KJ, McCarthy RJ, Spiess BD, et al. Effect of pulmonary artery catheterization on outcome in patients undergoing coronary artery surgery. Anesthesiology 1989; 70:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/6\">",
"      Aps C. Fast-tracking in cardiac surgery. Br J Hosp Med 1995; 54:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/7\">",
"      Appelbaum A, Kouchoukos NT, Blackstone EH, Kirklin JW. Early risks of open heart surgery for mitral valve disease. Am J Cardiol 1976; 37:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/8\">",
"      Vignon P, Mentec H, Terr&eacute; S, et al. Diagnostic accuracy and therapeutic impact of transthoracic and transesophageal echocardiography in mechanically ventilated patients in the ICU. Chest 1994; 106:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/9\">",
"      Slama MA, Novara A, Van de Putte P, et al. Diagnostic and therapeutic implications of transesophageal echocardiography in medical ICU patients with unexplained shock, hypoxemia, or suspected endocarditis. Intensive Care Med 1996; 22:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/10\">",
"      Imren Y, Tasoglu I, Oktar GL, et al. The importance of transesophageal echocardiography in diagnosis of pericardial tamponade after cardiac surgery. J Card Surg 2008; 23:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/11\">",
"      McKenney PA, Apstein CS, Mendes LA, et al. Increased left ventricular diastolic chamber stiffness immediately after coronary artery bypass surgery. J Am Coll Cardiol 1994; 24:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/12\">",
"      Fremes SE, Weisel RD, Baird RJ, et al. Effects of postoperative hypertension and its treatment. J Thorac Cardiovasc Surg 1983; 86:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/13\">",
"      Roberts AJ, Niarchos AP, Subramanian VA, et al. Systemic hypertension associated with coronary artery bypass surgery. Predisposing factors, hemodynamic characteristics, humoral profile, and treatment. J Thorac Cardiovasc Surg 1977; 74:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/14\">",
"      Estafanous FG, Tarazi RC. Systemic arterial hypertension associated with cardiac surgery. Am J Cardiol 1980; 46:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/15\">",
"      Kuttila K, Niinikoski J. Peripheral perfusion after cardiac surgery. Crit Care Med 1989; 17:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/16\">",
"      Downing SW, Edmunds LH Jr. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992; 54:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/17\">",
"      Christakis GT, Fremes SE, Koch JP, et al. Determinants of low systemic vascular resistance during cardiopulmonary bypass. Ann Thorac Surg 1994; 58:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/18\">",
"      Birdi I, Regragui I, Izzat MB, et al. Influence of normothermic systemic perfusion during coronary artery bypass operations: a randomized prospective study. J Thorac Cardiovasc Surg 1997; 114:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/19\">",
"      Steen PA, Tinker JH, Pluth JR, et al. Efficacy of dopamine, dobutamine, and epinephrine during emergence from cardiopulmonary bypass in man. Circulation 1978; 57:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/20\">",
"      Stephenson LW, Blackstone EH, Kouchoukos NT. Dopamine vs epinephrine in patients following cardiac surgery: randomized study. Surg Forum 1976; 27:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/21\">",
"      Uretsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990; 82:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/22\">",
"      Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/23\">",
"      Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993; 56:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/24\">",
"      Kotter GS, Kotrly KJ, Kalbfleisch JH, et al. Myocardial ischemia during cardiovascular surgery as detected by an ST segment trend monitoring system. J Cardiothorac Anesth 1987; 1:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/25\">",
"      Yokoyama Y, Chaitman BR, Hardison RM, et al. Association between new electrocardiographic abnormalities after coronary revascularization and five-year cardiac mortality in BARI randomized and registry patients. Am J Cardiol 2000; 86:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/26\">",
"      Chaitman BR, Alderman EL, Sheffield LT, et al. Use of survival analysis to determine the clinical significance of new Q waves after coronary bypass surgery. Circulation 1983; 67:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/27\">",
"      Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998; 116:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/28\">",
"      Leyh RG, Kofidis T, Str&uuml;ber M, et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg 2003; 125:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/29\">",
"      Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96:II.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/30\">",
"      Kristof AS, Magder S. Low systemic vascular resistance state in patients undergoing cardiopulmonary bypass. Crit Care Med 1999; 27:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/31\">",
"      Cremer J, Martin M, Redl H, et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996; 61:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/32\">",
"      Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997; 112:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/33\">",
"      Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/34\">",
"      Ortega Mateo A. Nitric oxide reactivity and mechanisms involved in its biological effects. Pharmacol Res 2000; 42:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/35\">",
"      Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004; 77:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/36\">",
"      Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/37\">",
"      Ballotta A, Saleh HZ, El Baghdady HW, et al. Comparison of early platelet activation in patients undergoing on-pump versus off-pump coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007; 134:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/38\">",
"      Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/39\">",
"      Munoz JJ, Birkmeyer NJ, Birkmeyer JD, et al. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: a meta-analysis. Circulation 1999; 99:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/40\">",
"      Bednar F, Osmancik P, Vanek T, et al. Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: results from the prospective randomized trial PRAGUE 11-Coronary Artery Bypass and REactivity of Thrombocytes (CABARET). J Thorac Cardiovasc Surg 2008; 136:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/41\">",
"      Zimmermann N, Kurt M, Wenk A, et al. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting? Eur J Cardiothorac Surg 2005; 27:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/42\">",
"      Zimmermann N, Gams E, Hohlfeld T. Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur J Cardiothorac Surg 2008; 34:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/43\">",
"      Peng MJ, Vargas FS, Cukier A, et al. Postoperative pleural changes after coronary revascularization. Comparison between saphenous vein and internal mammary artery grafting. Chest 1992; 101:327.",
"     </a>",
"    </li>",
"    <li>",
"     Sladden, RN, Berkowitz, DE. Cardiopulmonary bypass and the lung. In: Cardiopulmonary Bypass, Gravlee, GP, Davis, RF, Utley, IR (Eds), Williams and Wilkins, Baltimore 1993. p.468.",
"    </li>",
"    <li>",
"     Ramsey, J. The Respiratory, renal, and hepatic systems: Effects of cardiac surgery and cardiopulmonary bypass. In: Cardiopulmonary Bypass, Mora, CT (Eds), Springer, New York 1995. p.147.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/46\">",
"      Engoren M, Buderer NF, Zacharias A. Long-term survival and health status after prolonged mechanical ventilation after cardiac surgery. Crit Care Med 2000; 28:2742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/47\">",
"      Messent M, Sullivan K, Keogh BF, et al. Adult respiratory distress syndrome following cardiopulmonary bypass: incidence and prediction. Anaesthesia 1992; 47:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/48\">",
"      Trachte AL, Lobato EB, Urdaneta F, et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 2005; 79:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/49\">",
"      Lee JE, Hillier SC, Knoderer CA. Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 2008; 23:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/50\">",
"      Tuman KJ, McCarthy RJ, Najafi H, Ivankovich AD. Differential effects of advanced age on neurologic and cardiac risks of coronary artery operations. J Thorac Cardiovasc Surg 1992; 104:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/51\">",
"      Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral outcomes after coronary bypass surgery. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators. N Engl J Med 1996; 335:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/52\">",
"      Breuer AC, Furlan AJ, Hanson MR, et al. Central nervous system complications of coronary artery bypass graft surgery: prospective analysis of 421 patients. Stroke 1983; 14:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/53\">",
"      Corwin HL, Sprague SM, DeLaria GA, Norusis MJ. Acute renal failure associated with cardiac operations. A case-control study. J Thorac Cardiovasc Surg 1989; 98:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/54\">",
"      Chertow GM, Lazarus JM, Christiansen CL, et al. Preoperative renal risk stratification. Circulation 1997; 95:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/55\">",
"      Thakar CV, Worley S, Arrigain S, et al. Improved survival in acute kidney injury after cardiac surgery. Am J Kidney Dis 2007; 50:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38537/abstract/56\">",
"      Conger JD. Interventions in clinical acute renal failure: what are the data? Am J Kidney Dis 1995; 26:565.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1627 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38537=[""].join("\n");
var outline_f37_40_38537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21471558\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CARDIAC DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanical complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21471856\">",
"      Physiologic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Inadequate preload",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Excessive afterload",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21471923\">",
"      - Poor inotropy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dysrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      VASODILATORY SHOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HEMATOLOGIC DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PULMONARY DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NEUROLOGIC DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RENAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21471558\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1627\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1627|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/21/14685\" title=\"figure 1\">",
"      Impact of age on adverse cerebral outcomes after CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1627|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/13/9435\" title=\"table 1\">",
"      Physiologic values in postop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/40/8844\" title=\"table 2\">",
"      Inotropic agents in postop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/1/2075\" title=\"table 3\">",
"      Postcardiac surgery pl effusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35795?source=related_link\">",
"      Atelectasis: Types and pathogenesis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12247?source=related_link\">",
"      Causes and diagnosis of unilateral diaphragmatic paralysis and eventration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=related_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/4/38982?source=related_link\">",
"      Inhaled nitric oxide in adults with pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14423?source=related_link\">",
"      Methods of weaning from mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16728?source=related_link\">",
"      Pleural effusions following cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44469?source=related_link\">",
"      Treatment of diaphragmatic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21112?source=related_link\">",
"      Weaning from mechanical ventilation: Readiness testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_40_38538="Acute liver failure in adults: Management and prognosis";
var content_f37_40_38538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute liver failure in adults: Management and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38538/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38538/contributors\">",
"     Eric Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38538/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38538/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38538/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/40/38538/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/40/38538/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/40/38538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute liver failure refers to the development of severe acute liver injury with encephalopathy and impaired synthetic function (international normalized ratio [INR] of &ge;1.5) in a patient without cirrhosis or preexisting liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. While the time course that differentiates acute liver failure from chronic liver failure varies between reports, a commonly used cut-off is an illness duration of &lt;26 weeks.",
"   </p>",
"   <p>",
"    Acute liver failure may also be diagnosed in patients with previously undiagnosed Wilson disease, vertically-acquired hepatitis B virus, or autoimmune hepatitis, in whom underlying cirrhosis may be present, provided the disease has been recognized for &lt;26 weeks. On the other hand, patients with acute severe alcoholic hepatitis, even if recognized for &lt;26 weeks, are considered to have acute-on-chronic liver failure since most have a long history of heavy drinking. The approach to such patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22104?source=see_link\">",
"     \"Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute liver failure has also been referred to as fulminant hepatic failure, acute hepatic necrosis, fulminant hepatic necrosis, and fulminant hepatitis. Untreated, the prognosis is poor, so timely recognition and management of patients with acute liver failure is crucial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/3\">",
"     3",
"    </a>",
"    ]. Whenever possible, patients with acute liver failure should be managed in an intensive care unit at a facility capable of performing liver transplantation.",
"   </p>",
"   <p>",
"    This topic will review and the management and prognosis of acute liver failure in adults. The etiology, clinical manifestations, and diagnosis of patients with acute liver failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discussion that follows is consistent with the 2011 The American Association for the Study of Liver Diseases (AASLD)",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf\">",
"     guideline",
"    </a>",
"    for the management of acute liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233807110\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general management of a patient with acute liver failure includes ensuring the patient is being cared for in the proper setting, monitoring for worsening liver failure, treating complications, and providing nutritional support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233810318\">",
"    <span class=\"h2\">",
"     Setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute liver failure should be managed in centers with an active liver transplantation program and expertise in caring for these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2\">",
"     2",
"    </a>",
"    ]. Only 40 percent of patients with acute liver failure recover spontaneously, leaving many in need of a liver transplantation, and even those who do eventually recover are often gravely ill [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, patients admitted to hospitals without a liver transplantation program should be transferred as soon as possible since it can be hazardous to transfer patients later in the disease course because of severe coagulopathy and increased intracranial pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with grade I encephalopathy (",
"    <a class=\"graphic graphic_table graphicRef62922 \" href=\"mobipreview.htm?32/17/33051\">",
"     table 1",
"    </a>",
"    ) may be managed on a general medical ward, provided the environment is quiet and frequent neurologic checks (eg, every two hours) are performed. If there is progression to grade II encephalopathy, or for patients presenting with grade II, III, or IV encephalopathy, management in an intensive care unit is indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stimulation can lead to increased intracranial pressure and should be minimized. This may be challenging in an intensive care unit. Whenever possible, patient's rooms should be quiet, without audible monitors or alarms in the room, and dimly lit. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Cerebral edema'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233810325\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial laboratory tests are used to follow the course of a patient's liver failure and to monitor for complications. Serum aminotransferases and bilirubin should be monitored daily. More frequent monitoring (three to four times daily) should be performed for coagulation parameters, complete blood counts, metabolic panels, and arterial blood gasses. In particular, patients should be monitored and treated for hypoglycemia, hypokalemia, hypomagnesemia, and hypophosphatemia. We perform finger sticks to monitor blood glucose levels every six hours. (See",
"    <a class=\"local\" href=\"#H233812427\">",
"     'Metabolic abnormalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Decreasing aminotransferase levels may indicate spontaneous recovery but could also signal worsening liver failure with loss of hepatocyte mass. In patients who are improving, the bilirubin and prothrombin time will decline, whereas in those with worsening liver failure, the bilirubin and prothrombin time will continue to rise. Because of the prognostic importance of the prothrombin time, it is recommended that fresh frozen plasma only be given for invasive procedures or active bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H166750581\">",
"     'Bleeding prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H166750348\">",
"    <span class=\"h2\">",
"     Hemodynamic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic derangements are common in patients with acute liver failure due to low systemic vascular resistance. In addition, patients may have intravascular volume depletion because of decreased oral intake and extravasation of fluid into the extra-vascular space. As a result, most patients will require fluid resuscitation initially. Patients who are hypotensive should be resuscitated with normal saline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients who are acidotic can be resuscitated with half-normal saline with 75",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . Dextrose should be added to crystalloid solutions in patients with hypoglycemia. However, it is important to avoid overhydration since it may worsen cerebral edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link&amp;anchor=H8#H8\">",
"     \"Maintenance and replacement fluid therapy in adults\", section on 'Replacement fluid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients may not respond adequately to fluid resuscitation may require vasopressor support. The goal is to maintain a mean arterial pressure of at least 75 mmHg or a cerebral perfusion pressure of at least 50 to 60 mmHg. Norepinephrine is often preferred because it is thought to best augment peripheral organ perfusion with less tachycardia and better preservation of splanchnic blood flow than other agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/5\">",
"     5",
"    </a>",
"    ]. Vasopressin may be added in those who do not respond to norepinephrine to potentiate the effect of norepinephrine. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Treatment of intracranial pressure elevation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=see_link&amp;anchor=H376789843#H376789843\">",
"     \"Use of vasopressors and inotropes\", section on 'Norepinephrine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As is seen in patients with septic shock, patients with acute liver failure may develop adrenal insufficiency. Thus, if hypotension persists despite volume repletion and vasopressor support, a trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    is reasonable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16281?source=see_link&amp;anchor=H19#H19\">",
"     \"Corticosteroid therapy in septic shock\", section on 'Administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246365968\">",
"    <span class=\"h2\">",
"     N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;N-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    is used for the treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity, but it may be beneficial in other forms of acute liver failure. While additional studies are needed before this therapy can be routinely recommended for acute liver failure from causes other than acetaminophen toxicity, it is reasonable to give it to patients who are not candidates for liver transplantation, to patients in whom acetaminophen toxicity may be contributing to the liver failure (eg, a patient with acute hepatitis B who was taking acetaminophen for right upper quadrant pain), and to patients with an indeterminate cause for the acute liver failure.",
"   </p>",
"   <p>",
"    A placebo-controlled trial involving 173 patients with acute liver failure due to causes other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (mainly drug-induced liver injury, autoimmune hepatitis, hepatitis B virus, or indeterminate) found significantly higher transplant-free survival (40 versus 27 percent) in patients randomized to N-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (initial loading dose 150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour over one hour followed by 12.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour for four hours, then continuous infusions of 6.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for the remaining 67 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/8\">",
"     8",
"    </a>",
"    ]. The benefit appeared to be confined to patients with early stage hepatic encephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H166750581\">",
"    <span class=\"h2\">",
"     Bleeding prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute liver failure can develop severe coagulopathy and bleed due to the diminished capacity of the failing liver to synthesize coagulation factors. The most common site of bleeding is the gastrointestinal tract and patients should receive stress ulcer prophylaxis with an H2 blocker or proton pump inhibitor. Prophylactic administration of fresh frozen plasma is usually not recommended since it has not been proven to influence mortality in a small randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/9\">",
"     9",
"    </a>",
"    ], can interfere with assessments of liver function, and may lead to fluid overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/10\">",
"     10",
"    </a>",
"    ]. Fresh frozen plasma is indicated only in the setting of active hemorrhage or prior to invasive procedures, such as placement of intracranial pressure monitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In extreme settings, correction of the coagulopathy is necessary but cannot be achieved adequately with fresh frozen plasma, particularly in patients who are severely volume overloaded. Small pilot studies suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    (rFVIIa) may improve or normalize the serum prothrombin time and control bleeding in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a preliminary case series of three patients, rFVIIa (40",
"      <span class=\"nowrap\">",
"       microg/kg",
"      </span>",
"      IV) was used to temporarily correct coagulopathies in patients with liver failure who required an invasive procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/11\">",
"       11",
"      </a>",
"      ]. A follow-up report from the same authors suggested that the combination of rFVIIa plus fresh frozen plasma was superior to fresh frozen plasma alone for treating coagulopathies and may have had a beneficial effect on morbidity and mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another nonrandomized study, significantly more patients receiving rFVIIa were able to undergo intracranial pressure monitoring than those receiving fresh frozen plasma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/16\">",
"       16",
"      </a>",
"      ]. Such patients also had less anasarca and slightly better overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger, controlled studies are needed to better define the role of recombinant factor VIIa in patients with acute liver failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233814522\">",
"    <span class=\"h2\">",
"     Infection surveillance and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute liver failure are at increased risk of infection and sepsis from a wide variety of causes, so an aggressive approach to diagnosing and treating infections is necessary. The most common sites of infection are the respiratory tract, the urinary tract, and the blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/18\">",
"     18",
"    </a>",
"    ]. Localizing signs of infection, such as fever and sputum production, are frequently absent, and the only clue to an underlying infectious process may be worsening of encephalopathy or renal function.",
"   </p>",
"   <p>",
"    Guidelines from the American Association for the Study of Liver Diseases (AASLD) suggest that all patients (including those without signs of infection) should have routine (eg, daily) urine, sputum, and blood cultures, as well as chest radiographs to detect bacterial or fungal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2\">",
"     2",
"    </a>",
"    ]. While we agree with the AASLD suggestion, it is important to note that data are lacking regarding the value of surveillance cultures or radiographs in this population, and positive culture results in the absence of signs of infection may be due to colonization or contamination by bacterial or fungal organisms.",
"   </p>",
"   <p>",
"    In addition to surveillance cultures, we suggest an evaluation for possible infection in patients with signs or symptoms suggesting infection (eg, fever, cough, sputum production) or deteriorating clinical status, particularly if there is worsening encephalopathy or worsening renal function. In addition to urine and blood cultures for bacterial or fungal infection and diagnostic chest radiographs, patients with ascites should undergo diagnostic paracentesis if ascites is present.",
"   </p>",
"   <p>",
"    The role of prophylactic antibiotics is controversial. While a randomized trial with 59 patients with acute liver failure who were not infected at entry found that prophylactic antibiotics reduced the rate of infection, a survival benefit was not seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/19\">",
"     19",
"    </a>",
"    ]. Our approach to antibiotic prophylaxis is similar to that recommended by the AASLD. We do not give patients prophylactic antibiotics, but instead give them only if there is evidence of active infection, positive surveillance culture results, or clinical deterioration (progression to high-grade encephalopathy or evidence of systemic inflammatory response syndrome [SIRS]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, having a low-index of suspicion for fungal infection is important because fungal infections are frequently encountered and are often diagnosed too late to be effectively treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/20\">",
"     20",
"    </a>",
"    ]. We have a low threshold for initiating antifungal coverage for patients with signs of infection who are at increased risk for fungal infection, such as those who have had prolonged hospitalization, those receiving continuous venovenous hemodialysis, and those who have been receiving an antibiotic or glucocorticoids.",
"   </p>",
"   <p>",
"    If the decision is made to provide empiric broad spectrum antibiotic coverage, nephrotoxic antibiotics, particularly the aminoglycosides, and hepatotoxic antibiotics should be avoided. We often use",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35030?source=see_link\">",
"      piperacillin",
"     </a>",
"     /tazobactam",
"    </span>",
"    or a fluoroquinolone. In addition, surveillance cultures are not needed in patients receiving antibiotic prophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233814623\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional support is a vital component in the treatment of acute liver failure and should be initiated early. It is required to prevent catabolism of body stores of proteins and it may decrease the risk of gastrointestinal bleeding from stress ulceration in critically ill patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/21\">",
"     21",
"    </a>",
"    ]. To prevent protein catabolism, severe protein restrictions should be avoided; a daily intake of 60 grams of protein is reasonable for most patients with acute liver failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with grade I or II encephalopathy, oral or enteral feeding is usually sufficient to meet metabolic requirements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/22\">",
"     22",
"    </a>",
"    ]. Enteral feeding should be provided for patients with grade III or IV encephalopathy. Placement of a nasogastric tube can increase intracranial pressure (because of gagging) and should generally be performed only in patients who are intubated and sedated. If adequate enteral feeding cannot be provided, parenteral nutrition should be initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233810382\">",
"    <span class=\"h2\">",
"     Medications to avoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, sedation should be avoided because patients with acute liver failure have a severely impaired ability to clear sedatives, and the effects of sedation may mask the signs of worsening encephalopathy or cerebral edema. However, in patients with severe agitation that cannot be managed in any other way, short-acting benzodiazepines in low doses may be given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2\">",
"     2",
"    </a>",
"    ]. In patients who require sedative medications, benzodiazepines, barbiturates, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , are preferable to opioids because opioids can decrease the seizure threshold. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Hepatic encephalopathy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3\">",
"     'Cerebral edema'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because acute renal failure often complicates acute liver failure, nephrotoxic drugs should be avoided. In addition, intravenous contrast agents should be used with caution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233810228\">",
"    <span class=\"h2\">",
"     Unhelpful treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of interventions have been studied that are unhelpful for acute liver failure and should generally not be used.",
"   </p>",
"   <p>",
"    Such treatments include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids, which increase the risk of sepsis, although they may have a potential role in severe autoimmune hepatitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=see_link&amp;anchor=H150844353#H150844353\">",
"       \"Treatment of autoimmune hepatitis\", section on 'Fulminant hepatitis and acute liver failure'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hepatic regeneration therapy using insulin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Charcoal hemoperfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prostaglandin E, which appeared to have promise in uncontrolled studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/25\">",
"       25",
"      </a>",
"      ], but was subsequently shown to be ineffective in controlled studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233807383\">",
"    <span class=\"h1\">",
"     TREATMENT OF THE UNDERLYING CAUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For some causes of acute liver failure, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity, treatment aimed at the underlying cause may prevent the need for liver transplantation and decrease mortality. Because of this, quickly determining the cause of acute liver failure is crucial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=see_link&amp;anchor=H63223030#H63223030\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\", section on 'Determining the cause of acute liver failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233809776\">",
"    <span class=\"h2\">",
"     Acetaminophen toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;N-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    can dramatically improve the prognosis in patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity. Serious hepatotoxicity is uncommon and death extremely rare if N-acetylcysteine is administered within eight hours following acetaminophen overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. In patients who have developed acute liver failure, intravenous N-acetylcysteine decreases mortality and improves hepatic microcirculatory function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The threshold for giving N-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    should be low, because patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -induced acute liver failure may not have a clear history of acetaminophen overdose. As an example, doses as low as 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    can cause hepatotoxicity in regular alcohol users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, N-acetylcysteine should not only be given to patients with a history suggestive of acetaminophen toxicity, but also for those with acute liver failure of unknown etiology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233809783\">",
"    <span class=\"h2\">",
"     Hepatitis B infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral therapy with a nucleos(t)ide analogue may be beneficial in patients with acute liver failure from acute hepatitis B virus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/31-33\">",
"     31-33",
"    </a>",
"    ], though not all studies have shown a benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/34\">",
"     34",
"    </a>",
"    ]. However, even if not clearly beneficial for preventing the need for liver transplantation, nucleos(t)ide analogues should be given to transplantation candidates to help prevent post-transplantation recurrence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15402?source=see_link&amp;anchor=H19#H19\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\", section on 'Antiviral strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233809791\">",
"    <span class=\"h2\">",
"     Mushroom poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with Amanita phalloides ingestion, early administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    is recommended. Activated charcoal binds to amatoxin and is associated with improved survival when given early compared with supportive therapy alone, though whether it is beneficial once acute liver failure has developed is not clear. Additional therapies include administration of silibinin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=see_link&amp;anchor=H26667361#H26667361\">",
"     \"Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233809799\">",
"    <span class=\"h2\">",
"     Budd-Chiari syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods to restore hepatic drainage in patients with acute Budd-Chiari syndrome include transjugular intrahepatic portosystemic shunt placement, surgical decompression, or thrombolysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3434?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233809807\">",
"    <span class=\"h2\">",
"     Herpes simplex virus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected or documented herpes simplex virus infection should receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours with adjustment as needed based on the patient's renal function) for at least seven days or until herpes simplex virus infection has been excluded. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=see_link&amp;anchor=H55634786#H55634786\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\", section on 'Laboratory findings associated with specific diagnoses'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\", section on 'Hepatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233809822\">",
"    <span class=\"h2\">",
"     Wilson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute liver failure due to Wilson disease typically require liver transplantation, though plasma exchange to remove copper may act as a temporizing measure. Although hemodialysis, peritoneal dialysis, and hemofiltration have also been used, plasma exchange with fresh frozen plasma replacement is often preferred since it can remove relatively large amounts of copper in a short period of time. There is no role for chelation therapy in the management of acute liver failure due to Wilson disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/11/23737?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of Wilson disease\", section on 'Acute liver failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233814655\">",
"    <span class=\"h2\">",
"     Autoimmune hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether administration of glucocorticoids can prevent the need for liver transplantation in patients with acute liver failure from autoimmune hepatitis is unsettled, and there is concern over septic complications in patients receiving glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=see_link&amp;anchor=H150844353#H150844353\">",
"     \"Treatment of autoimmune hepatitis\", section on 'Fulminant hepatitis and acute liver failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach to managing such patients is to give a trial of glucocorticoids (40 to 60 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    per day for two weeks or less) while performing a transplant evaluation and closely monitoring the patient's clinical status and Model for End-stage Liver Disease (MELD) score, reserving liver transplantation for patients who do not improve. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=see_link&amp;anchor=H9#H9\">",
"     \"Patient selection for liver transplantation\", section on 'Pretransplant evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60325332\">",
"    <span class=\"h2\">",
"     Acute fatty liver of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific medical treatment for acute fatty liver of pregnancy. As a result, the primary treatment is prompt (usually emergent) delivery once the mother has been stabilized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24166?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute fatty liver of pregnancy\", section on 'Treatment and course'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H253412597\">",
"    <span class=\"h2\">",
"     When the underlying cause is unknown",
"    </span>",
"    &nbsp;&mdash;&nbsp;N-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    is used for the treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity, but it may be beneficial in other forms of acute liver failure. While additional studies are needed before this therapy can be routinely recommended for acute liver failure from causes other than acetaminophen toxicity, it is reasonable to give it to patients in whom acetaminophen toxicity may be contributing to the liver failure (eg, a patient with acute hepatitis B who was taking acetaminophen for right upper quadrant pain), and in patients with an indeterminate cause for the acute liver failure. (See",
"    <a class=\"local\" href=\"#H246365968\">",
"     'N-acetylcysteine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233807797\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Managing patients with acute liver failure requires a thorough understanding of the complications that may develop, including metabolic derangements, encephalopathy, cerebral edema, seizures, and renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233812427\">",
"    <span class=\"h2\">",
"     Metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common metabolic disturbances in acute liver failure include acid-base and electrolyte disorders. Acid-base disturbances are best managed by treating the underlying abnormality, such as infection or tissue hypoperfusion, and by administering treatments for toxins that may lead to acid-base disturbances and acute liver failure (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ). Hypokalemia, hyponatremia, and hypoglycemia are often seen and require correction, whereas hypophosphatemia, while also common, typically does not require treatment.",
"   </p>",
"   <p>",
"    Among the acid-base disorders, alkalosis is more common than acidosis in the early stages of acute liver failure and is frequently a mixed respiratory and metabolic abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/35\">",
"     35",
"    </a>",
"    ]. Metabolic alkalosis may contribute to hepatic encephalopathy by facilitating ammonia entry into the brain by promoting the conversion of ammonium (NH4+), a charged particle that cannot cross the blood-brain barrier, into ammonia (NH3), which can. As acute liver failure progresses, patients typically develop metabolic acidosis (due to lactic acidosis) with respiratory alkalosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common electrolyte disturbances are hypokalemia, hyponatremia, hypophosphatemia, and hypoglycemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypokalemia is common in both fulminant and subfulminant hepatic failure. Several factors may contribute, including diuretic therapy and increased sympathetic tone, since activation of the beta-2 adrenergic receptors promotes the uptake of potassium by the cells. One effect of hypokalemia is to increase renal ammonia production, and hypokalemia should be corrected if present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=see_link\">",
"       \"Clinical manifestations and treatment of hypokalemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6245?source=see_link&amp;anchor=H4#H4\">",
"       \"Hypokalemia-induced renal dysfunction\", section on 'Increased ammonia production'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyponatremia is more frequently seen in patients with subfulminant hepatic failure. Tissue hypoperfusion, leading to enhanced release of antidiuretic hormone, and impaired renal function combine to limit free water excretion. Hyponatremia should be treated, but care must be taken to avoid osmotic demyelination syndrome that may be seen with overly rapid correction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/30/3562?source=see_link\">",
"       \"Causes of hyponatremia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=see_link\">",
"       \"Overview of the treatment of hyponatremia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypophosphatemia is especially common in patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      -induced acute liver failure and those with intact renal function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/36\">",
"       36",
"      </a>",
"      ]. The presence of hypophosphatemia is good prognostic sign [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/37\">",
"       37",
"      </a>",
"      ]. The fall in plasma phosphate is due to movement into the cells and may be related to the metabolic and synthetic demands of a regenerating liver. Most patients with hypophosphatemia are asymptomatic, and treatment of the hypophosphatemia is usually not required. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15767?source=see_link\">",
"       \"Causes of hypophosphatemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2167?source=see_link&amp;anchor=H5#H5\">",
"       \"Diagnosis and treatment of hypophosphatemia\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypoglycemia, which occurs in more than 40 percent of the patients with acute liver failure, results from both depletion of hepatic glycogen stores and impaired gluconeogenesis and has been associated with increased mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. The plasma glucose concentration should be monitored closely, and hypertonic glucose solutions should be administered as needed to keep the level above 65",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Hepatic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic encephalopathy is one of the defining characteristics of acute liver failure, although the precise mechanism remains unclear (",
"    <a class=\"graphic graphic_table graphicRef62922 \" href=\"mobipreview.htm?32/17/33051\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/40\">",
"     40",
"    </a>",
"    ]. The most widely accepted theory is related to increased production of ammonia from nitrogenous substances within the gut lumen. No specific treatment for hepatic encephalopathy has been shown to improve overall outcomes. Severe protein restrictions in patients with acute liver promote protein catabolism and should be avoided.",
"   </p>",
"   <p>",
"    Whereas",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    is commonly used in patients with hepatic encephalopathy due to chronic liver disease, its use in acute liver failure is controversial. One study found a small increase in survival time among patients with acute liver failure who received lactulose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/41\">",
"     41",
"    </a>",
"    ]. However, there was no difference in the severity of encephalopathy or in overall outcomes. One concern with the use of lactulose is that it may lead to bowel distension that could result in technical difficulties during liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14506?source=see_link\">",
"     \"Hepatic encephalopathy: Pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=see_link&amp;anchor=H73466383#H73466383\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\", section on 'Neurologic examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4346?source=see_link\">",
"     \"Hepatic encephalopathy in adults: Treatment\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H233814623\">",
"     'Nutrition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We do not routinely treat patients with acute liver failure with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    . However, if lactulose is used, endotracheal intubation should be performed prior to its administration in patients with advanced (grade III or IV) encephalopathy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     Neomycin",
"    </a>",
"    , which is sometimes used in the treatment of hepatic encephalopathy, should be avoided because it is nephrotoxic. In addition, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    has been studied for the treatment of hepatic encephalopathy in patients with chronic liver disease, its role in patients with acute liver failure is unclear. We do not use rifaximin for the treatment of hepatic encephalopathy in patients with acute liver failure. (See",
"    <a class=\"local\" href=\"#H233810382\">",
"     'Medications to avoid'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Acute renal failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cerebral edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral edema is uncommon in patients with grade I or II encephalopathy, but it is present in 25 to 35 percent of those with grade III encephalopathy and in approximately 75 percent of those with grade IV encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/4,22\">",
"     4,22",
"    </a>",
"    ]. The consequences of cerebral edema include intracranial pressure (ICP) elevation, brain ischemia and hypoxia, and brainstem herniation, which are the most common causes of death in acute liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Liver transplantation is the only definitive treatment for cerebral edema, though uncontrolled ICP elevation is a contraindication to liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=see_link&amp;anchor=H73466383#H73466383\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\", section on 'Neurologic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classic signs of ICP elevation include systemic hypertension, bradycardia, and irregular respirations (referred to as Cushing's triad). Neurologic manifestations may include increased muscle tone, hyperreflexia, and altered pupillary responses. However, early in the course of acute liver failure, these signs and symptoms may be absent or difficult to detect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=see_link&amp;anchor=H73466383#H73466383\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\", section on 'Neurologic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Intracranial pressure monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the devastating consequences of ICP elevation and the difficulty in accurately assessing for its presence based upon clinical examination alone, some suggest invasive means of monitoring ICP to guide management. However, severe complications from ICP monitoring may develop, such as infection and bleeding, and observational studies of patients undergoing ICP monitoring did not find differences in overall survival between those who received ICP monitoring and those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. In the United States, approximately half of the liver transplantation programs routinely use ICP monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/47\">",
"     47",
"    </a>",
"    ]. Our practice is to perform ICP monitoring in those at greatest risk for cerebral edema, namely patients with grade IV encephalopathy or in patients with grade III encephalopathy that is rapidly progressing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'ICP monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intracranial pressure monitoring is used to follow:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ICP",
"     </li>",
"     <li>",
"      Cerebral perfusion pressure",
"     </li>",
"     <li>",
"      Cerebral oxygen consumption",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cerebral perfusion pressure is the difference between mean arterial pressure and ICP. Cerebral oxygen consumption is a function of cerebral blood flow and the oxygen gradient between arterial and jugular venous blood.",
"   </p>",
"   <p>",
"    Prior to catheter placement, a computed tomographic (CT) scan of the brain should be obtained. While CT scans do not provide a reliable assessment of ICP, they are useful to rule out other possible causes of rapidly altered mental status, such as intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/4\">",
"     4",
"    </a>",
"    ]. Before an ICP monitor is placed, any existing coagulopathy should be corrected. (See",
"    <a class=\"local\" href=\"#H166750581\">",
"     'Bleeding prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Four types of catheters have been used to measure ICP:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Epidural catheters &ndash; placed outside the dura mater",
"     </li>",
"     <li>",
"      Subdural catheters &ndash; placed beneath the dura mater",
"     </li>",
"     <li>",
"      Parenchymal catheters &ndash; placed directly into the brain parenchyma",
"     </li>",
"     <li>",
"      Intraventricular catheters &ndash; placed within a cerebral ventricle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantage of epidural catheters compared with the others is that they are less invasive and therefore cause fewer complications during placement. Their main disadvantage is that their recordings are not as accurate or reliable as the more invasive catheters.",
"   </p>",
"   <p>",
"    The major complications from ICP monitoring are infection and bleeding. A review of 262 patients demonstrated a lower complication rate with epidural catheters than with subdural or",
"    <span class=\"nowrap\">",
"     parenchymal/intraventricular",
"    </span>",
"    catheters (4 versus 20 and 22 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/38\">",
"     38",
"    </a>",
"    ]. Approximately 1 percent of patients died as a result of complications from the placement of epidural catheters compared with 4 to 5 percent from the placement of subdural and parenchymal catheters, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/38\">",
"     38",
"    </a>",
"    ]. For these reasons, epidural catheters are the most widely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246366036\">",
"    <span class=\"h3\">",
"     Transcranial Doppler ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcranial Doppler ultrasound is a newer method being studied for the detection of ICP elevation. It noninvasively measures the velocity of blood flow in the proximal cerebral circulation and can be used to estimate ICP based on characteristic changes in waveforms that occur in response to increased resistance to cerebral blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/48-51\">",
"     48-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H229243145\">",
"    <span class=\"h3\">",
"     Preventing intracranial pressure elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods to prevent ICP elevation include minimizing patient",
"    <span class=\"nowrap\">",
"     agitation/stimulation,",
"    </span>",
"    elevating the head of the patient's bed, maintaining optimal fluid balance, and prophylactic administration of hypertonic saline.",
"   </p>",
"   <p>",
"    Patients should be placed in an environment with minimal sensory stimulation since stimulation can raise ICP. For the same reasons, attempts should be made to keep the patient from becoming agitated. Nasogastric tube placement can cause gagging and thus should generally be performed only in patients who are intubated and sedated. Similarly, endotracheal suction should be minimized. In most cases the head of the patient's bed should be elevated to 30 degrees. However, bed elevation can also reduce cerebral perfusion. Thus, experts have recommended not raising the head of the bed if the cerebral perfusion pressure cannot be maintained at an appropriate level (ie, 50 mmHg) with bed elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/35,52\">",
"     35,52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H233810318\">",
"     'Setting'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H26#H26\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Position'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overhydration can elevate ICP, whereas hypotension due to intravascular volume depletion can decrease cerebral perfusion pressure. Thus, the fluid status of patients with acute liver failure should be closely monitored. (See",
"    <a class=\"local\" href=\"#H166750348\">",
"     'Hemodynamic management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The induction of hypernatremia may decrease water influx into the brain and thereby reduce cerebral edema and ICP. A potential clinical benefit was suggested in a randomized trial involving 30 patients with acute liver failure and grade III or IV encephalopathy who were randomly assigned to receive standard treatment plus hypertonic saline infusion to maintain serum sodium levels of 145 to 155",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or standard treatment alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/53\">",
"     53",
"    </a>",
"    ]. ICP decreased significantly relative to baseline over the first 24 hours in the treatment group, but not in controls. The incidence of ICP elevation was also significantly lower in the hypertonic saline group.",
"   </p>",
"   <p>",
"    Our approach is to prophylactically manage patients who are at high risk of developing cerebral edema with hypertonic saline (3 percent), with a goal serum sodium of 145 to 155",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    High-risk patients include patients with grade IV encephalopathy, high ammonia levels (&gt;150",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    or acute renal failure, and patients who require vasopressor support. Care must be taken when treating patients with hypertonic saline because an overly rapid induction of hypernatremia can lead to neurologic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Treatment of intracranial pressure elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with an elevated ICP, the goals of therapy are to reduce the ICP to below 20 to 25 mmHg and to maintain cerebral perfusion pressure above 50 to 60 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2,54\">",
"     2,54",
"    </a>",
"    ]. Approaches to lowering the ICP include administration of hyperosmotic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    ) and hyperventilation, though the benefits are often transient. Mannitol is our preferred first-line approach to treatment of a patient with an elevated ICP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60324522\">",
"    <span class=\"h4\">",
"     Hyperosmotic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperosmotic agents are often transiently effective in reducing cerebral edema. A bolus of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    (0.5 to 1.0",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    is typically the first-line therapy for patients with an elevated ICP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2\">",
"     2",
"    </a>",
"    ]. In small series, mannitol was shown to correct episodes of ICP elevation and improve survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. One or two additional boluses may be given if needed, provided the serum osmolality is &lt;320",
"    <span class=\"nowrap\">",
"     mOsm/L.",
"    </span>",
"    Patients receiving mannitol should be monitored for hyperosmolarity and hypernatremia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H30#H30\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Mannitol'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with acute liver failure commonly have compromised renal function and oliguria and may develop fluid overload with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    administration. In this setting, fluid should be removed via ultrafiltration or other continuous venous hemofiltration methods with a goal of removing three to five times the fluid volume of the infused mannitol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/22,36\">",
"     22,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32451?source=see_link\">",
"     \"Complications of mannitol therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertonic saline has been studied for the prevention of ICP elevation in patients with acute liver failure, but not for the treatment of ICP elevation once present. However, some transplant centers use hypertonic saline to treat ICP elevation in patients with renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60324564\">",
"    <span class=\"h4\">",
"     Hyperventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperventilation can be considered for patients with an ICP above 20 mmHg, but its effects are transient, and many patients spontaneously hyperventilate. We use hyperventilation for patients with impending herniation, but do not use it for the routine management of ICP elevation in the absence of impending herniation.",
"   </p>",
"   <p>",
"    Decreasing the PaCO2 to 25 to 30 mmHg via hyperventilation restores cerebrovascular autoregulation, resulting in vasoconstriction and a reduction in the ICP. However, in addition to the effects being temporary, there is concern that hyperventilation may worsen cerebral edema by causing cerebral ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In a randomized trial, hyperventilation did not reduce the incidence of cerebral edema or ICP elevation, but it did appear to delay the onset of cerebral herniation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H34#H34\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Hyperventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60324847\">",
"    <span class=\"h4\">",
"     Barbiturates",
"    </span>",
"    &nbsp;&mdash;&nbsp;If other measures to treat severe ICP elevation fail, a barbiturate coma should be induced with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    . Our approach is to give a pentobarbital bolus of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously. Barbiturates decrease ICP, but may also result in systemic hypotension and thus decrease cerebral perfusion pressure. Because barbiturate clearance is markedly reduced in the setting of acute liver failure, neurologic assessment will not be possible for prolonged periods of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60324951\">",
"    <span class=\"h4\">",
"     Treatments that do not work",
"    </span>",
"    &nbsp;&mdash;&nbsp;While glucocorticoids such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    are used in the management of ICP elevation related to brain tumors and some central nervous system infections, small randomized trials and observational studies have shown them to not be beneficial in patients with ICP elevation due to acute liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/55,60,61\">",
"     55,60,61",
"    </a>",
"    ]. Because of a lack of efficacy, combined with a concern for infection, glucocorticoids should",
"    <strong>",
"     not",
"    </strong>",
"    be administered for the treatment of ICP elevation in patients with acute liver failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Experimental therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;New therapies to prevent or treat cerebral edema and ICP elevation continue to be studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h5\">",
"     Induction of hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia decreases cerebral edema in animal models of liver failure, providing a rationale for study in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/62\">",
"     62",
"    </a>",
"    ]. A 2010 systematic review identified five case series that together suggested a benefit of moderate hypothermia combined with ICP monitoring with regard to ICP, cerebral perfusion pressure, and cerebral blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/63\">",
"     63",
"    </a>",
"    ]. The following illustrate findings from individual reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial report in humans included seven patients with uncontrolled ICP elevation in whom a core body temperature of 32 to 33 degrees C was achieved using cooling blankets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/64\">",
"       64",
"      </a>",
"      ]. Four patients who were candidates for liver transplantation survived after an average of 13 hours of hypothermia prior to liver transplantation. Their mean ICP decreased from 45 to 16 mmHg and their mean cerebral perfusion pressure increased from 45 to 70 mmHg during hypothermia. Three patients who were unsuitable for liver transplantation died upon rewarming.",
"     </li>",
"     <li>",
"      A subsequent study included 14 patients with acute liver failure who had ICP elevations that were unresponsive to standard medical therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/65\">",
"       65",
"      </a>",
"      ]. The patients' core temperatures were reduced to 32 to 33 degrees C using cooling blankets. Thirteen patients were successfully bridged to liver transplantation with a median of 32 hours of cooling. The mean ICP before cooling was 37 mm Hg and was reduced to 16 mm Hg within four hours of cooling. Mean arterial pressure and cerebral perfusion pressure increased, and the need for inotropic support was reduced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the potential benefits, hypothermia can also increase the risk of infection, cardiac dysrhythmias, and bleeding, all of which are known complications of acute liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/66\">",
"     66",
"    </a>",
"    ]. As a result, more experience is required before this therapy can be routinely recommended. However, it is a reasonable option as a bridge to transplantation in patients who have failed other treatments, including barbiturate-induced coma. (See",
"    <a class=\"local\" href=\"#H60324847\">",
"     'Barbiturates'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h5\">",
"     Indomethacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     Indomethacin",
"    </a>",
"    (25 mg IV over 1 minute) has been used in patients with elevated ICP refractory to other therapeutic modalities. It exerts its effects by causing cerebral vasoconstriction and can acutely decrease ICP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. While there are not enough data to recommend its use routinely, indomethacin can be considered in patients with an elevated ICP that fails to respond to standard treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60325048\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizure activity in patients with acute liver failure is common but may be difficult to detect if patients are intubated and receiving paralytics. In the control arm of one trial, 7 of 22 patients (32 percent) had subclinical seizure activity detected by electroencephalogram (EEG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/69\">",
"     69",
"    </a>",
"    ]. In patients who require sedation, we use sedatives with anti-seizure activity. In patients who do not require sedation, we obtain routine (daily) EEGs to monitor for seizure activity. In addition, we will obtain an EEG in patients with clinical evidence of seizure activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of the first seizure in adults\", section on 'Generalized seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seizures in patients with acute liver failure should be treated promptly because seizure activity increases ICP and may cause cerebral hypoxia. Consensus recommendations suggest treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , since patients with acute liver failure have a severely impaired ability to clear sedatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients who are refractory to phenytoin should receive short acting benzodiazepines.",
"   </p>",
"   <p>",
"    Trials examining prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    have had variable results regarding seizure prevention, though none has shown a survival benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial included 40 patients with acute liver failure who were randomly assigned to receive prophylactic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      by slow intravenous infusion at a rate not exceeding 50",
"      <span class=\"nowrap\">",
"       mg/min,",
"      </span>",
"      followed by 100 mg doses at eight-hour intervals) or to serve as controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/69\">",
"       69",
"      </a>",
"      ]. Subclinical seizure activity was observed less often in the group receiving phenytoin (15 versus 32 percent). Autopsy examinations were available in 19 patients and showed signs of cerebral edema less often in patients who had received phenytoin (22 versus 70 percent). However, a survival advantage was not detected with prophylactic phenytoin.",
"     </li>",
"     <li>",
"      No benefit from prophylactic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      was observed in a second randomized trial involving 42 patients with acute liver failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/70\">",
"       70",
"      </a>",
"      ]. Cerebral edema developed in 16 patients in the phenytoin group versus 15 in the control group. Similarly, seizures occurred in a similar proportion of patients (23 versus 25 percent, respectively). There was no overall mortality benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data do not support a role for prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    in the treatment of acute liver failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute renal failure complicates acute liver failure in approximately 30 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/22,36,71\">",
"     22,36,71",
"    </a>",
"    ]. The frequency of acute renal failure is higher (up to 75 percent) for etiologies of acute liver failure that are known to independently damage the kidneys, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/18,54\">",
"     18,54",
"    </a>",
"    ]. Once renal failure develops, it is usually progressive and is associated with a poor prognosis without liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Measures to preserve renal function include ensuring arterial perfusion by maintaining an adequate systemic blood pressure, identifying and treating infections promptly, and avoiding the use of nephrotoxic agents. If acute renal failure develops, continuous renal replacement therapies, such as continuous venovenous hemofiltration, are better tolerated than intermittent modes of hemodialysis with regard to stability in cardiovascular and intracranial parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=see_link&amp;anchor=H2#H2\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\", section on 'Possible differences between intermittent hemodialysis and CRRT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary edema and pulmonary infections are encountered in approximately 30 percent of patients with acute liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/22\">",
"     22",
"    </a>",
"    ]. Mechanical ventilation may be required to ensure adequate oxygenation. However, extreme caution must be used with positive end-expiratory pressure in patients with acute liver failure since it can worsen cerebral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30663?source=see_link\">",
"     \"Positive end-expiratory pressure (PEEP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233808137\">",
"    <span class=\"h1\">",
"     LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to proceed with liver transplantation depends upon the probability of spontaneous hepatic recovery. The goal is to differentiate patients who are likely to benefit from liver transplantation from those who are likely to recover spontaneously. In addition to optimizing organ allocation, correctly identifying patients likely to benefit from liver transplantation avoids life-long immunosuppression in patients who would have recovered without transplantation. In the United States and Europe, patients with acute liver failure who require transplantation are given the highest priority on the transplantation list. Of those who receive a transplant, one-year survival rates following liver transplantation are greater than 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to determining whether a patient is likely to recover spontaneously from acute liver failure, it is important to determine if the patient has contraindications to transplantation, such as severe cardiopulmonary disease or malignancy outside of the liver. In addition, in cases of intentional overdose, whether the patient is at high risk for future self-destructive behavior needs to be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/13/22743?source=see_link&amp;anchor=H14#H14\">",
"     \"Ethical issues in liver transplantation\", section on 'Suicidal overdoses/attempts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84582894\">",
"    <span class=\"h2\">",
"     Probability of spontaneous recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, the most important factors for predicting the outcome in acute liver failure are the degree of encephalopathy (",
"    <a class=\"graphic graphic_table graphicRef62922 \" href=\"mobipreview.htm?32/17/33051\">",
"     table 1",
"    </a>",
"    ), the patient's age, and the cause of the acute liver failure. These factors in part reflect the importance of the severity of the hepatic injury and the likelihood of reversal of the underlying process either spontaneously or with specific therapy (eg, N-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity).",
"   </p>",
"   <p>",
"    Spontaneous recovery is more likely with lower grades of encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I to II &ndash; 65 to 70 percent",
"     </li>",
"     <li>",
"      Grade III &ndash; 40 to 50 percent",
"     </li>",
"     <li>",
"      Grade IV &ndash; &lt;20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients younger than 10 or older than 40 years of age may have a lower likelihood of spontaneous recovery compared with patients between these ages. The importance of the etiology of the acute liver failure was demonstrated in a study of 308 patients with acute liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/76\">",
"     76",
"    </a>",
"    ]. The short-term (three-week) transplant-free survival rate overall was 43 percent. The transplant free survival rate was &ge;50 percent in patients with acute liver failure due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , hepatitis A, ischemia, or pregnancy-related acute liver failure. On the other hand, it was &lt;25 percent for those whose liver failure was due to hepatitis B, autoimmune hepatitis, Wilson disease, Budd-Chiari syndrome, cancer, or an indeterminate cause.",
"   </p>",
"   <p>",
"    Several other variables, such as the prothrombin time and arterial ammonia levels, have been used to predict the probability of recovery, but their predictive accuracy has not been well established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/54,77-81\">",
"     54,77-81",
"    </a>",
"    ]. Liver histology has not proven to be accurate for predicting outcome and is only used in cases of diagnostic uncertainty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=see_link&amp;anchor=H414607153#H414607153\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\", section on 'Liver biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84583086\">",
"    <span class=\"h2\">",
"     Prognostic models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several models have been developed for predicting the outcome in patients with acute liver failure to try to identify patients who are likely to benefit from liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/83-94\">",
"     83-94",
"    </a>",
"    ]. The King's College Criteria are the most widely used for selecting patients for liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/72\">",
"     72",
"    </a>",
"    ]. In addition, the Model for End-Stage Liver Disease (MELD) score, which is used to predict mortality in patients with chronic liver disease, has also been applied to patients with acute liver failure. Other scores that may also predict mortality in patients with acute liver failure include the Sequential Organ Failure Assessment (SOFA score) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/89,90\">",
"     89,90",
"    </a>",
"    ],the Clichy criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/92,93\">",
"     92,93",
"    </a>",
"    ], and the Acute Liver Failure Study Group (ALFSG) index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233813088\">",
"    <span class=\"h3\">",
"     King's College Criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The King's College Criteria were developed in a cohort of 588 patients with acute liver failure who were managed medically between 1973 and 1985 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/72\">",
"     72",
"    </a>",
"    ]. Recommendations for liver transplantation in acute liver failure were proposed based upon their outcomes (",
"    <a class=\"graphic graphic_table graphicRef77717 \" href=\"mobipreview.htm?26/33/27163\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The predictors are different based on the etiology of the acute liver failure (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    versus other causes). In patients with acute liver failure due to acetaminophen, recovery may be observed even in patients who have evidence of severe hepatocellular necrosis and synthetic dysfunction.",
"   </p>",
"   <p>",
"    In",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -induced acute liver failure, there are two broad criteria for referral for orthotopic liver transplantation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An arterial pH of less than 7.30, irrespective of grade of encephalopathy",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Grade III or IV encephalopathy with",
"      <strong>",
"       both",
"      </strong>",
"      a prothrombin time (PT) greater than 100 seconds and a serum creatinine concentration greater than 3.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (301",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For other causes of acute liver failure, referral for orthotopic liver transplantation is indicated for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A PT greater than 100 seconds, irrespective of the grade of encephalopathy",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Any",
"      <strong>",
"       three",
"      </strong>",
"      of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age less than 10 or greater than 40 years",
"     </li>",
"     <li>",
"      Unfavorable disease etiology, such as non-A, non-B viral hepatitis, idiosyncratic drug reactions, Wilson disease",
"     </li>",
"     <li>",
"      Duration of jaundice before development of encephalopathy greater than seven days",
"     </li>",
"     <li>",
"      PT greater than 50 seconds",
"     </li>",
"     <li>",
"      Serum bilirubin greater than 18",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (308",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted that PT values may not be directly comparable across different laboratories because of use of different tissue factors.",
"   </p>",
"   <p>",
"    The accuracy of the King's College Criteria has been evaluated in several studies and systematic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One systematic review of 14 studies of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      -induced liver failure estimated the overall sensitivity and specificity of the criteria for predicting mortality were 58 and 95 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study that included 145 patients with acute liver failure who were not transplanted, the positive and negative predictive values for mortality in those with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      toxicity were 88 and 65 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/96\">",
"       96",
"      </a>",
"      ]. The corresponding values for patients with other causes of acute liver failure were 79 and 50 percent, respectively. These values are slightly lower than the original King's College cohort. The relatively low negative predictive values indicate that these criteria are better able to predict patients with a poor prognosis than those with a good prognosis.",
"     </li>",
"     <li>",
"      Another systematic review of 18 studies of non-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      induced liver failure estimated a sensitivity for predicting mortality of 68 percent (95% CI 59-77%) and a specificity of 82 percent (95% CI 75-88%) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/97\">",
"       97",
"      </a>",
"      ]. Specificity was highest in studies of patients with high-grade hepatic encephalopathy (93 percent), and overall test characteristics were best in older studies. A possible explanation for this finding is that improvements in the care of patients with acute liver failure have modified the performance of the criteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84582496\">",
"    <span class=\"h3\">",
"     Model for End-stage Liver Disease (MELD) score",
"    </span>",
"    &nbsp;&mdash;&nbsp;MELD is a prospectively developed and validated chronic liver disease severity scoring system that uses a patient's laboratory values for serum bilirubin, serum creatinine, and the international normalized ratio (INR) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?18/2/18466?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). It was originally developed to predict survival following transjugular intrahepatic portosystemic shunt placement, but it has also been used to predict survival among patients with acute liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/88,98-101\">",
"     88,98-101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 91 patients with non-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -related acute liver failure, the MELD score was compared with the King's College Criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/98\">",
"     98",
"    </a>",
"    ]. The King's College Criteria had a sensitivity and specificity for mortality of 88 and 71 percent, respectively. Similar results were obtained when a MELD score of 32 or higher was used to predict mortality (sensitivity of 79 percent and specificity of 71 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233808211\">",
"    <span class=\"h2\">",
"     Experimental alternatives to liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of approaches for delaying or obviating the need for liver transplantation in patients with acute liver failure continue to be studied. Among the most promising are artificial hepatic assist devices, auxiliary liver transplantation, a liver dialysis system, and xenotransplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233808218\">",
"    <span class=\"h3\">",
"     Artificial hepatic assist devices and hepatocyte transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts have been made to develop an artificial hepatic assist device for acute liver failure that would operate on the same basic principles as hemodialysis for renal failure. However, developing a machine that performs the functions of the liver is inherently more difficult than developing one that performs the excretory functions of the kidneys because the liver performs a large number of diverse and vital synthetic functions. Results in patients treated with these systems have largely been disappointing and the systems are not widely available so they are generally not used in the management of patients with acute liver failure.",
"   </p>",
"   <p>",
"    Support systems designed to treat patients with liver failure fall into two main categories, non-cell-based systems, including plasmapheresis, albumin dialysis, and charcoal-based hemadsorption, and systems that incorporate living hepatocytes or hepatic tissue, also known as bioartificial liver support systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/102-104\">",
"     102-104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review that pooled 12 randomized controlled trials (with a total of 483 patients) using various bioartificial support systems concluded that overall they had no significant effect on mortality compared with standard medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. However, a meta-regression suggested that their effect depended upon the type of liver failure. A 33 percent reduction in mortality was observed in patients with acute-on-chronic liver failure (RR 0.67, 95% CI: 0.51 to 0.90), while no significant benefit was detected in those with acute liver failure.",
"   </p>",
"   <p>",
"    Transplantation of hepatocytes is also under investigation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/12/31944?source=see_link&amp;anchor=H4#H4\">",
"     \"Hepatocyte transplantation\", section on 'Management of acute liver failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233808225\">",
"    <span class=\"h3\">",
"     Auxiliary liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auxiliary liver transplantation involves placement of a reduced-size liver graft adjacent to the patient's native liver (auxiliary heterotopic liver transplantation) or in the hepatic bed after a portion of the native liver has been removed (auxiliary orthotopic liver transplantation). A potential advantage is that this procedure may support the patient while the native liver regenerates, obviating the need for chronic immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/54,107\">",
"     54,107",
"    </a>",
"    ]. In addition, because only a relatively small portion of liver is required, the graft can be obtained from a donor liver that is being used for a standard orthotopic liver transplantation or from a living-related donor, thereby increasing the number of available organs.",
"   </p>",
"   <p>",
"    There are also reports of auxiliary liver grafts being reused in second recipients with chronic liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/108\">",
"     108",
"    </a>",
"    ]. If the native liver recovers, the graft can be removed and transplanted into a second patient. While auxiliary liver transplantation shows promise, the procedure is technically difficult, and has not been adequately evaluated in controlled clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233808232\">",
"    <span class=\"h3\">",
"     Xenotransplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xenotransplantation (transplantation of a nonhuman organ) has been attempted for the treatment of acute liver failure. Prior to 1992, only 33 xenotransplantations had been performed in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/54\">",
"     54",
"    </a>",
"    ]. The longest graft survival was only nine months. Despite the initial disappointing results, this approach is being reevaluated, in part because of advances in immunosuppression and the ability to manipulate donor antigen expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/109-113\">",
"     109-113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233808239\">",
"    <span class=\"h3\">",
"     Other experimental approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     Granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) has been studied for the treatment of acute-on-chronic liver failure (ACLF). The theory behind the approach is that mobilization of bone marrow-derived stem cells with G-CSF may promote hepatic regeneration. In a randomized trial with 47 patients with ACLF, 23 were assigned to receive G-CSF 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    subcutaneously daily for five days and then every three days for a total of 12 doses, and 24 were assigned to receive placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/114\">",
"     114",
"    </a>",
"    ]. None of the patients had decompensated liver disease prior to the onset of ACLF. Patients treated with G-CSF had a higher actuarial probability of survival at 60 days than those treated with placebo (66 versus 26 percent) and were less likely to develop hepatorenal syndrome (19 versus 71 percent), hepatic encephalopathy (19 versus 66 percent), or sepsis (14 versus 41 percent). None of the patients who survived underwent emergent liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84582719\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, survival rates in patients treated for acute liver failure are greater than 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/76\">",
"     76",
"    </a>",
"    ]. Approximately 40 percent of patients will survive without needing a liver transplantation.",
"   </p>",
"   <p>",
"    The prognosis of patients who are listed for transplantation is variable and cannot always be predicted accurately. An illustrative study from the United States included 308 patients with acute liver failure, of whom 67 percent survived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/76\">",
"     76",
"    </a>",
"    ]. Of 135 patients who had been listed for transplantation, 66 percent received a transplantation, 22 percent died while awaiting transplantation, and 12 percent recovered without transplantation. In other series, death rates among patients listed for transplantation are as high as 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/115,116\">",
"     115,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following liver transplantation, the one-year survival rate is approximately 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/75\">",
"     75",
"    </a>",
"    ]. The majority of deaths among patients who undergo liver transplantation are due to neurologic complications or sepsis and occur within three months of the transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/40/38538/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/34/25122?source=see_link\">",
"       \"Patient information: Liver transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The general management of patients with acute liver failure includes ensuring the patient is being cared for in the proper setting, monitoring for worsening liver failure, treating complications, and providing nutritional support. (See",
"      <a class=\"local\" href=\"#H233807110\">",
"       'General management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute liver failure should be managed at a liver transplant center whenever possible. Patients with grade I encephalopathy (",
"      <a class=\"graphic graphic_table graphicRef62922 \" href=\"mobipreview.htm?32/17/33051\">",
"       table 1",
"      </a>",
"      ) may be managed on a general medical ward, provided the environment is quiet and frequent neurologic checks (eg, every two hours) are performed. If there is progression to grade II encephalopathy, or for patients presenting with grade II, III, or IV encephalopathy, management in an intensive care unit is indicated. (See",
"      <a class=\"local\" href=\"#H233810318\">",
"       'Setting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serial laboratory tests are used to follow the course of a patient's liver failure and to monitor for complications. Serum aminotransferases and bilirubin should be monitored daily. More frequent monitoring (three to four times daily) should be performed for coagulation parameters, complete blood counts, metabolic panels, and arterial blood gasses. We perform finger sticks to monitor blood glucose levels every six hours. (See",
"      <a class=\"local\" href=\"#H233810325\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For some causes of acute liver failure, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      toxicity, treatment aimed at the underlying cause may prevent the need for liver transplantation and decrease mortality. (See",
"      <a class=\"local\" href=\"#H233807383\">",
"       'Treatment of the underlying cause'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with hepatic encephalopathy due to acute liver failure, we suggest not routinely treating with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"       lactulose",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Lactulose has not been shown to improve overall outcomes, and it may lead to bowel distension that could result in technical difficulties during liver transplantation. However, if lactulose is used, endotracheal intubation should be performed prior to its administration in patients with advanced (grade III or IV) encephalopathy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hepatic encephalopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients at high risk for developing cerebral edema (ie, patients with grade IV encephalopathy or with grade III encephalopathy that is rapidly progressing), we suggest using intracranial pressure (ICP) monitoring to guide treatment for cerebral edema, rather than basing treatment decisions on the clinical signs of cerebral edema (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Early in the course of acute liver failure, signs and symptoms of cerebral edema may be absent or difficult to detect. Complications of cerebral edema include ICP elevation and brainstem herniation. However, ICP monitoring has not been shown to increase overall survival and is associated with complications such as infection and bleeding. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cerebral edema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General measures to prevent ICP elevation include minimizing stimulation, maintaining appropriate fluid balance, and elevating the head of the patient's bed. For patients who are at high risk of developing cerebral edema, we also suggest prophylactic treatment with hypertonic saline (3 percent), with a goal serum sodium of 145 to 155",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). High-risk patients include patients with grade IV encephalopathy, high ammonia levels (&gt;150",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      or acute renal failure, and patients who require vasopressor support. (See",
"      <a class=\"local\" href=\"#H229243145\">",
"       'Preventing intracranial pressure elevation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with ICP elevation, we suggest initial treatment with a bolus of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      (0.5 to 1.0",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      rather than hyperventilation therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). One or two additional boluses may be given if needed, provided the serum osmolality is &lt;320",
"      <span class=\"nowrap\">",
"       mOsm/L.",
"      </span>",
"      The goals of therapy are to maintain the ICP below 20 to 25 mmHg and the cerebral perfusion pressure above 50 to 60 mmHg. Patients receiving mannitol should be monitored for hyperosmolarity and hypernatremia. (See",
"      <a class=\"local\" href=\"#H60324522\">",
"       'Hyperosmotic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 40 percent of patients with acute liver failure will recover spontaneously with supportive care. Prognostic models have been developed to help identify patients who are unlikely to recover spontaneously, because the decision to proceed with liver transplantation depends in part upon the probability of spontaneous hepatic recovery. Of those who receive a transplantation, one-year survival rates are greater than 80 percent. (See",
"      <a class=\"local\" href=\"#H233808137\">",
"       'Liver transplantation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H84582719\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/1\">",
"      Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology 2012; 55:965.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf (Accessed on August 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/3\">",
"      Lee WM, Squires RH Jr, Nyberg SL, et al. Acute liver failure: Summary of a workshop. Hepatology 2008; 47:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/4\">",
"      Lee WM. Acute liver failure. N Engl J Med 1993; 329:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/5\">",
"      Stravitz RT, Kramer DJ. Management of acute liver failure. Nat Rev Gastroenterol Hepatol 2009; 6:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/6\">",
"      Harry R, Auzinger G, Wendon J. The effects of supraphysiological doses of corticosteroids in hypotensive liver failure. Liver Int 2003; 23:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/7\">",
"      Harry R, Auzinger G, Wendon J. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 2002; 36:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/8\">",
"      Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009; 137:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/9\">",
"      Gazzard BG, Henderson JM, Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 1975; 16:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/10\">",
"      Munoz SJ, Stravitz RT, Gabriel DA. Coagulopathy of acute liver failure. Clin Liver Dis 2009; 13:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/11\">",
"      Shami VM, Hespenheide EE, Macik BG, et al. Recombinant activated factor VII in fulminant liver failure: Complete but transient correction of the coagulopathy (abstract). Hepatology 2000; 32:397A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/12\">",
"      Chuansumrit A, Chantarojanasiri T, Isarangkura P, et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2000; 11 Suppl 1:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/13\">",
"      N&eacute;grier C, Lienhart A. Overall experience with NovoSeven. Blood Coagul Fibrinolysis 2000; 11 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/14\">",
"      Kaliciski P, Kamiski A, Drewniak T, et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc 1999; 31:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/15\">",
"      Kositchaiwat C, Chuansumrit A. Experiences with recombinant factor VIIa for the prevention of bleeding in patients with chronic liver disease undergoing percutaneous liver biopsies and endoscopic retrograde cholangiopancreatography (ERCP). Thromb Haemost 2001; 86:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/16\">",
"      Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/17\">",
"      Shami VM, Macik BG, Hespenheide EE, et al. Recombinant activated factor VII is superior to plasma alone in correcting the coagulopathy of fulminant hepatic failure (abstract). Hepatology 2001; 34:237A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/18\">",
"      Mas A, Rod&eacute;s J. Fulminant hepatic failure. Lancet 1997; 349:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/19\">",
"      Rolando N, Gimson A, Wade J, et al. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure. Hepatology 1993; 17:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/20\">",
"      Rolando N, Harvey F, Brahm J, et al. Fungal infection: a common, unrecognised complication of acute liver failure. J Hepatol 1991; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/21\">",
"      Raff T, Germann G, Hartmann B. The value of early enteral nutrition in the prophylaxis of stress ulceration in the severely burned patient. Burns 1997; 23:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/22\">",
"      Mu&ntilde;oz SJ. Difficult management problems in fulminant hepatic failure. Semin Liver Dis 1993; 13:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/23\">",
"      Woolf GM, Redeker AG. Treatment of fulminant hepatic failure with insulin and glucagon. A randomized, controlled trial. Dig Dis Sci 1991; 36:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/24\">",
"      O'Grady JG, Gimson AE, O'Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/25\">",
"      Sinclair SB, Levy GA. Treatment of fulminant viral hepatic failure with prostaglandin E. A preliminary report. Dig Dis Sci 1991; 36:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/26\">",
"      Sheiner P, Sinclair S, Greig P, et al. A randomized control trial of prostaglandin E2 in the treatment of fulminant hepatic failure (abstract). Hepatology 1992; 16:88A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/27\">",
"      Smilkstein MJ, Bronstein AC, Linden C, et al. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 1991; 20:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/28\">",
"      Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/29\">",
"      Prescott LF. Treatment of severe acetaminophen poisoning with intravenous acetylcysteine. Arch Intern Med 1981; 141:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/30\">",
"      Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/31\">",
"      Belongia EA, Costa J, Gareen IF, et al. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements 2008; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/32\">",
"      Roussos A, Koilakou S, Kalafatas I, et al. Lamivudine treatment for acute severe hepatitis B: report of a case and review of the literature. Acta Gastroenterol Belg 2008; 71:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/33\">",
"      Miyake Y, Iwasaki Y, Takaki A, et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med 2008; 47:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/34\">",
"      Dao DY, Seremba E, Ajmera V, et al. Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. Dig Dis Sci 2012; 57:1349.",
"     </a>",
"    </li>",
"    <li>",
"     O'Grady JG, Portmann B, Williams R. Fulminant hepatic failure. In: Diseases of the Liver, Schiff L, Schiff R (Eds), JB Lippincott, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/36\">",
"      Caraceni P, Van Thiel DH. Acute liver failure. Lancet 1995; 345:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/37\">",
"      Baquerizo A, Anselmo D, Shackleton C, et al. Phosphorus ans an early predictive factor in patients with acute liver failure. Transplantation 2003; 75:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/38\">",
"      Blei AT, Olafsson S, Webster S, Levy R. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 1993; 341:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/39\">",
"      Kaur S, Kumar P, Kumar V, et al. Etiology and Prognostic Factors of Acute Liver Failure in Children. Indian Pediatr 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/40\">",
"      Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997; 337:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/41\">",
"      Alba L, Hay JE, Lee WM. Lactulose therapy in acute liver failure. J Hepatol 2002; 36:33A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/42\">",
"      Williams R, Gimson AE. Intensive liver care and management of acute hepatic failure. Dig Dis Sci 1991; 36:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/43\">",
"      Ware AJ, D'Agostino AN, Combes B. Cerebral edema: a major complication of massive hepatic necrosis. Gastroenterology 1971; 61:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/44\">",
"      Stravitz RT. Critical management decisions in patients with acute liver failure. Chest 2008; 134:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/45\">",
"      McCashland TM, Shaw BW Jr, Tape E. The American experience with transplantation for acute liver failure. Semin Liver Dis 1996; 16:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/46\">",
"      Keays RT, Alexander GJ, Williams R. The safety and value of extradural intracranial pressure monitors in fulminant hepatic failure. J Hepatol 1993; 18:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/47\">",
"      Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005; 11:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/48\">",
"      Manno EM. Transcranial Doppler ultrasonography in the neurocritical care unit. Crit Care Clin 1997; 13:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/49\">",
"      Edouard AR, Vanhille E, Le Moigno S, et al. Non-invasive assessment of cerebral perfusion pressure in brain injured patients with moderate intracranial hypertension. Br J Anaesth 2005; 94:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/50\">",
"      Abdo A, L&oacute;pez O, Fern&aacute;ndez A, et al. Transcranial Doppler sonography in fulminant hepatic failure. Transplant Proc 2003; 35:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/51\">",
"      Aggarwal S, Brooks DM, Kang Y, et al. Noninvasive monitoring of cerebral perfusion pressure in patients with acute liver failure using transcranial doppler ultrasonography. Liver Transpl 2008; 14:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/52\">",
"      Durward QJ, Amacher AL, Del Maestro RF, Sibbald WJ. Cerebral and cardiovascular responses to changes in head elevation in patients with intracranial hypertension. J Neurosurg 1983; 59:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/53\">",
"      Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004; 39:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/54\">",
"      Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/55\">",
"      Canalese J, Gimson AE, Davis C, et al. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut 1982; 23:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/56\">",
"      Nath F, Galbraith S. The effect of mannitol on cerebral white matter water content. J Neurosurg 1986; 65:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/57\">",
"      Wendon JA, Harrison PM, Keays R, Williams R. Cerebral blood flow and metabolism in fulminant liver failure. Hepatology 1994; 19:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/58\">",
"      Ellis A, Wendon J. Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: pathophysiology and management. Semin Liver Dis 1996; 16:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/59\">",
"      Ede RJ, Gimson AE, Bihari D, Williams R. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol 1986; 2:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/60\">",
"      Hanid MA, Davies M, Mellon PJ, et al. Clinical monitoring of intracranial pressure in fulminant hepatic failure. Gut 1980; 21:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/61\">",
"      Rakela J, Mosley JW, Edwards VM, et al. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. Dig Dis Sci 1991; 36:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/62\">",
"      Traber P, DalCanto M, Ganger D, Blei AT. Effect of body temperature on brain edema and encephalopathy in the rat after hepatic devascularization. Gastroenterology 1989; 96:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/63\">",
"      Dmello D, Cruz-Flores S, Matuschak GM. Moderate hypothermia with intracranial pressure monitoring as a therapeutic paradigm for the management of acute liver failure: a systematic review. Intensive Care Med 2010; 36:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/64\">",
"      Jalan R, O Damink SW, Deutz NE, et al. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. Lancet 1999; 354:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/65\">",
"      Jalan R, Olde Damink SW, Deutz NE, et al. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology 2004; 127:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/66\">",
"      Stravitz RT, Larsen FS. Therapeutic hypothermia for acute liver failure. Crit Care Med 2009; 37:S258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/67\">",
"      Clemmesen JO, Hansen BA, Larsen FS. Indomethacin normalizes intracranial pressure in acute liver failure: a twenty-three-year-old woman treated with indomethacin. Hepatology 1997; 26:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/68\">",
"      Tofteng F, Larsen FS. The effect of indomethacin on intracranial pressure, cerebral perfusion and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure. J Cereb Blood Flow Metab 2004; 24:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/69\">",
"      Ellis AJ, Wendon JA, Williams R. Subclinical seizure activity and prophylactic phenytoin infusion in acute liver failure: a controlled clinical trial. Hepatology 2000; 32:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/70\">",
"      Bhatia V, Batra Y, Acharya SK. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure--a controlled clinical trial. J Hepatol 2004; 41:89.",
"     </a>",
"    </li>",
"    <li>",
"     O'Grady JG, Williams R. Acute liver failure. In: Gastrointestinal emergencies, Gilmore IT, Shields R (Eds), WB Saunders, Eastbourne 1992. p.104.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/72\">",
"      O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/73\">",
"      Jain S, Pendyala P, Varma S, et al. Effect of renal dysfunction in fulminant hepatic failure. Trop Gastroenterol 2000; 21:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/74\">",
"      Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993; 21:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/75\">",
"      Lidofsky SD. Liver transplantation for fulminant hepatic failure. Gastroenterol Clin North Am 1993; 22:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/76\">",
"      Ostapowicz G, Fontana RJ, Schi&oslash;dt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/77\">",
"      Miyake Y, Sakaguchi K, Iwasaki Y, et al. New prognostic scoring model for liver transplantation in patients with non-acetaminophen-related fulminant hepatic failure. Transplantation 2005; 80:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/78\">",
"      Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 2002; 36:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/79\">",
"      Clemmesen JO, Larsen FS, Kondrup J, et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999; 29:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/80\">",
"      Kumar R, Sharma H, Prakash S, et al. Persistent hyperammonemia is associated with complications and poor outcomes in patients with acute liver failure. Clin Gastroenterol Hepatol 2012; 10:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/81\">",
"      Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 2005; 41:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/82\">",
"      Hanau C, Munoz SJ, Rubin R. Histopathological heterogeneity in fulminant hepatic failure. Hepatology 1995; 21:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/83\">",
"      Dhiman RK, Seth AK, Jain S, et al. Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig Dis Sci 1998; 43:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/84\">",
"      Huo TI, Wu JC, Sheng WY, et al. Prognostic factor analysis of fulminant and subfulminant hepatic failure in an area endemic for hepatitis B. J Gastroenterol Hepatol 1996; 11:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/85\">",
"      Takahashi Y, Kumada H, Shimizu M, et al. A multicenter study on the prognosis of fulminant viral hepatitis: early prediction for liver transplantation. Hepatology 1994; 19:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/86\">",
"      Lake JR, Sussman NL. Determining prognosis in patients with fulminant hepatic failure: when you absolutely, positively have to know the answer. Hepatology 1995; 21:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/87\">",
"      Dhiman RK, Jain S, Maheshwari U, et al. Early indicators of prognosis in fulminant hepatic failure: an assessment of the Model for End-Stage Liver Disease (MELD) and King's College Hospital criteria. Liver Transpl 2007; 13:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/88\">",
"      Yantorno SE, Kremers WK, Ruf AE, et al. MELD is superior to King's college and Clichy's criteria to assess prognosis in fulminant hepatic failure. Liver Transpl 2007; 13:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/89\">",
"      Craig DG, Zafar S, Reid TW, et al. The sequential organ failure assessment (SOFA) score is an effective triage marker following staggered paracetamol (acetaminophen) overdose. Aliment Pharmacol Ther 2012; 35:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/90\">",
"      Craig DG, Reid TW, Wright EC, et al. The sequential organ failure assessment (SOFA) score is prognostically superior to the model for end-stage liver disease (MELD) and MELD variants following paracetamol (acetaminophen) overdose. Aliment Pharmacol Ther 2012; 35:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/91\">",
"      Kumar R, Sharma H, Goyal R, et al. Prospective derivation and validation of early dynamic model for predicting outcome in patients with acute liver failure. Gut 2012; 61:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/92\">",
"      Pauwels A, Mostefa-Kara N, Florent C, L&eacute;vy VG. Emergency liver transplantation for acute liver failure. Evaluation of London and Clichy criteria. J Hepatol 1993; 17:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/93\">",
"      Bernuau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986; 6:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/94\">",
"      Rutherford A, King LY, Hynan LS, et al. Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology 2012; 143:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/95\">",
"      Craig DG, Ford AC, Hayes PC, Simpson KJ. Systematic review: prognostic tests of paracetamol-induced acute liver failure. Aliment Pharmacol Ther 2010; 31:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/96\">",
"      Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria. J Hepatol 1997; 26:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/97\">",
"      McPhail MJ, Wendon JA, Bernal W. Meta-analysis of performance of Kings's College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. J Hepatol 2010; 53:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/98\">",
"      Parkash O, Mumtaz K, Hamid S, et al. MELD score: utility and comparison with King's College criteria in non-acetaminophen acute liver failure. J Coll Physicians Surg Pak 2012; 22:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/99\">",
"      Katoonizadeh A, Decaestecker J, Wilmer A, et al. MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. Liver Int 2007; 27:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/100\">",
"      Zaman MB, Hoti E, Qasim A, et al. MELD score as a prognostic model for listing acute liver failure patients for liver transplantation. Transplant Proc 2006; 38:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/101\">",
"      Schmidt LE, Larsen FS. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 2007; 45:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/102\">",
"      Nyberg SL, Misra SP. Hepatocyte liver-assist systems--a clinical update. Mayo Clin Proc 1998; 73:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/103\">",
"      Stockmann HB, Hiemstra CA, Marquet RL, IJzermans JN. Extracorporeal perfusion for the treatment of acute liver failure. Ann Surg 2000; 231:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/104\">",
"      Pless G, Sauer IM. Bioartificial liver: current status. Transplant Proc 2005; 37:3893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/105\">",
"      Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003; 289:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/106\">",
"      Liu JP, Gluud LL, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for liver failure. Cochrane Database Syst Rev 2004; :CD003628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/107\">",
"      Lodge JP, Dasgupta D, Prasad KR, et al. Emergency subtotal hepatectomy: a new concept for acetaminophen-induced acute liver failure: temporary hepatic support by auxiliary orthotopic liver transplantation enables long-term success. Ann Surg 2008; 247:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/108\">",
"      Ringers J, Dubbeld J, Baranski AG, et al. Reuse of auxiliary liver grafts in second recipients with chronic liver disease. Am J Transplant 2007; 7:2615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/109\">",
"      Starzl TE, Murase N, Thomson AW, et al. Regulation of immune reactivity and tolerance by antigen migration and localization: with particular reference to allo- and xenotransplantation. Transplant Proc 1999; 31:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/110\">",
"      Hara H, Gridelli B, Lin YJ, et al. Liver xenografts for the treatment of acute liver failure: clinical and experimental experience and remaining immunologic barriers. Liver Transpl 2008; 14:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/111\">",
"      Bonavita AG, Quaresma K, Cotta-de-Almeida V, et al. Hepatocyte xenotransplantation for treating liver disease. Xenotransplantation 2010; 17:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/112\">",
"      Kim K, Schuetz C, Elias N, et al. Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons. Xenotransplantation 2012; 19:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/113\">",
"      Ekser B, Lin CC, Long C, et al. Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation. Transpl Int 2012; 25:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/114\">",
"      Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012; 142:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/115\">",
"      Brown RS Jr, Russo MW, Lai M, et al. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003; 348:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/40/38538/abstract/116\">",
"      Bismuth H, Samuel D, Castaing D, et al. Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience. Ann Surg 1995; 222:109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3570 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-42B5A9483A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38538=[""].join("\n");
var outline_f37_40_38538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H233807110\">",
"      GENERAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233810318\">",
"      Setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233810325\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H166750348\">",
"      Hemodynamic management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H246365968\">",
"      N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H166750581\">",
"      Bleeding prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233814522\">",
"      Infection surveillance and prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233814623\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233810382\">",
"      Medications to avoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233810228\">",
"      Unhelpful treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H233807383\">",
"      TREATMENT OF THE UNDERLYING CAUSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233809776\">",
"      Acetaminophen toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233809783\">",
"      Hepatitis B infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233809791\">",
"      Mushroom poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233809799\">",
"      Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233809807\">",
"      Herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233809822\">",
"      Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233814655\">",
"      Autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60325332\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H253412597\">",
"      When the underlying cause is unknown",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H233807797\">",
"      MANAGEMENT OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233812427\">",
"      Metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Intracranial pressure monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H246366036\">",
"      - Transcranial Doppler ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H229243145\">",
"      - Preventing intracranial pressure elevation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Treatment of intracranial pressure elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H60324522\">",
"      Hyperosmotic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H60324564\">",
"      Hyperventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H60324847\">",
"      Barbiturates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H60324951\">",
"      Treatments that do not work",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Experimental therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Induction of hypothermia",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Indomethacin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60325048\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H233808137\">",
"      LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84582894\">",
"      Probability of spontaneous recovery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84583086\">",
"      Prognostic models",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H233813088\">",
"      - King's College Criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H84582496\">",
"      - Model for End-stage Liver Disease (MELD) score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233808211\">",
"      Experimental alternatives to liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H233808218\">",
"      - Artificial hepatic assist devices and hepatocyte transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H233808225\">",
"      - Auxiliary liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H233808232\">",
"      - Xenotransplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H233808239\">",
"      - Other experimental approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84582719\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3570\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3570|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/17/33051\" title=\"table 1\">",
"      Stages hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/33/27163\" title=\"table 2\">",
"      Kings College criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?21/23/21874?source=related_link\" title=\"calculator 1\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?18/2/18466?source=related_link\" title=\"calculator 2\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=related_link\">",
"      Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3434?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32451?source=related_link\">",
"      Complications of mannitol therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16281?source=related_link\">",
"      Corticosteroid therapy in septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2167?source=related_link\">",
"      Diagnosis and treatment of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/13/22743?source=related_link\">",
"      Ethical issues in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4346?source=related_link\">",
"      Hepatic encephalopathy in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14506?source=related_link\">",
"      Hepatic encephalopathy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/12/31944?source=related_link\">",
"      Hepatocyte transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6245?source=related_link\">",
"      Hypokalemia-induced renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/34/25122?source=related_link\">",
"      Patient information: Liver transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22104?source=related_link\">",
"      Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/11/23737?source=related_link\">",
"      Treatment of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_40_38539="Lynch syndrome SGO criteria";
var content_f37_40_38539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lynch syndrome risk assessment: Society of Gynecologic Oncologists guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Genetic risk assessment is recommended in women with the following characteristics (&gt;20-25 percent chance of having Lynch syndrome):",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Endometrial or ovarian cancer with a synchronous or metachronous colorectal cancer with the first cancer diagnosed prior to age 50",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Endometrial or colorectal cancer and meet the revised Amsterdam criteria",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           First or second degree relative with a known germline mutation in a mismatch repair gene",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Genetic risk assessment may be helpful in women with the following characteristics (&gt;5-10 percent chance of having Lynch syndrome):",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Endometrial or ovarian cancer with a synchronous or metachronous colorectal or other Lynch-associated cancer with the first cancer diagnosed at any age",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Endometrial or colorectal cancer diagnosed before age 50",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Endometrial or colorectal cancer with two or more first or second degree relatives with Lynch-associated cancers",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           First or second degree relative meets the above criteria",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Lancaster, JM, Powell, CB, Kauff, ND, et al. Gynecol Oncol 2007; 107:159.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38539=[""].join("\n");
var outline_f37_40_38539=null;
var title_f37_40_38540="NCI CTCAE hepatic toxicity grading";
var content_f37_40_38540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NCI Common Terminology Criteria for Adverse Events (CTCAE) grading of hepatic toxicity, v4.03",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        0",
"       </td>",
"       <td class=\"subtitle1\">",
"        1",
"       </td>",
"       <td class=\"subtitle1\">",
"        2",
"       </td>",
"       <td class=\"subtitle1\">",
"        3",
"       </td>",
"       <td class=\"subtitle1\">",
"        4",
"       </td>",
"       <td class=\"subtitle1\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alkaline phosphatase",
"       </td>",
"       <td>",
"        WNL",
"       </td>",
"       <td>",
"        &gt;ULN to 2.5 x ULN",
"       </td>",
"       <td>",
"        &gt;2.5 to 5 x ULN",
"       </td>",
"       <td>",
"        &gt;5 to 20 x ULN",
"       </td>",
"       <td>",
"        &gt;20 x ULN",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilirubin",
"       </td>",
"       <td>",
"        WNL",
"       </td>",
"       <td>",
"        &gt;ULN to 1.5 x ULN",
"       </td>",
"       <td>",
"        &gt;1.5 to 3 x ULN",
"       </td>",
"       <td>",
"        &gt;3 to 10 x ULN",
"       </td>",
"       <td>",
"        &gt;10 x ULN",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GGT (gamma-glutamyl transpeptidase)",
"       </td>",
"       <td>",
"        WNL",
"       </td>",
"       <td>",
"        &gt;ULN to 2.5 x ULN",
"       </td>",
"       <td>",
"        &gt;2.5 to 5 x ULN",
"       </td>",
"       <td>",
"        &gt;5 to 20 x ULN",
"       </td>",
"       <td>",
"        &gt;20 x ULN",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver failure (clinical)",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Asterixis; mild encephalopathy; limiting self-care ADL",
"       </td>",
"       <td>",
"        Moderate to severe encephalopathy; coma; life-threatening consequences",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Portal hypertension",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Decreased portal vein flow",
"       </td>",
"       <td>",
"        Reversal/retrograde portal vein flow associated with varices and/or ascites",
"       </td>",
"       <td>",
"        Life-threatening consequences; urgent operative intervention needed",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SGOT (AST) (serum glutamic oxaloacetic transaminase)",
"       </td>",
"       <td>",
"        WNL",
"       </td>",
"       <td>",
"        &gt;ULN to 3 x ULN",
"       </td>",
"       <td>",
"        &gt;3 to 5 x ULN",
"       </td>",
"       <td>",
"        &gt;5 to 20 x ULN",
"       </td>",
"       <td>",
"        &gt;20 x ULN",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SGPT (ALT) (serum glutamic pyruvic transaminase)",
"       </td>",
"       <td>",
"        WNL",
"       </td>",
"       <td>",
"        &gt;ULN to 3 x ULN",
"       </td>",
"       <td>",
"        &gt;3 to 5 x ULN",
"       </td>",
"       <td>",
"        &gt;5 to 20 x ULN",
"       </td>",
"       <td>",
"        &gt;20 x ULN",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADL: activities of daily living; LLN: lower limit of normal; NCI: National Cancer Institute; ULN: upper limit of normal; WNL: within normal limits.",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Common Terminology Criteria for Adverse Events, version 4.0, June 2010, National Institutes of Health, National Cancer Institute, file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38540=[""].join("\n");
var outline_f37_40_38540=null;
var title_f37_40_38541="Smoking outcome after MI";
var content_f37_40_38541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Smokers have a higher rate of survival after myocardial infarction because of a more favorable risk profile",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 342px; background-image: url(data:image/gif;base64,R0lGODlh/ABWAeYAAP///4CAgAAAAEBAQP+AgICZ/8DAwP8AAP/AwP9AQAAA3SAgIDAwMKCgoHBwcNDQ0LCwsFBQUKCz//Dw8MDN/yBN/xAQEEBm/2BgYAAz/5CQkODg4P+goICA7v/w8PDz/0BA5rDA//8gIP9QUP8QEMDA9/+wsP8wMDBZ///Q0HCN/xAQ31Bz//9wcP9gYP/g4GCA/5Cm//+QkBBA/1BQ6NDZ//Dw/TAw46Cg8uDm/yAg4dDQ+WBg6nBw7LCw9JCQ8ODg+0BNgIBAQKCj7yAyf39QUAAZf0BQj4AQEGBmgJ+T369wrwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD8AFYBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNsQYPhxsaARDO19gPAQIDhhsWFgwCDoUGAefo6err7O3u7/Dx8vP09fb39waoAwLchg4CNACwIGACoQAD8ClcyLChw4cQ2SVMZcBfIX76MB4MgK2jpnMULRLSqHEQSI8oK508VbFboQgCrImLZg5hAAQIUuqEtLLUAw0CGBgw6K+BgAgQBCwQVDMhARc7ozLqSYpfPwH6LDogyCDaRgQJpIpFRBXXuRcHxqrd2CtAEAoH/16sXVv2VgAjMBLknDu2ri23F1y04NuXoyUDiBND8xQgSQYTBzgQlur30dXLLjmdy5CDQ+TJOys7OrcAA2lync5doADAs2TQKEVb1gcgQATGAWAUEOQatkfZjsIZgMAg86ZzBVQM6u37GvBGRq9aSx0gxAVCJkgQaO7seSNtAbxSp4CiUIoTIzxwX+adEYQAG8Lj/pDBkIcRJ1KsT9ZeEUCsEWCAGwAZfHAIASSYsN8kKRBAAAfqRcJBAvpl0l8iFmAgFEIDosDaIdltt+AjLhxwQgIHhBUJAQfshcmFiGA1gAEYGPcRRxeEkMh56Y3ICAImCuKBDAAgQIAJI6RHQP8Cr6XgQgItqMdiTjIQoN6ECRAJwIMNAuBkAiO8ZpJhlwzAwAIwCUQdACrslsh9+fmoCFomtqDglgeQcEKeJ5AQ1wt6IngCnkZ+1sIBLYxwAJF5HhCXiU+NUAiMhzxAUFAGrZkcIwhCKCciJojg6AFQTQlAioTKcICChzZ4AItQAUCCCA6iGqSXB4jQggwRjrnJYp+AZF0jSB4QZq+fRviCZ2mZiuqUpkKbK6qn0uqgZNQCYEICfg7KFiYTAeDAbWuS94gHHCh67KcIiCADAqqG5ay8LaZgbLsk4FkskYoSgAAH21GLgAsmIEBCvt9WEt8CCQVQ3ID0SYKuug/itN//CyP4SYILUrZ4Kr05cSBqnFN64GcKHrigccAqvrCniRX6ethl/ZB5nGEFUoLukgmImmsCCVxr8aemUErIBAYwgAFi4mlmmIec4AQwzz6LALSDFeOEgFxEX2J0IQ9Eo0EDwRqWoylSYz0C0ED7OarVbLuANQHvau1i118TwoAD28Q0IJtu0pKC3VVi/STbL496Ytxz1601slHlPYiMDERArtOCSFDBMnbDO/fhbI/qKAlsA90C1hwMjYzkgsQ0DodrClKBBIS90PncQFd99Z3BsA4ATAI0YPnfABQQuJxpk9AjML5vEIEDEwwwHeaZb971IPdpN/f23Hfv/ffgf393/202V/KAYk3fSMjs12MX/vvwxy/+pOVTYlU/Nlpos+btF+N7A+gICPFkR7v+CcN3IxEQIiYAwAZkihDTkA/9CiEBFhjwgPWbxPmGY4H8DUIc/GAA2MCxAL8lTBD0MdAFf+G7+wkggwBIym1gMr3fxWQDSplgIVhQwBW2BYaRAOA5yEaWF9bGiIPghzX6wZRzhIsQm/LhD0+xDY5UkRBG6SATAdCU+oUgAzqS4i4kJyOaLSB9AAAKOQCipkG8xyg2qosKlCNGXUhuAA8YAMMGwMejeEMpBijhBgDgjw1AgDgmlFkhvhjGOtoFiJBwABEFAbtCNKCECyCiPyoSlBpSEv+GMbCeI/8CyUoYYJL6SwT7RlkLMtJMJDdLBP9YSYs7DiAcfMzQAA2xSlrGwncWoI0DFEg9RMzSl7DwnQAENIEIeNBrpaxADJCZzFI64j8126UhvthDaq4CgRrgYxuLKUswepMVCBzFc0J5zm9aEzqXgqX6GiHNdqbCdwso4S2JGctGcNOeVHwnI1wnLn7OsxESyEA3ARoKZSbNNs+0RH8SulCGanMSSusbasiJ0AxM06KgSGcax9lPSISgAr0EaUktMQFqDPGiCEVpRVWqEoEuwoURraklNJdSmlJCmUJhGkwhwdOZ+nQ0NlUEA5IqCQQW9ahNZSoiHLAAdKDyoJn/eCpUkZoJnA61EjwtAAVysFVF+G6DQo2dJyQAgwtkIAMXgEEjy/rJTKAVWBz9RA4ooAKF0lWRlvCqWklB0b+SLxNC3AZJU3mKhMZAhVsVKQAGYFDGniIELMgAC4zH2c6GgAKQrUUJSmADANigBEAwBQ5AsAOsmg8xEOjgV0PxAQl0trMquAAK3oqCC6hAAqF1hQIUQAMAlEABHTBFBxRQAtfa7zJSnUp0TfEBCoSgACiYAQxqAIvhMve4yQXAD0BAAx8IogM4GC8PSmuDHoAABMktQQd8QAMa2KADIMCBIHbAAxD0oLTLbe4POlDa1YLgB+fFwQ6Sy1/y6veElUjs/1Wdi4sawGAGKABuKxRwgxXowAfIBUAPFNADGijAvMO9gQ4UwAMA6GAFHeiBDgCw3BXcQAE2XoECgAAEG3fAxjRm7nL1O+ISKwDBOB4uEDjcAR4UF8JmmS4rapvd7a5CAfnFcoiBbAPiAgDLpgXzClbAgw6kNsBfBkGQS/CDE4tYAQtGLosF4eEOLFfNHN6vAnTQgx+UFsqiYGAAHOgNakxYsqawMIaNGgowg2C4yQVzmic96R3QYMUrAAKawRxgNHd6z5Les53RS2kA+AAEOr6BDk0BwqCMMBzyRPQpaivTU4D5uCE2sQ+Wi2Q1Tzq/JXh0nJvLaebugLgleHGQ6f97ZACYuAMlwEGkfV0CHvigBGNeNSlkaMMaboMcWwQsMbQ6CknzIMQ2MPEKeiCIUKvZxHvW76bVjGYcrPgGrQ2wDXS8AxvwQMcwpjQQbszh1gLafIQ+xBWvOAhLHSV42jYGT2PwIR+JtCIWCMADTWJEhgtiA2ciiAK7yAy27hYFumE0XyRrjicOQo3iEuAgYDKUEuqD5NegQAwKgFLjaRg0skYEDhcQSAEM0h8YWGZsjX7wkhsvs5v9bHApI2VB8PHqfNyoIS6pFE12o5n9YIAng46L2uZ2txno7W+n3hFX0iynP606Mqp7XaiLlbu/kXvR9L4Ms1+gAhmogG9vS/j/AkideXx/gDOzPlu+1IAChb/t2Xk7+MhLgAIVb4XvxHEVuE+C7GOhe+SNd4G/v1XwFzDeZ8laCmUaBQCmafw5MW/bApR+BhmYQelHX4DLY36sUc0EVojuAM8H37CE2Ot1R8+C0t/+rad3flyNl/nDYqKqSffjYJF/icf/fudijTglwtbMCGycwtxvKN+HIgrQp1/8k+AHBjy50ve3n+8N4PwCFvsivttfupuQR/JkWf+nfojFeRbAf9BUgOrEd/JHf+jHgBEICexngBIYUnI3FHeFRv13gRh4CWXUebLngcenEhuQWIM2giTIE+t3ftu3gh0ILkr3gTBYf5SQf/2w/38qWIMAqAkCaHyR4H4F+D8IqIAS5X882EIzWDY8OIGPUIE02IQLCC5AGHdSGINeU4Wfh4Q16DsAcXVa54RX2INlghk7OIaGIIQEiIZByHfFB4aJIGgJNwgboBi0IW5s+AhKKIKI0GoidBA0A395SIaasAAQGEN+REMQhBgAsRRNN4iJIFkPo3Adh0SFUEJXpYb254V8JA6XMymVWD9G4Yhc5ERcCIN7qBQcmEbjEHOLhYmDgHOQqIenqAhDV3RH5xLbQIqPOItpKHfaEA3Fd4iCwHWZ1DpfRxAQqInvJzlU1VJXcYc26IuRKHcDQA78kH+VhYXUuAh3xBECYAG1of+FXNWNhDgJW5F0t1EjZwiJkvMN/TAUGdeOg8g62qAP2jBIL2iOvzhF/GhWtRgsDRMRBFmQBnmQCNkOLpcLNlGQfESQDxkREQkRE0mRA/kQFRkA0siQtShSHsmFkvWRw4BoIjmNOpVXRzgMiOEJK/krG3kJLakJMSmTL3kYNfmPOJmTOrmTPNmTPvmTQBmUQjmURFmURnmUSJmUSrmUTNmUTvmUUBmVUjmVVFmVNIVXEEQNEFgTCdmVXvmVYBkPN/kJ2jCA3wBrYTiOYbmWbNmWDhmQiGAV+cNGA1EQgpiTzMhFA0gSWHGXOJmXLWEIfEkbTSEE47OTgDmAijgTTYT/EEggKT/JjD8RFOxXFEeRFLxISUWAMD7JjC6UFS6xFUGBRudAAjHDk3lZUyOgJT2Zmj91BEsgApCDl3CZGkRQAUHTmbXpNBWgBHHRmrt5M5qzJMA5RRUwBCLAO7QJgq9Ejo0AEpojMrNpjraES/v0N7OTmzoJTMK0jVOoOQbDNX/Jd8sEAM3knGQ4Oy4QK+OZCdhkiSWlOYBymNQITuLEhIMwO8TZnpnwHvGxiik5CJrjAe7Cn5fwHwYQILs0OwYzGPwITBrScrvEPy5zAuLpiw41I+z4gvUEAC1AAmIyiy10JmmiTRQwA24SKiIQonl4VpfCAC7IjYNQAyjAAiok/zIr6o5IiJUoCQAfwAIogHetIQLJ2aIOaBjj8lUFMANzJTIJcKFN+I4BwDDnMIk9OgghMAM2ij0sYiVXKDmcBF2N96NMSggv0DMycJorKDlIozRptY+HkKVbOggm4AKiEjQmMJ2bmHhiM2FrqAhkGgNCKiQmsCS5IjfykzqPw1Cbxzf9QIwn+QghAAOAl3ohEFwpUDjxszahIzqlMwJzo6g4AaVEk6GV84liiAgfcF1uVQFy1QkeYDdT4yCc2jaiAzdAg6hHggB6WhjClxR8g57eyHc1EEoXwHqtMDhaUzgtkAAvcyKnUzC92nZ8BzzCg6p/WgkfUAAZUABsJwuxWv+ozfqsULI9ntIdfOc80CM99KgIOfB3hgdavRCu3EMx1zKtLBScqSoJITB5aedbghoMO0OrxuIgytk7DmiGcMoJokepcGV436oLO3MopzM3WqOmpOSeV9eKhyCHLhhBHOiaq2p7gacboycByFoLhTo3zZo7b8M2FburOIGxDHI7DkKf1rcJS9WH3OBqhGApFlBC9OeahVCsvMcCGKYC1ecLymokWFM6PuMoiwMmLFs6PSM6P1M6FYuzIjUBDHMI3KaIM3dDOeSXs8BX2bVZwOcMsro9nUOzLNhVl7GNCwefSkRIAhCLpggMOcBWbgVXMKByC8KJfIQBMVq3NpNFVqH/tzZRDHvFcz0lJ5oIc3RJCG80gES7Vj3ne5JrjQ/whldnuIVwi4JESN1gSIg0tPraWLZneoG3ewVAcRQwqHQhdyE4t1uHSV6nl52kcKvbCrT3dM+Xe6W3Wb2HeRHLHkdKCBu6r9fgfeDXfH8LVxdgvLxnPLK7tI/0CQ2QlgG6HtVFAbV3vQXQVroFfb01feS7vrf1e9p7jpKAdXC4sHX0fex7v8nhfGj3VtJHfWRhu83Zrv8Xvtblv76bCUQnCLFHv/+oTGpSfAKMhkpoJuXJwA/Kd2B3FDE6hZH5uxysm4gVT8IKkEGJT/qkSxZMneSZFAUVwWPoUEvlTC78pXyX/1H94L0fXJyboAFG+L0gzAuZS1dBHLdAOcS0WMIe7MM67INzaJLL+SvhqHFXaqAy2bhOTMUcicTM+XYzLIW2JL84rMSomcSR+sOXoHjzO8UNXMMKq8YXLHyvt8BurMLCF0gGAMEp3I34FADZh62C4LGFloL9WMR8Wn4b7IevBkKD3MGZAIWIELaJdETglrdm+8YyOH+RGIo/SxAwMUmyaMaWgINKwX+IC0EhV8GlaMWM7IP84EGUK3OCQHNe25e9aMmXIMoJKA2AVLpIp3QEoY94iJgJi8mJYIy7m8Fit8igbEob7LwYmoETsIFdHKW2awCCNcd6LHfwgYJ+msNj3P/IzZyt2znMkCrGwnyAOdjDVkjIAdjK05yE+FeE79yF5ByFy0wJGjCW4vzEZTLCz0nGyOc7xHF/WiyDfIjN9emGWBfGZbzEdgTQhkW4jJfHCS23B33Fa9wJhjjPqHiKVorRtmwJb+iJHL2mCZuDANrQ3wzEEP1XkgMBMzIB4sDQKn3OlqAhMdcP3WzO41wmHCEOzuPH3mzTlXCNE5BDlQTSdGwJQCEOAjI8FP3MlyDT4bgBOKTOW1jQLMV+dbjBgLyIiqHMDj0KiAyIlyHWK71tiRjJdXjHZVvLS00KpWwIsNiYC5nW6qTJlvTWqXzXRD0Kr/yKEIfWfy0KpMt0FrH/i/+r1aRgzMhonsq42OzM0oydxZM9Ri0txJlNxKuM2ZUdZZ9tFxfplqRd2qbtDn79F6PtEBnZEK3NEK+9ELEt26sN26utz7MQkiC52whdjs5cS6dYkr89rFENv76g271t3DXN0+ssDDPZyLgdCc8Nk9FNgdVt3Zww3Va53dzd3d49CV9dCxGkAeEMC+cDzLcgaJstCWVdC/fzh7fgcOutCA6nR78AyeW8ChAwAbN83arAefOdCCWU0nah17dQun9hAQAR4JWiFCUk1AVuRfBJCzBnCw8QEx5XCxUhFOKw07UQ2LcAEN6ZTDTD4GDjDxmuC4eN3rIAE1WlkbbQ1kmH8AEsPgtCKw7+DQuObQslzpATTgsPIA4W4OHfXeRGfuRInuRK3k6IkSnnrUEDQOTd3Q8CgUM/nsk3d+VGnoM5bRjhhBSU1ADhZLgbIH8NUBEOUHyG8QA1EgFS7pRKERNBa0QAMS5+E3YlhAEPUEJ7w0m3FDw4tFQYAOFRyQ0RAA5XFA7m6Uf+cNTdsA1ZzhFJER5K4QDk7d3cAKxXZBH+wOmP3pcVwRGhHkN/Dt/bvUkTcEU0pFim+9hVhBhGFOo0AgEGAA6YnhlXBHYK/titvgEPPuqhDnJhR+BLXuzGfuzInuzKvuzM3uzO/uzQfoWBAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A review of 999 patients with an acute myocardial infarction found that smokers appeared to have a higher survival rate after a myocardial infarction compared to nonsmokers (top panel). However, the difference was no longer evident after adjusting for baseline and clinical variables (bottom panel). The apparent difference may be explained by smokers being younger and having a more favorable risk profile than nonsmokers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Gottlieb S, Boyko V, Zahger D, et al. For the Israeli Thrombolytic Survey Group. J Am Coll Cardiol 1996; 28:1506.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38541=[""].join("\n");
var outline_f37_40_38541=null;
var title_f37_40_38542="Glottic view with ELM";
var content_f37_40_38542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laryngeal inlet photograph with ELM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph of the glottis was obtained while the airway manager performed external laryngeal manipulation (ELM).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Orebaugh SL. Direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38542=[""].join("\n");
var outline_f37_40_38542=null;
var title_f37_40_38543="Refractive errors emmetropia myopia and hyperopia";
var content_f37_40_38543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Refractive errors: Emmetropia (A), myopia (B), and hyperopia (C)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 246px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     A)",
"    </strong>",
"    Emmetropia - eye with normal vision.",
"    <br>",
"     <strong>",
"      B)",
"     </strong>",
"     Myopia - nearsighted eye.",
"     <br>",
"      <strong>",
"       C)",
"      </strong>",
"      Hyperopia - farsighted eye.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from Yanoff M, Duker JS. Ophthalmology, Mosby 1999. Copyright &copy; 1999 Elsevier Science.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_40_38543=[""].join("\n");
var outline_f37_40_38543=null;
